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Abstract
Leukaemia is a complex form of blood malignancy characterized by the uncontrolled 
proliferation of haematopoietic cells and progressive accumulation of these cells 
within the bone marrow (BM) and secondary lymphoid tissues. The exact cause of 
leukaemia remains unknown. Leukaemia is a major problem worldwide affecting many 
people each year. However, current treatment options still have several limitations not 
least, the cytotoxicity of these therapies to normal cells and the fact that certain 
chemotherapy agents may cause bone marrow toxicity and organ damage.
Several epidemiological studies have shown that high intake of fruit and vegetables are 
associated with low incidence of a number of human cancers. Researchers suggest that 
pomegranates contain bioactive chemicals with potential for treatment and 
prevention of cancer. Pomegranate juice (PJ) have been shown to inhibit cellular 
proliferation and tumor growth and induce cell death via apoptosis in a number of 
cancer cell lines. However, to date, few studies have investigated the potential of PJ in 
the treatment of Leukaemia.
Here, PJ significantly induced apoptosis in 8 leukaemia cell lines and non tumour 
control cells although the lymphoid and 2 myeloid cell lines were affected to a greater 
extent than non-tumour control cells and 2 of the myeloid cell lines. Furthermore, PJ 
induced cell cycle arrest. These results provide evidence that PJ contain bioactive 
compounds that could be used in the treatment of Leukaemia.
Treatment of four Leukaemia cell lines with five fractions obtained from PJ by solid 
phase extraction demonstrated that only the acetonitrile fractions decreased 
adenosine triphosphate (ATP) levels in all Leukaemia cell lines. Acetonitrile fractions 
also significantly activated caspase-3 and induced nuclear morphology characteristic of 
apoptosis. S phase arrest was induced by acetonitrile fractions which matched S phase 
arrest seen previously following whole PJ treatments. The acetonitrile fractions 
contained higher phenol content than whole PJ whereas only low levels of phenols 
were seen in any other fraction. Liquid chromatography mass spectrometry (LC-MS)
4
analysis demonstrated that acetonitrile fractions were enriched in ellagitannins, ellagic 
acid, and hydroxycinnamic acid derivatives but depleted in anthocyanins.
The potential protective effect of a number of pure compounds that were either 
identified in the acetonitrile fraction of PJ were present in the other fractions of PJ or 
have been identified as PJ components in previous studies were studied on ATP levels 
in four human leukaemia cell lines. Among the 26 naturally occurring pomegranate 
compounds investigated, only seven compounds: delphinidin; cyanidin; pelargonidin; 
EGCG; gallic acid; ellagic acid; quercetin; and punicalagin induced 50% decrease in ATP 
levels in the studied leukaemia cell lines.
To compare the chemoprotective properties of anthocyanins found in PJ and to 
understand the relationship between anthocyanin chemical structure and 
chemoprotective activity, the inhibition of cell proliferation and induction of apoptosis 
in leukaemia cell lines was measured. Anthocyanins activity was found to be 
dependent on the ortho-hydroxyphenyl structure and the most potent glycosidic form 
of the anthocyanins with proliferation and apoptosis effects seen in anthocyanins with 
greatest hydroxyl groups and least glycosidic form, namely delphinidin. Delphinidin 
induced apoptosis through intrinsic and extrinsic pathways. Suggesting that delphinidin 
may have potential for use as a chemotherapeutic agent against leukaemia. 
Furthermore, EGCG, gallic acid, quercetin, and punicalagin induced apoptosis and 
resulted in cell cycle arrest in the majority of the leukaemia cell lines.
Together this study has shown that PJ is a rich source of bioactive compounds which 
could hold promise for treatment of leukaemia. The most promising compounds found 
within PJ were delphinidin, gallic acid, and punicalagin. Further investigation into these 
agents in the treatment and prevention of leukaemia are essential to develop these 
potential agents as future treatments.
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Table (continued)
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1. General In
1.1 Normal Regulatory Cellular Pathways
1.1.1 Normal Haematopoiesis
Haematopoietic stem cells (HSCs) are found in abundance within the bone marrow 
(BM) and have the ability to proliferate and differentiate into a variety of lineages 
(Congdon, 2008; Kondo, 2009). HSCs can generate lymphoid and myeloid precursors 
(Figure 1.8) (Kendo et al, 2003; Kondo, 2010). The lymphoid lineage produces T cells, B 
cells and natural killer (NK) cells. While the myeloid lineage produces red blood cells 
(erythrocytes), mast cells, megakaryocytes, granulocytes (neutrophils, eosinophils and 
basophils) and monocytes which go on to form macrophages (Figure 1.1). In addition 
HSC have been shown to give rise to cell types not directly associated with the 
haematopoietic system, such as osteoclasts (Kendo et al, 2003; Gabrilovich and 
Nagaraj, 2009; Kondo, 2010).
T lymphocytes play an essential part in antigen-recognition in the body's immunity 
(Alegre et al, 2001). The proliferation, differentiation and acquisition of effector 
functions of T cells requires the recognition of specific antigens, this is also important 
to provide help to other cell types which participate in the immune response, such as B 
cells and NK cells (Alegre et al, 2001). B lymphocytes respond to foreign particles, 
which are recognised by membrane bound IgM, upon binding they divide and 
differentiate into plasma cells (also called plasma B cells, effector B cells and 
plasmocytes), which produce large volumes of antibodies (Abs) with the same 
specificity as the original B-cell (Bernasconi et al, 2002) (Figure 1.1). B-cells are 
synthesized in the BM prior to release into the circulation where they migrate to 
secondary tissues such as the lymph nodes where differentiation to terminally 
differentiated plasma cells takes place (Calame, 2001). In healthy individuals, the 
proliferation, differentiation and release of cells from the BM is highly controlled, if 
defects arise in these processes this can lead to a number of human diseases such as 
leukaemia (Zone, 2001).
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Figure 1.1 Haematopoiesis and differentiation of myeloid stem cells and lymphoid stem cell. 
Modified from Nielsen et al, 1998
1.1.2 Cell Cycle
The cell cycle is the process by which a cell replicates its DNA and divides in a tightly 
control process that involves five separate phases: G0,G i, S (DNA synthesis), G2 and M  
(mitosis) (Figure 1.2) (Nurse, 2000). Firstly, in the G0 phase (quiescence cellular arrest) 
the cell arrests leaving the cell cycle and stops growing. However, even after long 
period of quiescence, cells are able to re-enter the cell cycle and proliferate (Heinrichs, 
2008). Cyclins and cyclin-dependent kinases are not expressed during this phase 
(Nurse, 2000; Blagosklonny, 2011). Growth phase 1 (Gi) is the first stage o f interphase 
and during this stage proteins and enzymes are synthesized preparing cells for DNA 
synthesis in S phase (Park and Lee, 2003). During S phase the quantity of chromosomal 
DNA is replicated to create exactly tw o identical chromosomes. Synthesis is completed  
as quickly as possible, because during synthesis the exposed base pairs are sensitive to
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external factors, and hence carcinogenic agents can induce mutation in the DNA 
(Figure 1.1) (Roger and King, 2006). Finally, during M phase the cell splits into two  
identical daughter cells (Vermeulen et al, 2003; Gwyneth et al, 2003) (Figure 1.1). The 
process of mitosis is fast, complicated and involves tw o processes; mitosis and 
cytokinesis. During mitosis the cellular chromosomes are divided between the tw o  
daughter cells in a highly controlled manner. Mitosis consists of four stages: prophase, 
metaphase, anaphase, and telophase (Figure 1.2). In contrast, cytokinesis is a separate 
process which starts at the same tim e as telophase in this stage the cells cytoplasm 
divides into half between tw o daughter cells (Vermeulen et al, 2003).
G1 Phase 
M Phase Cell grows
G2 Phase
Cell prepares to 
divide
Figure 1.2 The four separate phases of cell cycle process; Gi phase, S (synthesis) phase, G2 
phase and M phase (mitosis).
S Phase
Cell grows\
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1.1.2.1 Regulation of Cell Cycle
The regulation of cell cycle is critical to ensure faithful segregation of genetic material 
and thus allow normal development and maintenance of multicellular organisms 
(Vermeulin et al, 2003). Failure to coordinate such process can result in genomic 
instability, which may lead to cancer. Therefore, during the cell cycle there are a 
number of checkpoints which monitor and regulate the timing and progression though 
cell cycle, these take place at the Gi/S phase boundary, in S phase, and during G2/M  
phases. These checkpoints ensure that the correct sequence of events in particular the 
phase of cell cycle is completed successfully before a new phase is initiated (Harbour 
and Douglas, 2000; Meeran and Katiyar, 2008). The regulation of cell cycle involves 
two main protein families; the cyclin-dependent kinases (CDK) and the cyclins (Figure
1.3)
1.1.2.1.1 Cyclin-Cyclin-Dependent Kinases (Cyclin-CDKs)
The cyclin-dependent kinases (CDKs) are small serine/theonine protein kinases that 
play a critical role in triggering cell cycle events (Meeran and Katiyar, 2008). CDKs 
consist of a conserved catalytic kinase core of about 34 kDa, which is inactive by itself. 
Their activation requires association with regulatory subunits known as cyclins which 
lead to CDKs phosphorylation providing decisions for the cell to proceed though Gi 
into S phase, and from G2 to M phases (Table 1.1) (Schwartz and Shah, 2005; Meeran 
and Katiyar, 2008). CDK4 or CDK6 regulate events in the early Gi phase of the cell 
cycle; CDK2 triggers entry into S phase when phosphorylated with cyclin E; CDK2 
binding to cyclin A and CDK1 to cyclin A regulate the completion of the S phase while 
CDK1 binds to its specific cyclin partners cyclin B and is responsible for mitosis (Table 
1.1) (Boxem et al, 1999; Boxem and van den Heuvel, 2001). However, CDK-4 activity 
has a limited effect on the Gi/S phase of the cell cycle (Van den Heuvel, 2005; Meeran 
and Katiyar, 2008). CDK-4 is also responsible for the phosphorylation of retinoblastoma 
gene product (Rb), which is a tumour suppressor protein (See section 1.1.2.1.3). A 
number of other CDKs are found to work indirectly to regulate the cell cycle including 
CDK-5, (Cruz and Tasi, 2004) and two other CDKs: CDK-8 and -9 which are involved 
specifically in regulating transcription (Shim et al, 2002 ; Schwartz and Shah, 2005; 
Meeran and Katiyar, 2008).
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CDK4 Cyclin D l, D2, D3 G r  phase
CDK6 Cyclin D l, D2, D3 Gr  phase
CDK2 Cyclin E Gr S phase transition
CDK2 Cyclin A S phase
CDK1 Cyclin A G2-M phase transition
CDK1 Cyclin B M phase
CDK7 Cyclin H All cell cycle phases
Table 1.1 Cell cycle progression is promoted by Cyclins binding to CDKs at different stages. 
Modified from Meeran and Katiyar, 2008
1.1.2.1.2 Cyclin-Dependent Kinase Inhibitors (CDKIs)
Cell cycle is negatively regulated by cyclin-dependent kinases inhibitors (CDKIs) which 
are small inhibitory proteins (M eeran and Katiyar, 2008). There are tw o major families 
of CDKIs: the INK4 (inhibitor of CDK4) family and the Cip/Kip (kinase inhibitor protein) 
family (Vermeulen et al, 2003; Dai and Grant, 2003; Meeran and Katiyar, 2008). The 
INK4 family consists o f four members including: p l5 mk4b; p l6 mk4a; p l8 mk4c and p l9 'nk4d 
which specifically bind to CDK4 and CDK6 and inhibit their activity. Each m em ber of the 
INK4 family is encoded by a unique gene and there are 15- to 19-kDa polypeptides that 
share approximately 40% homology with one another (Vermeulen et al, 2003). The 
Cip/Kip family, includes; p2 i cipl/wafl/ p27K,pl and p57Kip2, which inhibit the activities of 
most CDKs (Vermeulen et al, 2003). Dis-regulation of molecules controlling the cell 
cycle plays an im portant role in tum our pathogenesis (M eeran and Katiyar, 2008). For 
example, alterations within CDKIs (e.g. p l6  and p21) have also been found in many 
human cancers (Dai and Grant, 2003; Vos et al, 2006). Because CDK dis-regulation is 
reported in most human tum our cells, pharmacological CDK inhibition has become an 
attractive approach regarding non-genotoxic and mechanism-based therapies in 
oncology (Figure 1.3) (Fischer and Gianella, 2003).
1.1.2.1.3 Retinoblastoma (Rb)
Retinoblastoma is an essential tum our suppressor protein, which inhibits cell cycle 
progression and blocks cell growth via preventing their entry to  S phase, and is often  
referred to as the gatekeeper of the cell cycle (Giacintiand Giordano, 2006; Burkhart 
and Sage, 2008). There are three members of the Rb family including; R b /p l0 5 , p l0 7
and R b 2 /p l30 , collectively referred to as 'pocket proteins'. The negative regulation of 
cellular transition from Gi to S phase can be inhibited when Rb protein is 
hypophoshorylated and then directly binds to the transactivation domain of E2F 
(group of genes of transcription factors that are involved in cell cycle regulation) (Qian 
et al, 1992; Stevaux and Dyson, 2002; Dimova et al, 2003; Burkhart and Sage, 2008). 
However, when it's a tim e for the cell to enter S phase the phosphorylation of Rb by 
CDK2/cyclin 2, preventing their inhibitory action and binding to  the E2F domain. Thus, 
loss o f Rb function may induce cell cycle dis-regulation and so lead to a tum our 
phenotype. Chromosomal mutations and inactivation of Rb is often considered a 
crucial component in the development of cancer (Giacintiand Giordano, 2006). Indeed 
alterations of the Rb gene are common in human cancers including; lung (Wikenheiser- 
Brokamp, 2006), brain (Jacks, eta l, 1992), liver (Hui et al, 1999) and leukaemia (Krug et 
al, 2002). Interestingly Rb inactivation is more frequently seen in acute myeloid 
leukaemia than in acute lymphocytic leukaemia (Tang et al, 1992).
Cyclin B/CDK1
Cyclin A/CDK2
Growth factor
Cyclin E/CDK2
Cyclin D/CDK4,6
Figure 1.3 The positive and negative regulatory proteins that are involved in cell cycle 
progression. Modified from Dai and Grant, 2003
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1.1.3 Programmed Cell Death (Apoptosis)
Apoptotic cell death occurs as a homeostatic mechanism to maintain cell populations 
in tissues throughout development and aging (Elmore, 2007). Apoptosis also takes 
place as a protective process when cells are damaged by disease or during immune 
reactions (Norbury and Hickson, 2001). There are a number of different conditions 
which are able to initiate apoptosis, including: cell stress and DNA damage, however, 
not all cells will undergo apoptosis in response to these stimuli (Elmore, 2007). A 
number o f classical morphological changes characterise the stages of apoptosis (Figure 
1.4) (Hacker, 2000). These changes include: cell shrinkage; membrane blebbing; 
nuclear DNA fragmentation; chromatin condensation and formation of apoptotic 
bodies (Figure 1.4) (Saraste and Pulkki, 2000). Apoptotic bodies then are rapidly 
phagocytosed by neighbouring macrophages, providing non-inflammatory clearance of 
cancerous and pre-cancerous cells, which reduces the chance of tissue damage 
resulting from inappropriate autoimmune responses (Ren and Savill, 1998; Hoffmann 
eta l, 2001).
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Figure 1.4 Morphological changes of apoptotic cells at different stages. Modified from 
Vaskivuo, 2002.
There are tw o major molecular signalling pathways for apoptosis which are highly 
complex, sophisticated and involve an energy-dependent cascade of molecular events, 
known as the extrinsic and intrinsic pathways (Figure 1.5). Both pathways are 
associated with enzymatic caspase activation (Brady, 2003; M artin , 2006; Ashkenazi,
2008).
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Figure 1.5 The intrinsic and extrinsic pathways of apoptosis. This figure has been modified 
from Fernandez eta l, 2010.
1.1.3.1 The Intrinsic Pathway
In the intrinsic pathway, apoptosis is initiated from inside the cell when pro-apoptotic  
stimuli, such as the absence of certain growth factors; cytokines; hormones; hypoxia or 
infections lead to initiation of death programs, this in turn causes activation of 
apoptosis (Saelens et al, 2004; Elmore, 2007; Yip and Reed, 2008). Commonly, these 
stimuli activate the expression of pro-apoptotic members of Bcl-2 family, such as Bax, 
leading to their transportation to the outer m embrane of mitochondria. Alterations in 
the inner mitochondrial membrane lead to changes in the mitochondrial perm eability  
transition (MPT) pore; loss of the mitochondrial transmembrane potential and release 
of mitochondrial pro-apoptotic proteins such as: cytochrome C; Second mitochondria- 
derived activator o f capsase/Direct IAP binding protein SMAC/Diablo and the serine 
protease HtrA2/Om i from the interm em brane space into the cytosol (Hill et al, 2004; 
Saelens et al, 2004; Garrido et al, 2006) (Figure 1.5). These proteins activate the  
caspase-dependent mitochondrial pathway. Upon the release of cytochrome C, it binds 
and activates Apoptotic protease activating factor 1 APAF-1) as well as procaspase-9, 
forming an "apoptosome" (Figure 1.5) (Hill et al, 2004; Khan (1) et al, 2006). The
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procaspase-9 cluster causes caspase-9 activation by self-cleavage which in turn 
activates the executioner caspase-3 (Figure 1.5).
1.1.3.1.1 Regulation of the Intrinsic Pathway
1.13.1.1.1 Bcl-2-Family
The Bcl-2-family includes a group of structurally similar proteins which play an 
important role in the regulation of the intrinsic pathway by controlling mitochondria 
membrane permeability and the release of pro-apoptotic factor: cytochrome c. Bcl-2 
proteins can divided into three groups: those that promote apoptosis (Bak, Bax, Bcl- 
rambo, Bcl-xs, BOK/Mtd); those that inhibit apoptosis (Bcl-2, Bcl-xl, Bcl-w, Mcl-1, Bcl-10, 
and Bcl-2 related protein Al); and the pro-apoptotic BH-3, the proteins which bind to 
and regulate the anti-apoptotic Bcl-2 proteins (Bad, Bid, Bik/Nbk, Bim, Blk, Bmf, 
Hk/DP5) (Table 1.2) (Cory and Adams, 2002; Elmore, 2007; Yip and Reed, 2008). The 
ratio between anti- and pro-apoptotic family members controls whether or not cells 
will undergo apoptosis (Elmore, 2007).
1.1.3.1.1.2 Non-Bcl2 Family Proteins
In addition to the Bcl-2 family proteins, Apoptotic inducing factor (AIF), endonuclease 
G and caspase-activated DNAse (CAD) are other proteins which have a pro-apoptotic 
function and are released from the mitochondria during the late stages of apoptosis 
(Table 1.3). AIF and endonuclease G translocate from the mitochondria and move to 
the nucleus and to induce DNA fragmentation and chromatin condensation (Joza et al, 
2001; Li et al, 2001). AIF and endonuclease G both function in a caspase-independent 
manner (Enari et al, 1998). In addition, caspase 3 is able to cleave the inhibitor of 
caspase activated DNAse (CAD) and allows CAD to cleave the DNA at random points 
between individual nuclosomes (Larsen et al, 2010). In contrast, there are some 
proteins which act as inhibitors including intracellular apoptosis inhibitor proteins (IAP) 
which regulate caspase activity by binding and inhibiting the activation of pro-caspases 
and the activity of mature caspases (Khan (1) et al, 2006) (Table 1.3). Some of these 
inhibitors are X-linked inhibitor of apoptosis protein (XIAP), Baculoviral IAP repeat- 
containing protein 3 (CIAP2) and Survivin (van Loo et al, 2002). SMAC/Diablo and
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HtrA2/0mi are described to stimulate apoptosis by inhibiting the activity of IAP (Table
1.3) (van Loo et al, 2002). SMAC/Diablo proteins are activated by the effect of 
apoptosis inducing factor (AIF) (Khan (1) etal, 2006; Martin, 2006).
1.1.3.2 The extrinsic Pathway
Extrinsic apoptosis is initiated from outside the cell, when an apoptotic signal is 
received by binding of pro-apoptotic ligands such as: Apo2L (apoptosis ligand 2); Apo3L 
(apoptosis ligand 3); TRAIL (tumour necrosis factor-related apoptosis-inducing ligand); 
Fas Ligand and TNF a  to their specific pro-apoptotic membrane death receptors such 
as DR4 (death receptor 4); DR5 (death receptor 5); Fas and TNF Rll (Figure 1.5) 
(Rodriguez et al, 2005; Martin, 2006; Ashkenazi, 2008). Upon binding, the death 
domain of each receptor (which is cytoplasmic domain of about 80 amino acids) react 
with Fas-associated death domain (FADD) (cytoplasmic domain which works as a 
bridge between the receptor and pro-caspase8) leading to recruitment and formation 
of the death-inducing signalling complex (DISC) (Figure 1.6) (Ashkenazi and Dixit, 1998; 
Locksley et al, 2001). Formation of the DISC can be initiated by each receptor 
independently by recruiting the adapter FADD and activates the initiator caspases-8 
and -10 (Figure 1.5) (Kischkel et al, 2000; Rodriguez et al, 2005; Elmore, 2007; 
Ashkenazi, 2008). Activated caspase 8 then in turn activates the executioner caspase 3. 
The activation of this effector caspase is essential for DNA fragmentation and 
chromosomal condensation. The cross linking between extrinsic and intrinsic pathway 
occurs when the active caspase 8 activates the pro-apoptotic member Bid (Bcl-2 
interacting domain), to trigger the release of cytochrome C (Fadeel and Orrenius, 2005; 
Martin, 2006; Elmore, 2007). This pathway can be inhibited by cellular FADD-like 
interleukin-ip-converting enzyme inhibitory protein (c-FLIP) (Figure 1.5).
1.1.3.3 The Tumour Suppressor Protein p53
Additionally, the tumour suppressor protein p53 can directly or indirectly regulate the 
expression and/or release of pro-apoptotic and anti- apoptotic proteins and proteins 
that control mitochondrial membrane permeability and therefore, can modulate the 
release of mitochondrial proteins within intrinsic apoptosis (Hofseth et al, 2004; 
Elmore, 2007). In addition, within the intrinsic pathway p53 increasing the expression
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of APAF-1, a crucial component of the apoptosome. Interestingly, p53 is also involved 
in regulation of extrinsic apoptosis through increasing the expression of cellular death 
receptors such as DR5. p53 can be induced as a result of many signals including; 
telom ere shortening; DNA damage; oncogene activation and over expression of 
tum our suppressor genes (M iura et al, 2004). Thus, it is apparent that p53 is a key 
tum our suppressor protein at the crossroads of cellular stress response pathways. 
Though these pathways, it can initiate cell-cycle arrest, DNA repair, chromosomal 
segregation, cellular senescence and differentiation (Hofseth et al, 2004). The different 
functions o f activated p53 are complex and highly dependent on co-expression of 
other factors which vary by cell type as well as by the severity and persistence of 
conditions of cell stress and genomic damage (Hanahan and W einberg, 2011). It has 
been shown that the loss of p53 in myeloid progenitor cells is associated w ith a high 
risk of developing AML, since p53 has a role in controlling cell proliferation though 
limiting self-renewal of normal HSCs (Zhao et al, 2010). Apoptosis mechanisms are 
highly complex and associated by complex cascades of intracellular events that include 
activation of pro-apoptotic Bcl-2 family, m em ber of the caspase family and several 
nucleases. Table 1.2 summarizes im portant proteins that involve in apoptosis.
Death receptors (Fas, TNFRII, 
DR3, DR4, DR5)
Death ligand (FasL, TNFa, 
TRAIL)
These are effective in the 
extrinsic pathway of 
apoptosis. The extrinsic 
pathway is initiated by 
interaction be
Elmore, 2007; Reuter et al, 
2008.
Caspase family (e.g. caspase 
2, 3, 6, 7,8, 9,10)
Caspases are a family of 
cytosolic aspirate-specific 
cysteine protease, play an 
important role in the 
initiation and execution of 
apoptosis.
Holdenrieder and Stieber, 
2004.
Inhibitor of apoptosis (IAP) 
(e.g. Survivin, (IXAP)
lAPs are inhibit apoptosis 
though inhibition pro­
panoptic members of the 
caspase family
Debatin et al, 2004; Duberz 
Daloz et al, 2008.
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Table (continued)
Bcl-2 family (e.g. Bcl-2, Bcl-xl, 
Bax, Bad, Bak, Bid)
Bcl-2 family proteins regulate 
the intrinsic pathway by 
controlling mitochondria 
permeability and release of 
the pro-apoptotic factor 
cytochrome c
Cory and Adams, 2002; 
Debatin et al, 2004; Elmore, 
2007)
Cytochrome c Cytochrome c is releases from 
the mitochondria into cytosol 
in response to pro-apoptotic 
stimuli and act as a cofactor 1 
initiating the activation of the 
APAF-l/caspase-9 complex.
Debatin etal, 2004; Elmore, 
2007
Apoptosis inducing factor 
(AIF)
AIF release from 
mitochondria into cytosol, 
and triggers chromatin 
condensation as part of the 
intrinsic caspse-9 mediated 
apoptosis
Joza et al, 2001;
SMAC/Diablo Sequestrates lAPs and hence 
favours caspase activation
Van Loo et al, 2002; Debatin 
et al, 2004; Elmore; 2007
Caspase-activated DNAse 
(CAD)
CAD degrades chromosomal 
DNA Enari et al, 1998
Apaf-1
Apaf-1 is a cytosolic protein 
that participates in the 
cytochrome c-dependent 
activation of caspase-3.
Debatin et al, 2004; Elmore, 
2007
p53 P53 is a tumour suppressor 
protein, play role in many 
cellular process including 
apoptosis
Debatin et al, 2004; Garwal 
and Shishodia, 2006; Elmore, 
2007
Table 1.2: Summary of proteins involved in apoptosis.
Deregulation within one or more of the normal regulatory pathways including; cell 
proliferation, differentiation, and apoptosis could result in cancerous cells developing, 
proliferating and evade death which can lead to the formation of cancer. These aspects 
are components of the hallmarks of cancers which are required for malignant 
transformation. Here the key hallmarks, which this study targets for potential 
treatm ents for leukaemia will be discussed further.
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1.2 Hallmarks of Cancer
Hanahan and W einberg (2011) initially defined six essential hallmarks of cancer, 
required for cells to become malignant and these included: (1) evading growth 
suppressors; (2) resisting cell death (apoptosis); (3) sustaining proliferative signalling; 
(4) inducing angiogenesis; (5) enabling replicative im m ortality and (6) activating 
invasion and metastasis (Pietras and Ostman, 2010; Hanahan and W einberg, 2011). In 
2011, they added four new hallmarks: (1) abnormal metabolic pathways; (2) evading 
the immune system; (3) chromosome abnormalities and unstable DNA, and (4) 
inflammation (Figure 1.6). Hallmarks which act as targets for new leukaemia therapies 
will be discussed further here. These include: resisting cell death, evading growth 
suppressors, and sustain proliferation signalling.
cancer
Figure 1.6 The ten hallmarks of cancer. Modified from Hanahan and Weinberg, 2011.
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1.2.1 Resisting Ceil Death
Resisting programmed cell death plays a key role in cancer cell survival. The most 
common mechanism by which cancer cells resist apoptosis is by modulation of p53 
either though gene deletions or mutations (Bouillet and Strasser, 2002; Junttila et al,
2009). Alternative mechanisms include the over expression of anti-apoptotic proteins 
such as Bcl-2, and Bcl-xL or by down regulating pro-apoptotic proteins such as Bax. 
Modulation of extrinsic apoptosis is also seen via decreased expression of death 
receptors (Hanahan and Weinberg, 2011).
1.2.2 Evading Growth Suppressors
Within normal healthy cells proliferation is tightly controlled by the CDK and CDKI. 
Particularly during Gi stage which is an essential checkpoint where the anti­
proliferation signals produce their activity to prevent further cell proliferation such as 
Rb. The Rb protein (see section 1.1.1.1.3) actively inhibits cell passage though the 
restriction (R) point in the Gi phase and decides whether or not a cell should proceed 
(Sherr and McCormick, 2002; Burkhart and Sage, 2008). Thus, cancer cells with 
mutated Rb remove this gatekeeper and allow ongoing cell proliferation. On the other 
hand, p53 functions to arrest the cell cycle once DNA damage is detected and acts as a 
central regulator of apoptosis (Hanahan and Weinberg, 2011; Hofseth etal, 2004). p53 
mutation is important in a number of cancers and is linked to poor prognosis in chronic 
lymphocytic leukaemia (CLL) patients (Zenz et al, 2010), and associated with the 
aggressive forms of Acute myeloid Leukaemia (AML) (Zaho etal, 2010).
1.2.3 Sustaining Proliferation Signalling
In normal cells, cell signalling is a highly controlled process; however this regulation is 
compromised during cancer (Hanahan and Weinberg, 2011). One of the important 
behaviours of tumour cells is their ability to proliferate uncontrolled. This can be 
achieved though; stimulating and sending signals to normal cells in the 
microenvironment to provide cancer cells with additional growth factors; increasing 
growth factor production by the cancerous cells and increasing the number of growth 
factor receptors expressed on the cell surface leading to auto proliferation stimulation 
(Korpal and Kang, 2010; Hanahan and Weinberg, 2011).
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1.3 Leukaemia
Leukaemia is a complex form of blood malignancy characterized by the uncontrolled 
proliferation of haematopoietic cells and progressive accumulation of these cells 
within the BM and secondary lymphoid tissues, which can spill over into the peripheral 
blood and other organs. This accumulation prevents the production of other vital 
normal blood cells such as red blood cells and platelets resulting in anaemia, bleeding 
and immunodeficiency (Buffler and Kwan, 2005; Alitheen et al, 2011).
1.3.1 Causes of Leukaemia
The exact cause of leukaemia remains unknown (Greaves, 1997; Buffler and Kwan, 
2005; Buffler et al, 2005; Eden, 2010). Leukaemia is thought to have multifactorial 
causes which involve interaction between different aspects originating from the 
environmental as well as human genetics (Buffler et al, 2005). However there are a 
number of factors involved which increase the chance of leukaemia developing.
Exposure to Certain Chemicals: The risk of leukaemia may be increased by exposure to 
certain chemicals. For example long-term exposure to high levels of benzene is a risk 
factor for AML (Weng et al, 2004; Buffler and Kwan, 2005; Rossi et al, 2000). In 
addition, Smoking is known to be linked to cancers of the mouth, lung, and throat, but 
studies have shown that it can also affect cells which do not come into direct contact 
with smoke (Weng et al, 2004; Buffler and Kwan, 2005).
Age and Gender: Leukaemia is more common in men than women and the risk of 
getting leukaemia increases with age, but the reasons for this are not clear (Weng et al,
2004).
Family History: Most cases of leukaemia are not thought to have a strong genetic 
linkage; however having a close relative in some types of leukaemia enhances the risk 
of getting the disease. For example, in identical twins, where one developed AML 
before they were a year old increased the risk of the second twin developing AML 
demonstrating a genetic linkage (Amigou etal, 2011).
High-Dose Radiation Exposure: Exposure to high-dose radiation (for example as being
a survivor exposed to the Hiroshima and Nagasaki atomic bombs or nuclear factor
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accident) is known to be associated with increased risk of leukaemia such as CLL (Weng 
et al, 2004; Buffler and Kwan, 2005; Rossi et al, 2000).
Viral infection: Epstein-Bar virus (EBV) and human T-cell lymphoma leukamia virus 
(HTLV-1) have been implicated in the development of leukaemia. The EBV is a 
herpisvirus that can inhibit B-lymphocytes and nasopharyngeal cells. The HTLV-1 virus 
is closely assocated with T-cell lymphocytic leukaima found in Japan, Africa (Lackritz, 
2000)
Genetic abnormalities: Genetic defects and abnormalities are key risk factors 
associated with the incidence of certain types of leukaemia (Table 1.3) (Buffler and 
Kwan, 2005; Rossi et al, 2000; Amigou et al, 2011). A number o f syndromes that result 
from genetic mutations present at birth seem to increase the risk of leukaemia. These 
include; bloom syndrome, blackfan-diamond syndrome, and fanconi anaemia. Down 
syndrome and trisomy 8 which are caused by chromosome problem present at birth 
are also linked to  raise the risk of leukaemia (W eng et al, 2004; Buffler and Kwan, 
2005; Rossi et al, 2000).
Exportin 1 [XPOl) mutation CLL Puente et al, 2011
JAK2 mutation Acute leukaemia Biondi etal, 2000; Peacock, 2000; Deschle 
et al, 2006; Deschler and Lubbert, 2006; 
Malinge et al, 2007
Loss or deletion of 
chromosome 5,7, Y, and 9, 
translocations
AML Deschler and Lubbert, 2006
Notchl mutation ALL Weng et al, 2004; Mansour et al, 2007
PAX5 mutation ALL Mullighan et al, 2007
Philadelphia (Ph) 90% CML Fainstein, et al, 1987
chromosome translocation 
between chromosome 9 and 
22
30% ALL
t (15; 17) translocation AML Kakizuka et al, 1991
Table 1.3 Genetic abnormalities associated with certain types of leukaemia.
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1.3.2 Incidence of Leukaemia
Leukaemia is a major problem worldwide affecting many people each year. It is 
estimated that more than a quarter of million people died from leukaemia in 2008. 
Leukaemia is the ninth most common cancer death in the UK (Table 1.4) and the fifth 
in the USA. About 4,500 people died from leukaemia in the UK in 2010 and 23,540 in 
USA in 2012 (Cancer Research UK, 2013; Leukaemia & Lymphoma Research, 2013).ln 
France, during the period 2000 to 2004, leukaemia and lymphoma was the most 
frequent cancer accounting for 41% of the total diagnosed malignancies (Lacour et al, 
2010). In 2013, around 4,800 people are expected to be diagnosed with leukaemia and 
more than 23,000 people expected to die from leukaemia in USA (Siegel et al, 2012)
Generally leukaemia occurs with varying frequencies at different ages and is more 
common in adults than children. Overall leukaemia is more common in males than 
females (Table 1.4). Leukaemia causes about one-third of all cancer deaths in children. 
Acute lymphoblastic leukaemia (ALL) is the most common type in children. More than 
50% of all leukaemia diagnosed in children are ALL and the risk for getting it, is highest 
in children under 5 years old (Cancer Research UK, 2013). In the USA, ALL accounted 
for 74% of new leukaemia cases in children (Leukaemia & Lymphoma Research, 2013). 
AML and CLL are the most common type in adults (Table 1.4) (Cancer Research UK, 
2013; Leukaemia & Lymphoma Research, 2013). In USA, more than 14,500 new cases 
of AML were reported in adult and 10,370 deaths from this blood malignancy 
(American cancer society, 2013). Moreover, according to Leukaemia & Lymphoma 
Research around 2200 people are diagnosed with AML in the UK annually.
In Leukaemic relative survival rate vary according to patient's age at diagnosis, gender, 
and type of leukaemia (Leukaemia & Lymphoma Research, 2013). The death rates from 
leukaemia are very low in people under age of 50 years old, but rise dramatically in the 
over 60's (Cancer Research UK, 2012). In the USA, the mortality rate from chronic 
myeloid leukaemia (CML) showed a decrease in 2005 comparing to the five years 
before while the AML showed a significant increase in the same period of time (Radich,
2010). In the UK, between 2005 and 2009, 44% of people survived from leukaemia for 
at least five years post diagnosis (Cancer Research UK, 2013). Moreover, mortality 
rates for both men and women from leukaemia shows a very gradual decline between
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the late 1970's and 2008 in the UK (Leukaemia & Lymphoma Research, 2012). 
Therefore an improved understanding of the pathogenesis of leukaemia and the 
development of novel drugs is essential to improve the prognosis of leukaemia 
patients.
■ iij!i
Male Female Persons Male Female Persons
ALL 391 311 702 125 93 218
CLL 1931 1206 3137 673 463 1136
AML 1399 1164 2563 1253 1057 2310
CML 364 274 638 113 115 248
Table 1.4: UK leukaemia incidence (2009) and mortality (2010). Modified from Cancer 
Research UK.
1.3.3 Leukaemia Classification
A number of classifications for hematopoietic blood malignancies have been identified 
such as French-American-British (FAB), Revised European-American Lymphoma (REAL) 
and 2001 and 2008 World Health Organization (WHO) classifications. These 
classification systems were based on the identification of distinct tumours using clinical 
features, immunophenotype, genetic information, molecular and morphological 
investigation of the peripheral blood (PB) and BM specimens (Gralnick et al, 1977; 
Neame et al, 1989 and Vardiman et al, 2009). In addition, these classification have 
some similarity, for example the diagnosis of AML is usually dependant on the level of 
blast cells as in the blood or bone marrow smears, however, the most important 
difference between the 2001 W HO system and FAB classifications for the diagnosis of 
this disorder was the lowering of the blast threshold from 30% to 20% in the PB or BM 
smears (Vardiman et al, 2002). According to the 2008 W HO classification, the name 
myeloid includes all granulocytic cells (neutrophil, eosinophil, basophil), 
monocytic/macrophage, erythoid, megakaryocytic and mast cell lineages, while the  
lymphoid malignancies include T-cell and B-cell lineages (Figure 1.1) (Vardiman, 2010). 
Moreover, within the updated W HO classification the definitions of some well- 
established disorders such as CLL, plasma cell neoplasm's and W aldenstrom  
macroglobulinemia (W M ) were improved (Morgan, 2003; Owen et al, 2003; Hallek et
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al, 2008; Vardiman, 2010) and tumour location and age groups, such as the elderly and 
children were linked to the incidence of certain types of leukaemia (Campo et al, 2011). 
Leukaemia classification is important to determine the cellular maturation degree and 
origin of the leukaemia cells from where they were originated which is an important 
tool to determine therapeutic choices and patient's survival.
However in this thesis the four main classification of leukaemia were used to describe 
the types of cells studied as most research studies related to leukaemia treatment are 
based on this classification and by using such classification we can identify stage of 
cellular maturation and the origin of the leukaemic cells. Within this thesis the 
classification system divides leukaemia into four large groups, including: acute, which 
is a rapidly progressing disease that results in the accumulation of immature cells in 
the bone marrow and blood, or Chronic, which progresses more slowly and allows 
partially mature cells to form. These can be either myeloid or lymphoid origin (Peacock, 
2000; Leukaemia & Lymphoma Research, 2012). If leukaemia begins in early forms of 
myeloid cells including red blood cells, platelets or white blood cells (but not T, B, 
lymphocytes, or NK cells) this is considered as myeloid leukaemia. Conversely, in 
lymphoblastic leukaemia the cancer starts in early form of lymphocytes in bone 
marrow. Therefore, there are generally four types of leukaemia commonly termed: 
AML, ALL, CML and CLL (Peacock, 2000). The first three of these types arise from HSCs 
whilst CLL is derived from mature B lymphocytes.
1.3.4 Leukaemia Treatment
The goal of current leukaemia treatments is to kill the leukaemic cells and allow 
normal cells to form in the BM. The treatment dependes on a number of factors such 
as histologic type of leukemia, its stage, and prognostic features (patient's age and 
overall health) (Appelbaum etal, 2006). Chemotherapy is the most common treatment 
for most types of leukaemia and their side effects vary depending on the type of 
therapy. Bone marrow transplantation is a relatively straightforward medical 
procedure. Diseased or damaged bone marrow can be replaced by donated bone 
marrow from healthy patient, which helps treat, and often cure, many serious, life- 
threatening conditions, including leukaemia (Laughlin et al, 2004). This choice of
leukaemia treatment provides a very high rate of success (Laughlin et al, 2004).
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Radiotherapy can be used as part of the preparation for BM transplantation to destroy 
the cancerous BM with the leukaemia cells using very high level of energy (Walch et al, 
2013). Radiation may also use as single therapy for different types of malignant 
diseases such as breast cancer (Radiation et al, 2006). In addition, growth factor 
treatments such as granulocyte colony stimulating factor (G-CSF) may be used to 
stimulate the BM to synthesis more blood cells to decrease the risk of infection that is 
generated as a result of low level of WBC following the chemotherapy (Dombret et al, 
1995; Lowenberg et al, 2003). The survival rate in patients with AML was about 9% 
higher following the treatment with chemotherapy plus G-CSF than patients who did 
not receive G-CSF (Lowenberg et al, 2003).
Targeted cancer therapy is a type of medical treatment designed to treat cancer by 
blocking the growth and spread of cancer by interfering with specific target molecules 
involved in tumour growth and progression rather than simply interfering with rapidly 
dividing cells (e.g. chemotherapy). Targeted therapies can cause cancer cell death by 
inducing apoptois or arresting cell cycle.
1.3.4.1 Targeting Apoptosis
To date, many of the crucial players in the system of apoptosis regulation are identified 
and can be targeted by therapeutic strategies which include Bcl-2 proteins, caspases, 
and death receptors. Therefore, identification of the major regulators increases 
research into developing therapeutic approaches to intervene either in a pro- or anti- 
apoptotic direction (Ghobrial et al, 2005). Another approach is to classify the agents as 
those that target the extrinsic pathway, intrinsic pathway, or the proteins regulating 
apoptosis (Ghobrial et al, 2005). In addition some drugs aimed to control apoptosis 
indirectly by targeting protein kinases, transcriptional factors, phosphatases, 
proteasomes and cell surface receptors (Ghobrial etal, 2005) (Table 1.5).
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Extrinsic pathway TRAIL DR4 and DR5 Havell et al, 1988
Monoclonal antibodies 
agonist to Dr4 and Dr5 
(HGS-ETR1, HGS-ETR2, 
and HGS-TR2J)
DR4 and DR5 Ghobrial et al, 2005
Intrinsic pathway Arensic trioxide Direct effect on the 
mitochondria inner 
membrane
Zangemeister- 
Wittke et al, 2000
Lonidamine Direct effect on the 
mitochondria inner 
membrane
Oudard et al, 2003
G31S9 Bcl-2 O'Brein et al, 2007
Antisense Bcl-xl Bcl-xl Zangemeister- 
Wittke et al, 2000
The common 
pathway
Apoptin Caspases Van der etal, 2002
Survivin IAP Zaffaroni and 
Diadone et al, 2000
Table 1.5: Apoptosis drugs targets
1.3.4.2 Targeting Cell Cycle
The cell cycle is a series o f events which allow the cell to grow and proliferate. 
Im portant parts of the cell cycle mechanism are the CDKs which, when activated, 
provide a means for the cell to  move from one phase of the cell cycle to the next 
(Section 1.1.2.1) (Schwartz and Shah 2005). The CDKs are regulated positively by 
cyclins and regulated negatively by naturally occurring CDKIs (Section 1.1.2.1.1 and 
1.1.2.1.2). Cancer is characterised by a dysregulation of the cell cycle such that cells 
overexpress cyclins or do not express CDKIs and thus, continue to undergo unregulated 
cell growth (Section 1.1.2.1). The cell cycle also works to protect the cell from DNA 
damage. Therefore, cell cycle arrest is a survival mechanism which gives the cancer 
cells the opportunity to repair their damaged DNA. Recently, in clinical trials are a 
series of targeted agents that directly in inhibit CDKs, inhibit unrestricted cell growth, 
and induce growth arrest (Schwartz and Shah 2005). In addition the aim of a number 
of studies has focused on these drugs as inhibitor transcriptions. A number of targeting  
cell cycle cancer therapies are summarise in table 1.6.
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Flavopiridol classified as CDKI because of its high 
affinity for CDKs and its ability to 
induce cell cycle arrest. It has been 
shown to inhibit CDKI, CDK2, CDK4, 
and CDK6.
Losiewicz et al, 1994; 
Carlson etal, 1996
UCN-01 Associated with Gi/S cell cycle arrest, 
associated with induction of 
p21CIP/Wafl, and desphosphorylation 
of CDK2.
Kawakami et al, 1996
CYC202 a potent inhibitory of CDK2 
Affect the cell cycle at Giand G2/M  
phases
NcClue et al, 2002
N-acyl-2-
aminothiazole analog
Is selective inhibitory for CDK2/cyclin E Shapiro et al, 2003
E7070 Targets the Gi phase of the cell cycle 
by depleting cyclin E and inducing p53 
and p21.
Terret et al, 2003
Imidazopyridines Is selective inhibitory for CDK2 Byth et al, 2003
Bryostatin-1 Produces transient induction of p21 
and subsequent dephsophrylation, 
inactivation of CDK2, and inhibition of 
tumour cell growth
Asiedu etal, 1995
Table 1.6: Cell cycle drugs targets
1.3.5 Complications associated w ith  common leukaemia therapy
1.3.5.1 Cancer recurrence
Recurrence o f cancer, Is when tum our comes back again commonly when the therapy  
is completed. Moreover, no signs or symptoms for the disease are seen during a period 
of weeks, months or years. In some types of tum our the recurrence is expected and 
considered as a part of the disease cycle such as CML (Kantarjian et al, 2002). 
Remission, a state in which no cancerous cells can be found in the body, can be either 
tem porary or permanent. Sometimes remission is temporary, and patients relapse and 
cancer recurs in the same place where the disease first began (primary site) or in 
different places in the body (secondary site). Unfortunately, the most frequent causes 
of treatm ent failure and drug resistance are associated with relapse w here curing the  
cancer becomes more difficult (Giralt et al, 1994; Leukaemia and Lymphoma Research, 
2013). Moreover, patient's survival after relapse is poor and ranges from  21% to 33%
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(Rubintz et al', 2006). The rate of complete remission (CR) is related to patient age, for 
example patients with AML younger than 60 years have remission rates of 60-80%  
(Lowenberg et al, 1999), whereas remission rates of 40-65% was seen in those 60 
years and older, who represent the majority of the AML population (Hiddemann et al, 
1999; Leopold et al, 2002). A number of studies have shown that combination 
therapies between two chemotherapies agents induced higher rates of CR, for 
example, more than 40% of patients with AML achieved a CR and long-term survival 
following the treatment with cytosine arabinoside and an anthracyclin (Juliusson et al,
2005).
1.3.5.2 Resistance to chemotherapy
Development of multidrug resistance (MDR) against anti-cancer drugs is a serious 
problem during the treatment of leukaemia and other cancers (Gottesman, 2002; 
Luqmani, 2008). Once MDR develops, using high doses of chemotherapy agents to 
overcome resistance is ineffective and my lead to further toxic effects and resistance 
are more stimulated (Ozben, 2006). Multidrug resistance severely limits the 
effectiveness and inhibits cytotoxic effects of chemotherapy in a number of common 
tumours and is responsible for the overall poor efficacy of cancer chemotherapy 
(Liscovitch et al, 2002; Akan et al, 2005). The resistance can be either acquired as a 
cellular response to drug exposure or inherited in some cancerous cells leading to 
altered target enzyme; increased drug degradation, decrease drug absorption and/ or 
enhanced DNA repair (Luqmani, 2008). Mutations within some vital genes such as p53 
(tumour suppression gene) have been reported to play an important role in multidrug 
resistance via inhibiting apoptotic production within tumour cells (Gottesman et al, 
2002).
1.3.5.3 Side effects
It is very common for patients to experience side effects as a direct result of cancer 
treatments. The occurrence of side effects following the anti-cancer agent treatment 
are varies depending on different factors such as patient's age, overall health, type of 
cancer, its size and how close the cancer to other important organ such as the brain 
(Cancer Research UK, 2013). However, there are a number of common side effects 
associated with the majority of chemotherapies including; nausea, sickness, vomiting,
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feeling weak, tiredness, hair loss, depression and Low white blood cell count (Cancer 
Research UK, 2013). In addition, high dose chemotherapy or radiotherapy is associated 
with ovarian failure and infertility as a result of ovarian damage following the 
treatment; however, this depends on patient's age and treatment protocol (Meirow 
and Nugent, 2001). Some side effects are serious medical conditions that need to be 
treated whereas; many side effects are inconvenient or upsetting but are not harmful 
to the patient's health and disappear when the treatment finished (Leukaemia and 
Lymphoma Research, 2013).
Because blood cancer treatments have become more aggressive during the last 20 
years (Redd et al, 2001), the need for new treatments for leukaemia to improve 
patient's health and reduce the side effects associated with such therapy has become 
essential.
1.4 Potential for Naturally Sourced Bioactive Compounds
1.4.1 Dietary compound overview
Cancer is a complex disease, in which there is genetic variability among not only 
different types of cancer but also among different patients with the same type of 
cancer, and even among different cells within same tumor. As a consequence, the 
targeting of a single molecular target for therapeutic purposes might not be sufficient 
to elicit the desired outcome. Different nutrients, specifically dietary botanicals, can 
play a role in the regulation of both normal and pathologic process (Aggarwal and 
Shishodia, 2006). An improved understanding of the regulatory role of these nutrients 
may help in the prevention and treatment of various cancers. For more than a decade, 
there has been considerable interest in the use of naturally occurring botanicals for 
prevention of disease including prevention of various cancers (Aggarwal and Shishodia,
2006). Several epidemiological studies have shown that high intake of fruit and 
vegetables are associated with low incidence of a number of human cancers 
(Neuhouser, 2004; Pavia et al, 2006; Boffetta et al, 2010; Key, 2010). Fruits and 
vegetables are excellent source of fibre, vitamins, and minerals, but they also contain 
bioactive compounds including polyphenols. Polyphenols are an integral part of human 
diet flavonoids and phenolic acids representing the majority of polyphenols present in 
fruits and vegetables such as pomegranate. These compounds have been shown to
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have anti-carcinogenic effects in vitro and in in vivo models by modulating im portant 
cellular and molecular mechanisms related to carcinogenesis such as modulation cell 
cycle and induction of apoptosis (Ahn et al, 2003; Brusselmans et al, 2003; Miyoshi et 
al, 2003; Roy et al, 2005; Hafeez et al, 2008; Zaini et al, 2011). Therefore, apoptotic 
induction and cell cycle arrest within tum our cells has become excellent targets for 
potential cancer treatm ents and are proposed to decrease mortality from malignancy 
(Paschka etal, 1998; Brady, 2003; Dorai and Aggarwal, 2004).
1.8.2 Targeting cell cycle
Disruption of the normal regulation of cell cycle progression and division are im portant 
events in the development o f cancer. For more than a decade, there has been 
significant interest in the use of naturally occurring botanical agents for the prevention 
of disease including preventing of cancers. Several dietary agents or nutrients have
been shown to affect the cell cycle regulation on the treatm ent o f cancer (Table 1.7).
Apigenin Cereals and G2/M  phase Human colon Wang et al,
herbs carcinoma cell lines 
(SW480, HT-29, and 
Caco-2)
2000
S phase Leukaemia cell lines 
(Jurkat and MOLT-3)
Mahbub et 
al, 2013
Go/Gi Leukaemia cell lines 
(HL-60 and CCRF- 
CEM)
Mahbub et 
al, 2013
Chrysin Passion Go/Gi Leukaemia cell lines Mahbub et
flowers (Jurkat, CCRF-CEM, 
THP-1, U937, KG-la, 
and K562)
al, 2013
Cis- Stilbene Go/Gi Leukaemia cell lines 
(Jurkat, CCRF-CEM, 
THP-1, and U937)
Mahbub et 
al, 2013
Acidic bogs Cranberry Gx phase Human breast 
cancer cells (MCF-7)
Sun and Liu, 
2006
Curcumin Turmeric, G2/M  and S Glioma cell line Liu et al,
curry and phase (U251) 2007
mustard
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Table (continued)
EGCG Green tea Gx phase Human Ovarian 
Carcinoma Cell 
Line(SKOV-3 and 
OVCAR-3)
Huh et al, 
2004
Ellagic acid Avocado, red
berries,
grapes,
strawberries,
raspberries
Gi phase Human bladder 
cancer Cells (T24) 
and cervical 
carcinoma (CaSki)
Li et al, 
2005; 
Narayanan 
et al, 1999.
Emodin Rhubarb G2/M  phase 
G0/G i phase
Human
promyelocytic 
leukaemia cells (HL- 
60)
Leukaemia cell lines 
(Jurkat, CCRF-CEM, 
and THP-1)
Chen et al, 
2004
Mahbub et 
al, 2013
Falcarinol Carrots S phase Leukaemia cell lines 
(CCRF-CEM and 
MOLT-3)
Zaini et al., 
2013
Flavones and 
flavonols
green tea, 
chocolate, red 
wine
G2/M  phase Human esophageal 
squamous 
carcinoma cell line 
(KYSE-510)
Zhang et al, 
2009
Gallic acid Guava,
geraniaceae
G2/M Human prostate 
carcinoma cell 
(DU145)
Agarwal (1) 
et al, 2006
Glycyrrhetinic
acid
Licorice root G0/G i phase Human hepatoma 
cell (HepG2)
Satomi et al, 
2005
Hydroxytyrosol Virgin olive oil Go/Gx phase Human
promyelocytic 
leukaemia cells (HL- 
60)
Fabiani etal, 
2002
Luteolin Celery and 
green pepper
G0/Gx phase Human colon cancer 
cell line (HT-29)
Lim et al, 
2007
Lycopene Tomatoes and
tomato
products
G2/M  phase Human prostate 
cancer cells (LCNaP)
Hwang and
Bowen,
2004
Parthenolide Feverfew Gq/G x Hepatocellular 
carcinoma lines 
(Hep3B, HepG2,)
Ralstin et al, 
2006
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Table (continued)
Proanthocyanidins Grape seeds Gx phase Human epidermoid Meeran and 
carcinoma (A431) Katiyar, 
2007
Quercetin Apple, onion, 
black and 
green tea and 
cranberry
S phase and 
G2/M  phase
Human acute 
lymphoblastic 
leukaemia T 
precursor (MOLT-4) 
and Human lung 
cancer cell line (NCI- 
H20
Mertens- 
Talcott and 
Percival, 
2005; Yang 
et al, 2006
Resveratroi grapes and 
red wine
S phase Human prostate 
cancer cells (LCNaP)
Benitez et al, 
2007
Rhubarb G0/G i phase 
S phase
Leukaemia cell lines 
(CCRF-CEM, MOLT- 
3, and HL-60 
Leukaemia cell lines 
(Jurkat and K562)
Mahbub et 
al, 2013
Mahbub et 
al, 2013
Silymarin/silibinin Plant 
flavonoid 
from milk 
thistle
G2/M  phase Human prostate 
carcinoma cell 
(DU145)
Deep and 
Agarwal (2), 
2006
Sulforaphane Cauliflower, 
broccoli, and 
Brussels 
sprouts
M phase Human pancreatic 
cancer cell lines 
(MIA PaCa-2 and 
PANC-1)
Pham et al, 
2004
Tannic acid Oak park and 
leaves
G0/G i phase Human leukaemia 
cell (Jurkat)
Nam et al, 
2001
Table 1.7: Effect of Natural dietary bioactive compounds on cell cycle
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1.8.3 Targeting apoptotic cell death
Apoptosis helps to  establish a natural balance between cell death and cell renewal in 
mature animals by destroying excess, damaged, or abnormal cells. However, the  
balance between survival and apoptosis often tips towards the form er in cancer cells. 
Dis-regulation in pro-apoptotic or anti-apoptotic proteins can inhibit the apoptotic 
process and allow cells to proliferate. Leukaemia cells could cause this imbalance and 
evade apoptosis though numerous mechanisms (see section 1.2.1) (Lessene et al, 
2008; Hanahan & Weinberg, 2011). Several naturally occurring bioactive chemicals 
have been shown to induce apoptosis (Table 1.8) though both intrinsic and extrinsic 
pathways (Vermeulen eta l, 2005; Khan (1) eta l, 2006).
Apigenin Plant Breast cancer Induced apoptosis, Choi and Kim,
seeds cells (MDA- triggered caspase 2009; Chung
fruits and 
vegetables
MB453, SK-BR-3)
Colon cancer 
cells (HT-29,
APC, HT-29-GAL)
Prostate cancer 
cells (22Rvl, PC- 
3)
activation.
Release cytochrome c, up- 
regulation Bax
Induced apoptosis, 
decrease levels of Bcl-xl, 
Bcl-2
et al, 2007.
Choi and Kim, 
2009; Shukla 
and Gupta, 
2008
Choi and Kim, 
2009; Shukla 
and Gupta, 
2008
Acidic bogs Cranberry Human breast 
cancer cells 
(MCF-7)
Cell cycle arrest and 
apoptosis
Sun and Liu, 
2006
Chrysin Passion
flowers,
Rhubarb
Leukaemia cell 
lines (Jurkat, 
CCRF-CEM, THP- 
1, U937, KG-la, 
and K562)
Induced apoptosis Mahbub et al, 
2013
Curcumin Turmeric, Lung cancer cell Induce Bax, inhibit NF-KB Dorai and
curry,
mustard
line (H1299) and activation of caspases Aggarwal, 
2004; Phillai 
et al, 2004
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Table (continued)
Capsaicin Red
peppers
Breast cancer 
cells (MCF-7, 
SKBR-3, MDA- 
MB231) and
Induced apoptosis, Thoennissen 
et al, 2010, 
Chou et al, 
2009.
Colon cancer 
cells (HCT116, 
HT-29, 
Colo320DM)
Induced apoptosis via 
Reactive oxygen species 
(ROS) generation, activated 
caspase-3
Sanchez et al, 
2007, Yang et 
al, 2009.
Daidzein Soybean Breast cancer 
cells (MCF-7, 
MDA-MB-453)
Down-regulation of Bcl-2, 
up-regulation of Bax, and 
release of cytochrome C 
from the mitochondria into 
the cytosol, Activation 
caspase-3,-9,-7
Jin etal, 
2010; Hsu et 
al, 2010; Choi 
and Kim, 
2008
Colon cancer 
cells (Lovo)
Release Cytochrome c
Jin et al, 2010
Prostate cancer 
cells (LnCap, 
PC3)
Induced apoptosis
Choi and Kim, 
2008; Guo et 
al, 2004
Delphinidin Strawberry
and
pomegran
ate
Human prostate 
cancer cells 
(PC3)
Activation of caspases, 
increase in Bax, decrease in 
Bcl-2, nuclear 
condensation and 
fragmentation.
Lazze et al, 
2004; Hafeez 
et al, 2008
EGCG Green tea Cervical cancer 
cell line (CaSki) 
Human cervical 
cancer cell line 
(HeLa)
Induced apoptosis by 
TRAIL sensitization
Ahn et al, 
2003;
Brusselmans 
et al, 2003; 
Zou et al, 
2010
Falcarinol Carrots Leukaemia cell 
lines (CCRF CEM 
and MOLT-3)
Induced apoptosis, 
increase caspase 3,8 and 9 
activity, release 
cytochrome c from 
mitochondria
Zaini et al, 
2013
Flavones Green tea, 
chocolate, 
red wine
Human 
esophageal 
squamous cell 
carcinoma cell 
line (KYSE-510)
Cleavage of caspase-9 and 
caspase-3
Zhang et al, 
2009
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Table (continued)
Flavonols Green tea, 
chocolate, 
red wine
Human 
esophageal 
squamous cell 
carcinoma cell 
line (KYSE-510)
Cleavage of caspase-9 and 
caspase-3
Zhang etal, 
2009
Gingerol Ginger Human T 
lymphoma cells 
(Jurkat)
Release of cytochrome C 
from mitochondria, 
down regulation of Bcl-2 
and enhancement of Bax.
Miyoshi et al, 
2003
Genistein Soy beans, 
Chickpea
Breast cancer 
(MDA-MB-231, 
MCF-7) and 
colon cancer 
(SW480, HT-29)
Induced apoptosis, induced 
caspase-3 activity, 
increased cytochrome c 
release; down-regulation 
of Bcl-2 and up regulation 
of Bax
Hsu et al, 
2010; Li et al, 
2008; Ferene 
et al, 2010
Rhubarb Leukaemia cell 
lines (CCRF-CEM, 
MOLT-3, and HL- 
60)
Induced apoptosis Mahbub et al, 
2013
Liquiritigenin Licorice Human cervical 
cancer cell line 
(HeLa)
Up-regulation of p53 and 
Bax, along with down- 
regulation of Bcl-2 and 
survivin.
Liu etal, 
2010
Luteolin Tea, fruits, 
vegetables 
, celery,
Colon cancer 
cells (HT-29, 
HCT116)
Induced apoptosis Do Lim et al, 
2007; Chiu 
and Lin, 2008
Lycopene Tomatoes
and
tomato
products
Breast cancer 
cells (MCF-7 and 
MDA-MB-231)
Induced apoptosis, down- 
regulation of Bcl-2, up 
regulation of Bax
Wan and 
Zhang; 2007 
Chalabi et al, 
2006;
lycopene 
phytocomple 
x (LycoC)
Tomatoes
and
tomato
products
Human
promyelocytic 
leukaemia cells 
(HL-60)
Loss of mitochondrial 
transmembrane potential
Ettore et al, 
2010
Quercetin Apple, 
onion, 
black and 
green tea  
and
cranberry
Human lung 
cancer cell line 
(NCI-H209)
Decrease of the 
mitochondrial membrane 
potential, release of 
cytochrome C, up- 
regulation of Bax, down- 
regulation of Bcl-2
Yang et al, 
2006
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Table (continued)
Resveratrol Grapes Human 
pancreatic 
cancer cells 
(PANC-1 and 
AsPC-1). 
Human breast 
cancer cell line 
(MCF-7)
Induced apoptosis by TRAIL 
sensitization and release of 
cytochrome C from 
mitochondria, activation of 
caspases, and induction of 
p53-dependent 
transcriptional activation.
Clement et 
al,, 1998& 
Ding and 
Adrian, 2002; 
Pozo-Guisado 
et al, 2005
Sulforaphane Cauliflowe 
r, broccoli, 
and
Brussels
sprouts
Transformed 
mouse (SV40-)
Increase in the protein 
levels of both Bax and Bak
Choi and 
singh, 2005
Table 1.8: Effect of natural dietary bioactive compounds on induction of apoptosis.
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1.9 Aim and objective:
The aim of this study was to test the hypothesis that extracts from pomegranate 
contain bioactive compounds with strong anti-proliferative effects, and induce 
apoptosis in human leukaemia cell lines. The specific objectives for this study were to:
A) Investigate the effect of whole PJ on human myeloid and lymphoid leukaemia cell 
lines and non-tumour control cells in terms of induction of apoptosis and inhibition of 
cell cycle.
B) Identify active compounds within PJ which are inducers of apoptosis and/or 
inhibitors of cell cycle.
63
2. Standard Materials and Methods
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2.1  P rep ara tio n  o f P o m eg ran ate  Juice Extracts (PJ)
Fresh pomegranates were purchased from Sainsbury's (Sainsbury's, Sheffield, UK)
which were originally cultivated in India. Pomegranates were washed, peeled and 
edible parts separated from the pith. Edible parts were juiced using a pulp ejector 
juicer (L'EQUIP). The pomegranate juice extract (PJ) was then centrifuge at 1000 g for 
35 minutes and filtered though 0.22pm  sterile syringe filters (Invitrogen, Paisley, UK) to  
remove any fibre. The filtered juice was stored at -80°C. Before treatm ent PJ was 
diluted (1:1) with complete media and recentrifuged at lOOOg for 15 minutes to  
remove any precipitate.
2 .2  Cell lines and C ulture
2.2.1 Cell Lines
In this study, four human lymphoid cell lines; CCRF-CEM (Table: 2.1), SUP-B15 (Table: 
2.2), MOLT-3 (Table: 2.3), Jurkat (Table: 2.4) and four myeloid human leukaemia cell 
lines; HL-60 (Table: 2.5), KG la  (Table: 2.6), THP-1 (Table: 2.7), and K562 (Table: 2.8) 
together with non-tumour CD133 positive haematopoietic stem cells (Table: 2.9) 
(LONZA) were used.
Organism: Homo sapiens (Human)
Organ: Peripheral blood
Disease: Acute lymphoblastic leukaemia
Morphology Lymphoblast
Cell type: T lymphoblast
Tumour source: Primary
Age: 4 years juvenile
Gender Female
Growth properties Suspension
Expression of p53: Null
Comment: CCRF-CEM is a lymphoblast cell line derived by G.E. Foley, et al. 
Cells were derived from peripheral blood buffy coat of a child 
(CEM) with acute lymphoblastic leukaemia who had originally 
presented with lymphosacroma in 1964 (Foley et al, 1965).
Table 2.1: CCRF-CEM cell line description. LGC Standards, 2013.
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Organism: Homo sapiens (Human)
Organ: Bone marrow
Disease: Acute lymphoblastic leukaemia
Morphology Lymphoblast
Cell type: B lymphoblast
Tumour source: Primary
Age: 8 years
Gender Male
Growth properties Suspension
Expression of p53: Null
Comment: SUP-B15 cell line was derived from malignant cells collected from 
a bone marrow of an 8 year old child with Philadelphia 
chromosome positive B cell ALL. The cells express multiple B 
linage markers, but do not express T cell marker (Fainstein. et al, 
1987).
Table 2.2: SUP-B15 cell line description. LGC Standards, 2013.
Organism: Homo sapiens (Human)
Organ: Peripheral blood
Disease: Acute lymphoblastic leukaemia
Morphology Lymphoblast
Cell type: T lymphoblast
Tumour source: Primary
Age: 19 years
Gender Male
Growth properties Suspension
Expression of p53: Wild
comment: MOLT-3 was derived from the same patient as the MOLT- 
4 cell line (ATCC: CRL-152). The MOLT-4 cell line was 
established from cells taken from a patient in relapse 
who had received multidrug chemotherapy (Minowada et 
al, 1972).
Table 2.3:MOLT-3 cell line description. LGC Standards, 2013.
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Organism: Homo sapiens (Human)
Organ: Peripheral blood
Disease: Acute T cell leukaemia
Morphology Lymphoblast
Cell type: T lymphocyte
Age: 14 years
Gender Male
Growth properties Suspension
Doubling time 24 h
Expression of p53: Null
comment: This is a clone of the Jurkat-FHCRC cell line, a derivative of Jurkat 
cell line. The Jurkat cell line was established from the peripheral 
blood of a 14 year old boy by Schneider, et al (1972) and was 
originally designated JM (Schneider et al, 1977).
Table 2.4: Jurkat cell line description. LGC Standards, 2013.
Organism: Homo sapiens (Human)
Organ: Peripheral blood
Disease: Acute promyelocytic leukaemia
Morphology Myeloblastic
Cell type: Promyeloblast
Tumour source: Primary
Age: 36 years
Gender Female
Growth properties Suspension
Expression of p53: Null
Comments HL-60 is a promyelocytic cell line derived by 
Collins, et al. (1978). HL-60 cells 
spontaneously differentiate.
Table 2.5: HL-60 cell line description. LGC Standards, 2013.
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Organism Homo sapiens (Human)
Organ Bone marow
Disease Acute myelongenous leukaemia
Morphology Myeloblast
Age: 59 years
Gender: Male
Growth properties: Suspension
Expression of p53: Null
Comment: The KG-la cell line is derived from the KG- 
1(ATCC: CCL-246) and is almost identical. The 
variant subline was isolated by Koeffler et al, 
1980 and was composed of undifferentiated 
promyeloblast
Table 2.6: KG-la cell line description. LGC Standards, 2013.
H H H H H H H H H IIH H flH H i
Organism: Homo sapiens (Human)
Organ: Peripheral blood
Disease: Acute monocytic leukaemia
Morphology Monocyte
Cell type: Monocyte
Tumour source: Primary
Age: 1 year infant
Gender Male
Growth properties Suspension
Doubling time Approximately 26 hr
Expression of p53: Null
Comment: THP-1 cells are phagocytic and have Fc and 
C3b receptors and lack surface and 
cytoplasmic immunoglobins (Tsuchiya etal, 
1980, Skubitz et al, 1983).
Table 2.7 THP-1 cell line description. LGC Standards, 2013.
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Organism: Homo sapiens (Human)
Organ: Bone marrow
Disease: Chronic myelongenous leukaemia (CML)
Morphology lymphoblast
Cell type: B lymphoblast
Tumour source: Primary
Age: 53 years
Gender Female
Ethnicity: Caucasian
Comment: K562 established from pleural effusion of 53 
year old female with chronic myelongenous 
leukaemia (Lozzio, 1975). Studies have shown 
the K562 blasts are multipotential, 
hematopoietic malignant cells that 
spontaneously differentiate into recognisable 
progenitors of the erythrocyte, granulocyte 
and monocytic series Andersson et al, 1979).
Table 2.8: K562 cell line description. LGC Standards, 2013.
Organism: Homo sapiens (Human)
Organ: Bone marrow, cord blood, and fetal liver
Disease: Normal
Cell type: Haematopoietic stem cell
Cell source: Primary
Growth properties Suspension
Comment: These cells were used as a control population of non- 
carcinogenic primary cells to investigate the effects on 
hematopoietic stem cells, which are often the cell types 
affected by leukaemia therapies.
Table 2.9: CD133 cell line description. Lonza, 2013.
2.2.2 Culture
All cells were cultured in 75cm2 flasks (Invitrogen, Paisley, UK) at a density o f 2 x 106 
cells/ml in RPMI 1640 medium (Invitrogen) supplemented with 10% (v/v) foetal bovine 
serum, 1.5 m M Glutamine and lOOpg/ml penicillin/streptomycin (complete RPMI) and 
incubated at 37°C in a 5% C 02atmosphere. Cultures were maintained by the addition 
of fresh complete RPMI every 2 to 3 days.
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2.2.3 Mycoplasma Testing
Mycoplasma are a class of Mollicutes that represent a large group of specialized 
bacteria, which are characterized by their lack of rigid cell wall. Mycoplasma are small 
and flexible, which make them able to pass though conventional microbiological filters 
(0.2 pM). Mycoplasma compete with the cells for the nutrients in culture media which 
results in reduction in the rate of cell proliferation and changes in cellular responses 
including gene expression (Drexler et al, 2002). The degree of infection is varied and 
depends on the mycoplasm species, cell type and culture condition (Dvorakova et al, 
2005).
Here, the MycoAlert™ assay (Lonza) was used to ensure cultures were mycoplasma 
negative every two months. MycoAlert™ assay is a selective biochemical assay that 
exploits the activity of certain mycoplasma enzymes. The presence of these enzymes 
allows a rapid screening procedure which provides sensitive detection of 
contaminating mycoplasma in a test sample. The viable mycoplasma are lysed and the 
enzymes react with MycoAlert™ substrate catalyzing the conversion of adenosine 
diphosphate ADP to adenosine triphosphate ATP. The presence or absence of 
mycoplasma can be detected by measuring the level of ATP in a sample both before 
and after the addition of MycoAlert™ substrate. If no mycoplasma enzymes are 
present the second reading shows no increase for the first reading, in contrast reaction 
of mycoplasma enzymes with their specific substrate in the MycoAlert™ substrate 
causes raised ATP levels. The ATP is detected via a bioluminescent reaction (Figure 2.1). 
The light intensity emitted is directly proportional to the ATP concentration and was 
measured using a luminometer.
Luciferase
ATP + Luciferin + 02 ,------ — - r  Oxyluciferin+ AMP + PP, + C02 + LIGHT
Mg2*
Figure 2.1: Luminescent reaction to detect ATP in mycoplasma test. Modified from Promega.
70
2.2.3.1 Methodology
MycoAlert™ reagent and MycoAlert™ substrate were reconstituted in MycoAlert™ 
assay buffer. Two millilitres of cell culture supernatant of each tested sample was 
transferred into a centrifuge tube, and spun at 400 g for 5 minutes. One hundred 
microlitres of cleared supernatant was transferred into white 96 well plates (Fisher 
Scientific), and 100 pi MycoAlert™ reagent was added to each sample and incubated 
for 5 minutes at room temperature Following incubation time the plate was placed in 
a Wallac Victor 2 1420 luminescence detector to measure luminescence (Reading A). 
Finally 100 pi of MycoAlert™ substrate was added to each sample and incubated for a 
further 10 minutes before remeasuring the luminescence using the Wallac Victor 2 
1420 luminescence detector (Reading B). This shows the increased to determine 
increased detection of ATP (Reading B).
2.2.3.2 Analysis
The ratio was calculated for each well using a luminometer reading A (before adding 
the MycoAlert™ Substrate) and luminometer reading B (after adding the MycoAlert™ 
Substrate). The increase in ATP levels over 10 minutes were calculated using the 
following equation
R^o
Reading B
All cultures were negative for mycoplasma for the full duration of the project.
2.3 Assays of Cell Proliferation
2.3.1 Trypan Blue Exclusion Assay
Trypan blue exclusion assay was used to quantify the number of live and dead cells in 
suspension culture (Strober, 2001). Trypan blue is a vital dye which is only able to 
enter dead cells, staining them blue. Live cells have an intact cell membrane; therefore 
do not take in the dye from surrounding medium. In contrast dead cells do not have an 
intact and functional membrane and therefore do take up the dye from their 
surroundings. This results in the ability to easily distinguish between live and dead cells 
(Strober, 2001).
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Here the countess™ automated cell counter (Invitrogen) was used which uses state of 
the art optics and image analysis to autom ate cell counting. The countess™ autom ated  
cell counter is used to determ ine cell count and viability (live, dead and total cells) 
following trypan blue staining technique.
2.3.1.1 Methods
Following treatm ents, suspended cells were mixed to minimize clumping o f the cells. 
Then cell suspension was mixed 1:1 with 0.4% trypan blue solution (Sigma) and 
incubated at room tem perature for 5 minutes. Following incubation 10 pi of stained 
cells was added into the countess™ chamber slide. Then the countess™ chamber slide 
was inserted into the instrument and the image of cells was adjusted to  focus for 
analysis.
2.3.1.2 .Analysis
Live cells have bright centres and dark edges and dead cells have a uniform blue colour 
throughout the cell with no bright centre. The average number of live and dead cells 
was calculated and all treated samples were normalized to controls (Figure 2.2).
9
o
O *
*
Figure 2.2: Cell countess analysis image comparing live and dead cells. Live cells: have bright 
centres and dark edges. Dead cells: have a uniform blue colour throughout the cell with no 
bright centre.
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2.3.1.3 Statistical Analysis
Data are presented as the mean ± SEM and were analyzed by Stats Direct using a 
Shapiro W ilke test to  check for normality. Data were shown to be non-parametric, and 
thus a Kruskal-Wallis and Connover-lnman post-hoc test was used to  test for 
significance. P < 0.05 was considered significant.
2.3.2 CellTiter-Glo°Luminescent Cell V iability Assay
The nucleotide adenosine triphosphate (ATP) is the primary energy source for all 
metabolic reactions and is found in all intact cells. It serves as a tool for the functional 
integrity of living cells as all cells need ATP to remain alive and carry out their 
specialized functions (Crouch et al, 1993). Interruption o f cellular processes due to 
chemical effects, cell injury and physical damage, or depletion o f essential nutrients or 
oxygen results in a decrease in ATP levels (M atthew  et al, 2009, Crouch et al, 1984). 
Therefore measurement of ATP is essential to the study of cell viability. The use of ATP 
bioluminescence to measure cell proliferation has been shown with leukaemic cell 
lines (MOLT-4 and HL-60) where significant correlations between increased cell 
number and ATP levels w ere observed (Crouch et al, 1993).
The CeHTiter-Glo\um inescent Cell Viability Assay (Promega) is a homogeneous 
method used to identify the number of live cells in culture based on quantification of 
the level of ATP present that signals the presence of metabolically active cells. The 
homogeneous form at results in cell lysis and generation of a luminescent signal 
proportional to the amount of ATP present (Kangas et al, 1984). The am ount of ATP is 
directly proportional to the number of cells. The CellTiter-Glo*Luminescent Cell 
Viability Assay relies on the production o f light caused by the reaction o f ATP with  
luciferase. The em itted light is proportional to ATP concentration inside the cell. The 
luciferase reaction is summarized in figure 2.3.
Luciferase
ATP + Luciferin + 0 , > Oxyluciferin + AMP + PP, + CO, + LIGHT
Mg2*
Figure 2.3: The luciferase reaction. Mono-oxygenation of luciferin is catalyzed by luciferase in 
the presence of Mg2+, ATP and molecular oxygen. Modified d from Promega.
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2.3.2.1 Methods
Ten millimetres of CellTiter-Glo*Buffer was transferred to the bottle containing 
CellTiter-Glo*Substrate to reconstitute the lyophilized enzyme/substrate mixture which 
forms the CellTiter-Glo® Reagent. Then the reagent was mixed by gently vortexing for 
10 minutes. Following treatment, cell culture white-96 well plate and its contents were 
equilibrated at room temperature for 30 minutes. A hundred microliters of Cell Titer- 
Glo® Reagent was added to each well, mixed well for 2 minutes on an orbital shaker at 
400 rpm to induce cell lysis. The plate was allowed to incubate at RT for 10 minutes 
prior to luminescence detection using the Wallac 1420 luminescence detector 
(PerkinElmer, Waltham, USA). Control wells were prepared containing medium and 
treatments without cells to obtain a value for background luminescence.
2.3.2.2 Analysis
Background readings were subtracted from all test measurements. The average from 
the luminescence readings was calculated and all treated samples were normalized to 
controls.
2.3.2.3 Statistical Analysis
Averages and Standard error of the means (SEM) were calculated and Stats Direct was 
used to test whether data followed a normal distribution using a Shapiro Wilke test. As 
the data did not follow a normal distribution, a Kruskal-Wallis and Connover-lnman 
post hoc tests were used to investigate significant differences. Results were considered 
statistically significant when P < 0.05.
2.3.3 MTS Assay
The CellTiter 96*Aqueous One solution Cell Proliferation Assay (Promega) is a 
colourmetric method for determining the number of live cells in proliferation assays. 
The celltiter 96*Aqueous One Solution Reagent contains a novel tetrazolium 
compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-arboxymethoxyphenyl)-2-(4-sulfophenyl)- 
2H-tetrazolium, inner salt; MTS] and electron coupling reagent (phenazineethosulfate; 
PES). PES has enhanced chemical stability, which allows it to be combined with MTS to 
form a stable solution. The MTS tetrazolium compound is bioreduced by cells into a 
coloured formazan product that is soluble in culture medium (Figure 2.4). This 
conversion is presumably accomplished by NADH or NADH produced by
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dehydrogenase enzymes in metabolically active cells. The quantity of formazan is 
directly proportional to the number of living cells in culture.
2.3.3.1 Methodology
Following treatment, 20 pi of CellTiter 96*Aqueous One Solution Reagent was 
pippetted into each well of the 96 well plate containing the samples in 100 pi of 
culture medium. The plate was allowed to incubate at 37°C for 2 hours in a humidified, 
5% C02 atmosphere prior to recording absorbance at 490nm using Wallac 1420 
colourmetric detector. Control wells were prepared containing medium without cells 
to obtain a value for background.
2.3.3.2 Analysis
The absorption values for the background readings in the wells with complete medium 
were subtracted from the control and treated samples. Then the average for control 
and treated cells was calculated and the result of treated samples was normalized to 
the average of control cells.
2.3.3.3 Statistical Analysis
Average and Standard error of the mean (SEM) was calculated and Stats Direct was 
used to test whether data followed a normal distribution using a Shapiro Wilke test. 
Data did not follow a normal distribution, thus Kruskal-Wallis and Connover-lnman 
post-hoc tests were used to investigate significant differences. Results were 
considered statistically significant when P < 0.05.
Here, results of cell viability using trypan blue exclusion assay and CellTiter- 
Glo*Luminescent Cell Viability Assay were shown to be more reliable. CellTiter- 
Glo*Luminescent Cell Viability Assay required only few minutes to generate a 
measurable signal and providing an advantage over MTS assay that requires 2 h 
incubation to develop a signal. CellTiter-Glo*Luminescent Cell Viability Assay was also 
more suitable enumerating low cell counts due to high sensitivity. In addition the MTS 
assay showed high background levels, which may have been due to the fact that most 
of compounds used here were coloured and interfere in the assay (Table 2.10).
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5 minutes 10 minutes 2 h
Cell counting ATP MTS reduction
lx lO 4 cells/ml 50 cells in a 96 well plate 800 cells in a 96 well plate
Optics and image 
analysis luminescence Colourmetric
Table 2.10: Comparison of cell proliferation assay; Trypan blue exclusion assay, CellTiter- 
Glo*Luminescent Cell Viability Assay and CellTiter 96*Aqueous One solution Cell Proliferation 
Assay.
2.4 Assays of Apoptosis
2.4.1 Annexin V /P I FITC Flow Cytom etry Assay
The asymmetric distribution of plasma membrane phospholipids between inner and 
outer leaflets is a characteristic feature of healthy cells. Under physiological conditions, 
choline phospholipids (phosphotidylcholine, sphingomyelin) are exposed on the  
external surface of the plasma membrane while amino phospholipids 
(phosphatidylserine, phosphatidylethanolamine) are located on the internal surface of 
plasma m embrane (Fadok et al, 1992, Koopman et al, 1994, van Engeland et al, 1998). 
During apoptosis the membrane phospholipid phosphatidylserine (PS) translocates to 
the outside leaflet of the membrane. Exposition of PS to the external cellular 
environment provides signals to macrophages, which then become attracted and 
initiate phagocytosis of the apoptotic cells (Figure 2.5).
Since detection of exposed PS provides an early quantification o f apoptosis, here 
fluorochome-tagged 36-kDa anticoagulant protein Annexin V was used. Annexin V is a 
35-36 kDa Ca2+ dependent phospholipids-binding protein which has a high affinity to  
bind to cells with exposed PS (van Engeland et al, 1998). Annexin V conjugated to  
fluorochomes including FITC, which retains its high affinity for PS and thus serves as a 
sensitive probe for flow  cytometric analysis o f apoptotic cells. Annexin V-FITC staining 
can identify apoptosis at earlier stages of apoptosis when PS is exposed on the external 
surface of plasma membrane. Annexin V-FITC staining precedes the loss o f membrane
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integrity that accompanies the latest stages of cell death resulting from either 
apoptosis or necrosis. Thus, here Annexin V-FITC (Beckton-Dickinson) was used in 
conjunction with propidium iodide (PI) (Sigma), a plasma membrane permeability 
marker, to distinguish between live, early apoptotic, late apoptotic and dead cells 
(Figure 2.5). Viable cells have minimal Annexin V and PI fluorescence. Cells that are in 
an early stage of apoptosis stain brightly with Annexin V-FITC but exclude PI. Finally, 
cells that are in late stages of apoptosis or are already dead stain intensely with both 
markers (Figure 2.4).
2.4.1.1 Methodology
Following treatment, cells were harvested into 1.5 ml Eppendorf tubes and centrifuged 
at 400 g, 4°C for 5 min. Supernatant was removed and cells washed once in 100 pi cold 
Dulbecco's phosphate buffered saline (DPBS) (Invitrogen). Following washing, 
supernatant was removed and cells resuspended in 100 pi binding buffer (BB) (10 mM 
HEPES/NaOH, pH7.4, 140 mM NaCI, 2.5 mMCaCI2) (Beckton-Dickinson). After washing 
with BB twice, cells were resuspended in 50 pi of BB and 5 pi of Annexin V-FITC. Cells 
were gently mixed and incubated for 15 min in the dark. Labelled cells were 
transferred to FACS tubes, and 300 pi of PI (50pg/ml) (Sigma)) was added and mixed 
gently; samples were then read directly on the flow cytometer (FACS Calibur 
cytometer (Becton-Dickinson, UK)) measuring fluorescence for FITC and PI. Control 
samples (unstained cells, cells stained with Annexin V-FITC only and cells stained with 
PI only) were prepared within each experiment to set up compensation and quadrants.
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Plasma
membrane
Phosphotedylserine
Figure 2.4: Schematic representation of phospholipid phosphatidylserine (PS) translocate to 
outside leaflet of the membrane
2.4.1.2 Analysis
Data were recorded from 10,000 cells per sample and analyzed using FlowJo software 
(Tree Star, Ashland, OR). A dot plot was used to  provide a tw o -p aram eter display of 
FITC and PI. Control samples (unstained cells, cells stained with Annexin V-FITC only 
and cells stained with PI only) were prepared within each experim ent to  set up 
compensation and quadrants makers. Quadrant markers were applied to distinguish 
populations that are considered negative, single positive, or double positive. The dot 
plot in Figure 2.6 shows the lower left quadrant (live cells) displays events that are 
negative for both annexin V and PI. The lower right quadrant (early apoptotic cells) 
contains events that are positive for the Annexin V but negative for the PI. The upper- 
right quadrant (late apoptotic and dead cells) contains events that are positive for both 
annexin V-FITC and PI (Figure 2.5).
Nucleus
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Figure 2.5: Flow cytometry analysis of Annexin V-FITC/PI. Live cells (lower left quadrant) are 
Annexin V and PI negative, early apoptotic cell (lower right quadrant) are Annexin V-FITC 
positive and PI negative and cells that are in late apoptosis or already (uper right quadrant) 
dead are both Annexin V-FITC and PI postive.
2.4.1.3 Statistics
Data was presented as the means ± SEM and were analyzed by Stats Direct using 
Shapiro Wilke test to check for normality. Data was shown to be non-parametric, and 
thus a Kruskal-Wallis and Connover-lnman post hoc test was used to  test for 
significance. P < 0.05 was considered significant.
2.4.2 DAPI Staining
Apoptotic cells can be distinguished from healthy and necrotic cells by classic 
morphological changes which are an im portant tool in apoptosis research. These 
features include cell shrinkage, membrane blebbing, chromatin condensation and 
nuclear fragmentation (Kerr et al, 1972, Wyllie et al, 1980, Galluzi et al, 2007). Such 
features can be observed under a fluorescence microscope using a DNA specific dye.
Here 4, 6-Diamidino-2-phenylindole (DAPI) was used. DAPI (Sigma) nucleic acid stain 
preferentially stains dsDNA; strongly binding to AT clusters in the minor groove 
(Gonzalez-Juanatey et al, 2004). Binding of DAPI stain to dsDNA results in 
approximately 20-fold increase in fluorescence, due to displacement o f w ater
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molecules from both DAPI and the minor groove (Barcellona et al, 1990). However the 
DAPI stain is not completely permeable, thus cells must be fixed and permabilised to 
enable it to pass through normal cell membranes and the blue fluorescence is then 
observed by fluorescent microscope via excitation by UV light at 350 nm. In cells 
undergoing apoptosis, the DNA has condensed and thus apoptotic nuclei will produce 
higher fluorescence intensity than live cells.
2.4.2.1 Methodology
Following treatment, cells were transferred to Eppendorf tubes, and centrifuged for 5 
min at 400 g, at 4°C. The cells were then washed twice in 100 fj\ of cold DPBS. Cells 
were then resuspended in 100 /d of 4% (v/v) paraformaldehyde/DPBS for 10 minutes. 
Following fixation, cells were transferred to slides via a 20-min cytospin at 1,000 rpm 
(Shandon Cytospin 3 Centrifuge). Slides were then dried at room temperature and 
lOOjd of DAPI stain (10 pg/ml) (Sigma) applied to cells for 10 min in the dark at room 
temperature. Excess DAPI stain was removed and slides mounted in 90% glycerol and 
coverslips applied and sealed with nail varnish. An Olympus BX60 fluorescence 
microscope was used to assess the morphology of cell nuclei using UV light at 
excitation wavelength of 350 nm.
2.4.2.2 Analysis
Quantitative analysis of cell populations was performed based on counting of 200 
randomly-selected cells and the percentage of apoptotic features determined for each 
sample. DAPI nuclear morphological analysis demonstrated apoptotic cells with 
irregular edges around the nucleus, intense staining, and chromatin concentration in 
the nucleus and an increased number of nuclear body fragments in late apoptotic cells. 
Live cells demonstrated clear-edged, round and uniformly stained with DAPI (Figure 
2.6).
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Figure 2.6: Analysis of apoptosis of HL-60 cell line using DAPI staining. Live cells are indicated 
by the green arrows, and apoptotic cells are indicated by the red arrows.
2.4.3 Caspase-3 Activity
Caspase-3 activation plays a central role during the apoptotic process. Caspase 3 is 
expressed by most leukaemic cells as a 32kDa proenzyme (Estrov et al, 1998). In 
response to several stimuli, caspase-3 is cleaved and generates tw o subunits o f 17 and 
12 kDa that fit together in a double heterodim er showing activity (Nicholson et al, 
1995). This enzyme is activated by caspase-8 and caspase-9 and serves a convergence 
point for different signalling pathways. The active enzyme cleaves and activates other 
caspases such as caspase-6 and-7 as well as other targets such as nuclear enzyme poly 
ADP-ribose polymerase (PARP) and DNA fragmentation factor (DFF) (Fernandes- 
Alnemri et al, 1994). Because active caspase 3 is considered as a common effector in 
several apoptotic pathways, it can be a good marker to detect early apoptotic cells.
Here, the DEVD-NucView™ 488 caspase-3 substrate (Cambrige Bioscience) was used 
which is a fluorescence probe that allows detection of caspase-3 activity in living cells 
in real tim e. NucView 488 DNA dye is attached to  caspase-3 substrate peptide 
sequence DEVD. W hen linked to the substrate peptide, the dye is unable to  bind to  
DNA and remains non-fluorescent. The substrate crosses the plasma m em brane to
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enter the cytoplasm, where it can be cleaved by caspase-3 to  release the high affinity 
DNA dye that migrates to the cell nucleus to stain the nucleus with bright green 
fluorescence (Figure 2.7).
DEVD
Figure 2.7: Schematic showing the principle of intracellular caspase-3 detection using 
NucView™ 488 caspase-3 substrate. Modified from Biotium.
2.4.3.1 Methodology
Following treatm ent, 200 pL of cell suspension was added to flow cytometry tubes,
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and 5 pL of NucView 488 Caspase-3 substrate added directly into the cell suspension 
and mixed well, cells were incubated for 20 minutes at room tem perature protected 
from the light. Following incubation 300 pL of Dulbecco's Phosphate-Buffered Saline 
(DPBS) (Invitrogen, Paisley, UK) was added and samples analyzed directly on FACS 
Calibur Cytometer (Becton- Dickinson, UK) measuring fluorescence in the green 
detection channel FL-1 for FITC.
2.4.3.2 Analysis
Data was recorded from 10,000 cells per sample and analysed using FlowJo software 
(Tree Star, Ashland, OR, USA). Data were displayed as a single param eter histogram, 
showing FITC signal value against the number of events. A negative control was used to 
determ ine where the markers will be placed in the histogram. Histogram markers were  
used to specify a range of events for FITC. On the first histogram, marker M l  placed 
around the caspase-3 negative cells (live cells). M arker M 2 was placed to the right of 
M l  to assign caspase-3 positive cells (apoptotic cells) (Figure 2.8).
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Figure 2.8: Flow cytometry histograms of caspase-3 activation using FlowJo software. 
Histogram (A): negative control of Jurkat cell line. Histogram (B) Jurkat cell line treated with PJ 
for 24 h. M l indicate population negative for caspase-3 and M2 indicates population positive 
for caspase-3.
2.4.3.3 Statistical Analysis
Averages and Standard error of the mean (SEM) were calculated for both control and 
treated samples were calculated. Stats Direct was used to test w hether data followed a 
normal distribution using a Shapiro Wilke test, the majority of data was non-parametric 
thus a Kruskal-Wallis and Connover-lnman post hoc test was used to investigate 
statistical significance. Results were considered statistically significant when P < 0.05.
2 .5  Cell cycle Analysis by F low  C yto m etry
The cell cycle consists of four distinct phases Gi, S, G2 and M phases. Cells in the G0/G i  
phase have a defined amount (2x) of DNA (a diploid chromosomal DNA content). 
During S phase, cells contain between (2x and 4x DNA levels. W ithin the G2 or M  
phases (G2/M ) , cells have twice the amount of DNA (tetraploid chromosomal 4x DNA 
content) (Figure 1.2).
Based on measuring the DNA content of individual cells with a DNA binding 
fluorescence dye, one is able to obtain information about their distribution across cell 
cycle by using flow cytometry. A dye which intercalates with DNA and then becomes 
fluorescent such as propidium iodide (PI) is used, where DNA content is directly
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proportional to the amount of fluorescent signal (Nunez, 2001). A variety of 
fluorescent probes have been developed for the flow cytometric analysis of cycling 
cells such as PI and 7-aminoactinomycin D (7-AAD), Hoechst 33342 and 33258 and 4'6'- 
diamidino-2-phenylindole (DAPI) (Nunez, 2001). Here, PI the most widely used 
fluorescent dye to stain the total cellular DNA was used. PI has red fluorescence and is 
excited at 488-nm wavelength of light. As PI can stain both double stranded RNA 
(dsRNA) and DNA (dsDNA), cells must be incubated with RNase to remove any double 
stranded RNA and ensure that PI staining is DNA specific. Additionally as PI is excluded 
by the plasma membrane of live cells, cells are fixed and permeabilized prior to adding 
the dye.
2.5 .1  M ethod
Following treatment, cells were centrifuged for 5 min at 400 g, at 4 °C, and washed 
twice in 100 y\ ice-cold DPBS. Following washing, cells were stored at -20°C in 80% 
ethanol overnight. Fixed cells were then washed twice with 100 g\ cold DPBS and 
resupended in 50/d of RNaseA (0.1 unit/ml) (Sigma) and 300 /d of PI (50 /fg/ml) (Sigma). 
Cells were incubated at 4°C overnight prior to analysis with the FACS Calibur with 
excitation at 488 nm and emission at 585 nm using the FL2 channel.
2.5 .2  Analysis
Data was recorded from 10,000 cells per sample and processed using FlowJo software 
(Tree Star, Ashland, OR, USA). Firstly, the forward scatter (FS) and side scatter (SS) 
were used to identify single cells (Figure 2.9 A). Then, a dot plot was applied showing 
pulse width vs. pulse area to gate out doublets and clumps (Figure 2.9 B). The gated 
single cells were plotted in a histogram, as the populations that represent PI histogram 
(Go/Gi, S, and G2/M ) are not discrete (Figure 2.9 C). The Waston Pragmatic 
mathematical model was used to define the population and assign percentage values 
in each phase. The Waston model fits Gi and G2 with Gaussian curves and makes no 
assumptions about the shape of the S phase distribution. It fits the region between the 
identified G0/G i populations exactly by first subtracting the G0/G i and G2/M  portions 
of the data and then builds a function that fits what remains. Because both G2 and M 
phases have an identical DNA content they cannot be discriminated based on their 
differences in DNA content.
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Figure 2.9: Cell cycle analysis based on flow cytometry using flowJo software. A: forward 
scatter (FS) and side scatter (SS). B: pulse width vs. pulse area to gate out doublets and clumps. 
C: PI histogram.
2.5.3 Statistical Analysis
Averages and Standard error of the mean (SEM) were calculated and Stats Direct was 
used to test w hether data followed a normal distribution using a Shapiro W ilke test. 
Data did not follow a normal distribution, thus Kruskal-Wallis and Connover-lnman 
post hoc tests were used to  investigate significant differences. Results were considered 
statistically significant when P < 0.05.
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3. Bioactive Actions of whole 
Pomegranate Juice Extract on Leukaemia 
Cell Lines In vitro
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3.1 Introduction
3.1 .1  Pomegranate
3.1.1.2 Pomegranate History
Pomegranate is one of the oldest known edible fruits. Its history dates to very ancient 
times (Mars, 2000). Pomegranate cultivation and usage are greatly embedded in 
human history and its utilization has been found in many ancient cultures as food as 
well as medical remedies (Longtin, 2003). In Greek mythology it represents life 
generation and marriage. Sculpture representations of the fruit are found on ancient 
monuments of Egypt and the Assyrian ruins (Longtin, 2003; Jurenka, 2008). Thus fruit 
that has featured prominently by many of the major religions of the world such as 
Islam, Chistianity, Buddhism and Zoroastrianism. In Islam for example, the Koran 
describes four gardens with shade, springs, and fruits-including the pomegranate. 
Legend holds that each pomegranate contains a seed that comes down from paradise 
(Langley, 2000; Longtin, 2003).
Pomegranate trees are native to the region of Persia and the Himalayan ranges of India. 
There are over thousands of cultivars of pomegranate which are spreading throughout 
the Mediterranean, China, India, as well as the American Southwest (California and 
Arizona) and Mexico (Levin, 1994; Langley, 2000).
Pomegranates are used in several systems of medicine for a variety of diseases. In the 
Indian Ayurvedic system of medicine, the pomegranate is considered "a pharmacy 
unto itself" and is used as a general tonic and to treat diarrhoea, ulcers and parasitic 
infections (Frawely, 1986; Khan, 1991; Jurenka, 2008). Pomegranate are also 
considered an important part of the Unani system of medicine practice in the Middle 
East and India where it is popularly served as a remedy for diabetes mellitus (Jurenka, 
2008). Pomegranate termed "superfruit" has long been a symbol of life, longevity, and 
health (Mahdihassan, 1984). It was also chosen as a logo for the Millennium Festival of 
Medicine and features in the coat of arms of the British Medical Society and three 
royal colleges (Figure 3.1) (Langley, 2000).
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Gynaecologists
Figure 3.1: Pomegranate in coats of arms of the British medical society and three royal 
colleges. Modified from Langley, 2000
3.1.2.2 Botanical Description
Pomegranate (Punico granatum L.) belongs to the family punicacease which consists of 
only two species, Punica granatum and Punica protpunica. Pomegranate grows as a 
small tree or a large shrub reaching 12-16 ft tall, and can live over 20 years. It has spiny 
branches, glossy lance shaped leaves, with bark turning grey with age (Lansky and 
Newman, 2007; Jurenka, 2008).
The tree bears large, red, white or variegated flowers that eventually become the fruit. 
Its fruit is classified as a large berry, growing up to 5 inches in diameter, delimited by a 
leathery peel, contained within are numerous arils, each a single seed surrounded by a 
translucent juice containing sac. Thin acrid-tasting membranes extended into interior 
of the fruit from the peel, giving a latticework for suspending the arils (Lansky and 
Newman, 2007; Jurenka, 2008).
Figure 3.2: Illustrated pomegranate fruit and tree.
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3.1.2.3 Pomegranate Chemical Constitutes
Different types of phytochemicals have been identified within the different parts of the 
pomegranate tree, including fruits and seeds. The major class of pomegranate 
phytochemicals is the polyphenols (phenolic rings bearing multiple hydroxyl groups) 
that predominant in the fruit (Viuda-Marrots et al, 2010). Pomegranate fruit 
polyphenols include flavonoids (flavonols, flavanols, and anthocyanins), condensed 
tannins and hydrolysable tannins (ellagitannins and gallotannins). Other 
phytochemicals identified from pomegranate are organic and phenolic acids, sterols, 
and titerpenoids and alkaloids (Artik, 1998; Halvorsen et al, 2002; Afaq et al, 2005; 
Lansky and Newman, 2007).
The major source of dietary pomegranate phytochemicals is the fruit. The fruit can be 
divided to three parts, the seeds, the arils and the peel including the interior network 
of membranes (Figure 3.3). Edible part of the fruit (50%) represents 40% arils (juice 
obtain from arils) and 10% seeds. The juice contain 85% water, 10% total sugar mainly 
fructose and glucose, and 1.5% pectin (Aviram etal, 2000; Tezcan etal, 2009)
Minerals in pomegranate juice include iron, calcium, cerium, chloride, copper, 
chromium, caesium, potassium, magnesium, manganese, molybdenum, sodium, 
rubidium, selenium, scandium, tin, strontium, and zinc (Waheed et al, 2004). Alkaloids 
were mainly found in the juice as well as in the bark of the both stem and the root. 
There are two main types of alkaloids involving piperidines and pyrolinidines identified 
in pomegranate plants (Badria, 2000). Organic acids in pomegranate juice are mainly 
straight chain fatty acids, of which citric acid and malic acid are the major compounds 
with content up to 4.5 and 1.75 g/L, respectively. In addition, tartaric acid and 
succininc acid were also identified in the juice of pomegranate (Poyrazoglu et al, 2002; 
Tezcan et al, 2009).
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Figure 3.3: Illustrates pomegranate fruit parts (peel, arils and seeds).
The main classes of polyphenols found in pomegranate juice are the flavonoids, 
phenolic acids, and hydrolysable tannins. The soluble polyphenol content in 
pomegranate juice has been identified to vary within the limits o f 0.2% to 1.0% (Ben 
Nasr et al, 1996).
The flavonoids in pomegranate juice include flavonols flavan-3-ols and anthocyanins. 
Flavonols that have been identified in pomegranate juice include quercetin and rutin 
(Artik, 1998), and flavan-3-ols such as catechin, epicatechin, and epigallocatechin 3- 
gallate (EGCG) (De Pascula-Teresa et al, 2000). Anthocyanins are the largest and most 
im portant group of flavonoids present in the juice. They are responsible for the red 
colour of pomegranate juice (Hernandez et al, 1999). The main anthocyanins identified 
in pomegranate juice are cyanidin-3-glucoside, Cyanidin-3,5-diglucoside, pelargonidin- 
3-glucoside, pelargonidin-3,5-diglucoside, delphinidin-3-glucoside, delphinidin-3,5- 
diglucoside (Hernandez etal, 1999; Reed et al, 2005).
Phenolic acid are non-flavonoids polyphenols. They can be divided into tw o main 
types: (1) hydrocynammic acid, principally caffiec acid, p-cumaric acid, and chlorogenic 
acid; and (2) hydrobenzoic acid, mainly ellagic acid and gallic acid.
Hydrolysable tannins are high molecular weight plant polyphenols. They are found in 
the arils and account for 92% of the antioxidant activity of pomegranate fruit (Gil et al,
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2000). The predominant hydrolysable tannins in pomegranate juice is punicalagin, 
which is responsible for about 50% of its antioxidant capacity (Gil et al, 2000).
The chemical composition of pomegranates can vary depending on the cultivar, 
growing region, climate, maturity and storage conditions and part of the plant 
(Poyrazoglu et al, 2002; Barzegar et al, 2004; Fadvi et al, 2005). It has been reported 
over the years by different researches significant variations in organic acids, phenolic 
compounds, sugar, and minerals found in pomegranates (Aviram et al, 2000; 
Mirdehghan and Rahemi, 2007). Gozlekci and his colleagues (2011) investigated the 
total phenolic distribution of peel, juice, and seed extracts of four Turkish 
pomegranate cultivars using Folin-Ciocalteu colourmetric method, demonstrating the 
phenolic compounds altered depending on cultivars and fruit parts.
3.1.2.4 Bioavailabity and Toxicity of Pomegranate
Despite the evidence in favour of pomegranate use, extensive studies are needed to 
fully understand its possible contribution to human health before recommending its 
regular consumption. The absorption, bio-availability, bio-distribution, and metabolism 
profile of pomegranate compounds has not yet been completely characterized. A small 
number of clinical studies have tested the metabolic profile of certain pomegranate 
derived compounds, such as ellagic acid. Seeram et al, 2006 reported that healthy 
subjects who consumed 10 ml of concentrated PJ exhibited presence of ellagic acid 
metabolites in plasma as well as in urine. It has been proposed that dimethylellagic 
acid glucuronide in human plasma and urine samples after consumption of the fruit 
juice concentrate is a reliable biomarker of pomegranate intake (Seeram et al, 2006). 
In general, the metabolites present in humans following PJ consumption matches 
those found in rats fed with pomegranate extracts (Cerda et al, 2003a).
Pomegranate and it's constitutes have safely been consumed for centuries across the 
world without any adverse effects. Toxicity of punicalagin, an abundant antioxidant 
polyphenol in PJ, was investigated in rats (Jurenka, 2008). Demonstrating no toxic 
effects or significant differences were detected in the treatment group compared to 
controls (Cerda et al, 2003b). In another study, no toxic effect on blood chemistry 
analysis for kidney, liver and heart was observed in patients with carotid artery
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stenosis who consumed PJ for up to three years. However, a number of studies have 
shown toxic effect after intake of pomegranate products (Lansky and Newman, 2007) 
and Hedge et al, (2002) reported allergic reactions after consumption of pomegranate 
fruit.
3.1.2.5 Pomegranate and Health
Recent years, have seen a great interest on the part of consumers, researchers, and 
the food industry into how food products may help maintain health and the role that 
diet plays in the prevention and treatm ent of many illnesses has become widely 
accepted (Johanningsmeier and Harris, 2011). At the present tim e, considerable 
importance is given to functional foods that provide physiological benefits and are 
useful in disease prevention or slowing the progression of chronic diseases in a manner 
beyond their basic nutritional functions (Johanningsmeier and Harris, 2011).
This fruit, which has been consumed and used as medicinal food in M iddle East for 
thousands of years, has recently gained popularity in various parts of the world 
(Johanningsmeier and Harris, 2011). The current explosion of research into 
pomegranates is evidenced by a science direct search from 2000 to 2012, revealing a 
significant increase in new scientific papers concerning pomegranate (Figure 3.4).
Scientific studies on pom egranate from  2000 to  2012
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Figure 3.4: Increase in the number of scientific papers on pomegranate and its constituents 
from 2000 to 2012.
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The high antioxidant content of pomegranate the fruit and juice as compared with 
other fruits and antioxidant beverages has been the basis for much of proposed health 
benefits and has stimulated interest in research on potential nutraceutical and 
functional food applications. Seeram et al, 2008b have reported that PJ had a higher 
antioxidant potency composite index and total polyphenol content in comparison to 
common fruit juices (orange, grape-fruit, grape, cranberry, pear, pineapple, apple, red 
wines, iced tea and black cherry); as demonstrated by using four antioxidant tests 
(Trolox equivalent antioxidant activity (TEAC), total oxygen radical absorbance capacity 
(ORAC), free radical scavenging capacity by 2,2-diphenyl-l-picrylhydrazyl (DPPH), and 
ferric reducing antioxidant power (FRAP); and the antioxidant activity was at least 20% 
higher than any of the other juices tested. In addition, pomegranate juice was shown 
to have a 3-fold higher antioxidant activity than that of red wine and green tea (Gil et 
al, 2000) and 2-, 6- and 8-fold higher levels than those identified in grape, grapefruit, 
and orange juices, respectively (Azadzoi et al, 2005; Rosenblat and Avriam, 2006). The 
high antioxidant activity may relate to the variety of phenolic compounds present in 
pomegranate, including punicalagin, ellagic acid derivatives and anthocyanins. Such 
compounds are identified for their properties to scavenge free radicals and to inhibit 
lipid oxidation in vitro (Gil etal, 2007; Noda et al, 2002).
The functional and medicinal effect of pomegranate fruits and its derivatives have 
shown to act as anti-diabetic (Katz et al, 2007), anti-viral (Neurath et al, 2005), anti­
tumour and anti-inflammatory (Ahmed et al, 2005) and improve cardiovascular 
diseases such as atherosclerosis, hyperlipidemia and hypertension (Aviram et al, 2000; 
Fuhman et al, 2010). They also help to prevent Alzheimer's disease (Singh et al, 200) 
and improve sperm quality (Turk et al, 2010) and they can improve skin (Pachco- 
Palencia et al, 2000; Afaq et al, 2009) and oral health (Vasconcelos et al, 2003) (Figure 
3.5).
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Figure 3.5: Functional and medicinal effect of pomegranate. Modified from E Mendoza et al, 
2011
In terms of anti-tum our properties pomegranate has shown potential in the treatm ent 
of solid tum our as anti-proliferative, and pro-apoptotic agents in many cancer cell lines 
and animal models of colon, breast, prostate, skin and lung cancers (Table 3.1). Of 
these, prostate cancer has been the most well studied, and it has made significant 
progress in assessment of the chemo preventive and therapeutic potential of 
pomegranate derived phytochemicals in prostate cancer with an initial phase II clinical 
trial reporting a significant prolongation of prostate cancer antigen doubling tim e in 
patients with prostate cancer (Pantuck et al, 2006). However, few  studies have 
investigated the potential of pomegranate juice extract (PJ) in the treatm ent of 
leukaemia. Kawaii and Lansky (2004) evaluated the effect of fresh and ferm ented  
pomegranate juice on HL-60 human leukaemia cell line differentiation. Their study 
demonstrated that treatm ent with PJs induced differentiation of HL-60 cells and 
inhibition of cellular proliferation (Kawaii and Lansky, 2004). No studies to  date have
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investigated the effects of PJs on non-tumour cells, and thus selective toxicity to  
cancer cells has not previously been investigated.
Breast Juice, seed-oil, 
fermented juice 
polyphenols, 
extract
Kim et al. (2002) Mehta and Lansky (2004), Toi et 
al. (2003), Jeune et al. (2005), Khan et al. (2009), 
Grossmann et al. (2010), Adams et al. (2010), Tran 
etal. (2010).
Prostate Seed-oil, fermented 
juice polyphenols, 
extract, juice
Seeram etal. (2005), Lansky (2) et al. (2005), 
Albrecht etal. (2004), Seeram et al. (2007), 
Sartippour et al.(2008), Malik et al. (2005), Hong et 
al. (2008), Rettig et al. (2008), Koyoma et al.
(2010), Kasimsetty etal. (2009), Pantuck etal. 
(2006)
Lung Fruit extract Khan et al. (2006a)
Colon Seed-oil, juice Kohono et al. (2004), Adams et al. (2006), 
Saruwatari et al.{2008), Sharma (2010)
Skin Seed-oil, fruit extract Hora et al. (2003), Pacheco-Palencia et al. (2008). 
Zaid et al. (2007), Syed et al. (2006)
Leukaemia Fresh and fermented 
juice
Mertens-Talcott and Percival (2005), Kawaii and 
Lansky (2004)
Table 3.1: Summary of studies of pomegranate different cancers.
3 .2  O b jec tive
This study investigated the hypothesis that PJ can induce cell death and prevent 
cellular replication to a greater extent in leukaemia cells than non tum our control cells.
3 .3  E xp erim en ta l Design
3.3.1 Treatm ent
Eight leukaemia cell lines 4 lymphoid (Jurkat, SUP-B15, MOLT-3 and CCRF-CEM) and 4 
myeloid (HL-60, THP-1, K562, KGla) in addition to CD133 (Normal human HSCs) were  
maintained as described in section 2.2.2. PJ was prepared as mentioned in section 2.1 
and used for the treatm ent of cells at concentrations: 0%; 6.25; 12.5 and 25% for 24
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and 48 h following treatm ent induction of apoptosis and cell cycle arrest were  
investigated (Table 3.2).
Trypan blue PJ 6.25%, 12.5%, and 
25%
8 leukaemia cell 
lines + non-tumour 
HSsc
24 and 48 hr
Annexin V- 
FITC/PI
PJ 6.25%, 12.5%, and 
25%
8 leukaemia cell 
lines + non
24 and 48 hr
DAPI Satining PJ 6.25%, 12.5%, and 
25%
8 leukaemia cell 
lines + non
24 and 48 hr
Cell cycle PJ 6.25%, 12.5%, and 
25%
8 leukaemia cell 
lines
24 and 48 hr
Table 3.2: Experimental design for Chapter 3.
3.3.2 Assessment of Apoptosis
W e investigated the effect of PJ in terms of induction of apoptosis by using tw o  
techniques; Annexin V-FITC/PI and DAPI staining.
3.3.2.1 Annexin V-FITC /P I Stain Assay
Cells were plated in 12 well plate at cell density 5x10s per well and incubated with PJ at 
different concentrations (6.25%, 12.5% and 25%) for 24 and 48 h. Annexin V/PI FITC 
stains were used to detect apoptosis based on flow cytometry as described previously 
2.4.1. Data was recorded from 10,000 cells per sample and analysed using FlowJo 
software (Tree Star).
3.3.2.2 DAPI Stain
Following treatm ent with PJ at concentrations 6.25%, 12.5% and 25% for 24 and 48 h 
at cell density 5 x l0 4, cells were stained with DAPI to observe apoptotic morphology as 
explained before in section 2.4.2. Cells were investigated using Olympus BX60 
fluorescence microscope using UV light at excitation wavelength 350 nm.
3.3.3 Cell viability Assay
All cell lines in addition to normal HSCs were seeded in 12 well plates and at 
concentration 5x10s per well and treated with PJ at concentration 6.5%, 12.5% and 
25% PJ for 24 and 48 h. Cell viability was measured by trypan blue exclusion using the  
countess™ automated cell counter as described in section 2.3.1. All experiments w ere
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performed in quadruplicate. Percentage of cell viability was calculated by normalizing 
to untreated samples.
3.3 .4  Cell Cycle Analysis
The effect of PJ on cell cycle of all leukaemia cell lines and normal HSCs were 
investigated using a PI stain, and analyzed using flow cytometry as describe in section
2.5 following treatment with PJ at concentration 6.25%, 12.5% and 25% for 24 h at cell 
density 5x10s. Data from 10,000 cells per sample were recorded and percentages of 
cells within G0/Gi, S and G2/M  cell cycle phase were determined with FlowJo software 
and Waston (pragmatic) analysis of cell cycle (Tree Star).
3.3.5 Statistical Analysis
Average and Standard error of the mean (SEM) was calculated and Stats Direct was 
used to test whether data followed a normal distribution using a Shapiro Wilke test. 
Data did not follow a normal distribution, thus Kruskal-Wallis and Connover-lnman 
post hoc tests were used to investigate significant differences. Results were considered 
statistically significant when P < 0.05.
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3 .4  Results
3.4 .1  Effect o f PJ on Induction o f Apoptosis Using Annexin V-FITC/PI 
based on Flow Cytom etry
A significant (P < 0.05) decrease in the number of live cells and increase in the number 
of apoptotic and dead cells when assessed at 24 and 48 h post treatment with PJ was 
seen in all leukaemia cell lines ( Figure 3.6 and 3.7). However, within the leukaemia cell 
lines and non-tumour primary HSCs different levels of sensitivity were observed, 
where was the most affected of all the leukaemia cell lines while THP-1 was the least 
affected leukaemia cell lines. In myeloid cell lines KG-la was the affected cells 
comparing with the same lineage of cells. Interestingly, CD133 (non-tumour primary 
HSCs) was the least affected cells compared to all leukaemia cell lines (Figure 3.6 and 
3.7).
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Figure 3.6: Annexin V-FITC/ PI of live cell populations normalized to untreated controls in 4 
lymphoid leukaemia cell lines (CCRF-CEM, JURKAT, MOLT-3, SUP-B15), 4 myeloid leukaemia 
cell lines (KG-la, HL-60, K562, THP-1), and non-tumour hematopoietic stem cells (CD133) 
following treatment PJ for 24 h. n=3.
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Figure 3.7: Annexin V-FITC/ PI of live cell populations normalized to untreated controls in 4 
lymphoid leukaemia cell lines (CCRF-CEM, JURKAT, MOLT-3, SUP-B15), 4 myeloid leukaemia 
cell lines (KG-la, HL-60, K562, THP-1), and non-tumour hematopoietic stem cells (CD133) 
following treatment PJ for 48 h. n=3.
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CCRF-CEM the most affected cell line and showed a significant (P < 0.05) decrease in 
viable cells following 24 and 48h treatm ent with 6.25%, 12.5% and 25% of PJ (Fig 3.8). 
At low concentration (6.25%) o f PJ approximately 90% decrease in the number of live 
cells was observed following 24 and 48 h. Treatm ent with high concentration of PJ 
(25%) showed no live cells remaining after 24 or 48h. Both early apoptotic and dead 
cells were significantly (P < 0.05) increased following treatm ent with all concentrations 
of PJ after 24 and 48 h incubation (Fig 3.8).
CCRF-CEM
B 0% I  6.25% U 12.50% H 25%
24hrs 48hrs
Live Apoptotic Dead Live Apoptotic Dead
Figure 3.8: Annexin V-FITC/ PI based on flow cytometry following treatment with PJ (0%, 
6.25%, 12.5% and 25%) for 24 and 48 h on CCRF-CEM. Mean ± SEM. * indicates significant 
difference (P < 0.05) vs. untreated control. n= 3.
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Jurkat cell lines following treatm ent with PJ after 24 and 48 h incubation showed a 
significant (P < 0.05) decrease in the number of live cells in a dose dependent manner 
at 6.25%, 12.5% and 25% (Figure 3.9). M ore than 80% decrease in the number of live 
cells was detected at low concentrations (6.25%) of PJ following incubation times. At 
high concentration (25%) of PJ approximately 97% and 99% decrease in live cells was 
observed after 24 and 48 h incubation respectively. Apoptotic and dead cells showed a 
significant (P < 0.05) increase at all concentrations following 24 and 48 h (Figure 3.9).
JURKAT
B O %  ■  6 .2 5%  M 12 .50%  H  25%
24hrs 48hrs
Live Apoptotic Dead Live Apoptotic Dead
Figure 3.9: Annexin V-FITC/ PI based on flow cytometry following treatment with PJ (0%, 
6.25%, 12.5% and 25%) for 24 and 48 h on Jurkat. Mean ± SEM, * indicates significant 
difference (P < 0.05) vs. untreated control. n= 3.
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MOLT-3 cell lines illustrated a significant (P < 0.05) decrease in the number of live cells 
following treatm ent with PJ at concentration 6.25%, 12.5% and 25% (v/v) following 24 
and 48 h incubation (Figure 3.10). At concentration 12.5% and 25% following 48 h 
treatm ent with PJ more than 99% decreased in the number of live cells was detected. 
The number of apoptotic and dead cells significantly (P < 0.05) increased following 
treatm ent with PJ at all concentrations following 24 and 48 h incubation times (Figure 
3.10).
MOLT-3
*  0% rn 6.25% w 12.50% m 25%
24hrs 48hrs
Live Apoptotic Dead Live Apoptotic Dead
Figure 3.10: Annexin V-FITC/ PI based on flow cytometry following treatment with PJ (0%, 
6.25%, 12.5% and 25%) for 24 and 48 h on MOLT-3. Mean ± SEM. * indicates significant 
difference [P < 0.05) vs. untreated control. n= 3.
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SUP-B15 cells also showed a significant (P < 0.05) decrease in the number of live cells 
and significant increase in the number of apoptotic and dead cells after treatm ent with 
PJ following 24 and 48 h incubation (Figure 3.11). Treatm ent with lowest concentration 
(6.25%) of PJ showed the smallest decrease in the number of live cells compared with  
other lymphoid cell lines with 46% and 30% decrease following 24 and 48 h 
respectively (Figure 3.11).
SUP-B15
he 0%  ■  6.25% y  12.50% H 25%
48hrs24hrs
Live Apoptotic Dead Live Apoptotic Dead
Figure 3.11: Annexin V-FITC/ PI based on flow cytometry following treatment with PJ (0%, 
6.25%, 12.5% and 25%) for 24 and 48 h on SUP-B15. Mean ± SEM * indicates significant 
difference (P < 0.05) vs. untreated control. n= 3.
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KG-la showed the greatest sensitivity to PJ than the other myeloid leukaemia cell lines. 
Live cells showed a significant (P < 0.05) decrease when treated with 6.25%, 12.5% and 
25% after 24 and 48 h when compared to  control (Figure 3.12). Percentage o f live cell 
population was not significantly different between tim e points when treated with  
6.25% of PJ. The number o f live cells decreased by half after 48 h compared with 24 h 
incubation following treatm ent with 12.5% of PJ (P < 0.05). At highest concentration  
25% of PJ caused 98% decrease in the number of live cells. Significant increase in the  
number o f apoptotic and dead cells was shown after treatm ent with all concentrations 
of PJ (Figure 3.12).
KG-la
MO%  M 6.25% M 12.50% Hi 25%
24hrs 48hrs
Live Apoptotic Dead Live Apoptotic Dead
Figure 3.12: Annexin V-FITC/ PI based on flow cytometry following treatment with PJ (0%, 
6.25%, 12.5% and 25%) for 24 and 48 h on KGla. Mean ± SEM. * indicates significant 
difference (P < 0.05) vs. untreated control. n= 3.
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Treatm ent HL-60 cell lines with PJ also showed a significant decrease in the number of 
live cells and increase in the number of apoptotic cells at all concentrations (6.25%, 
12.5% and 25%) after 24 and 48 h (P < 0.05) (Figure 3.13). Following 24 h the number 
of live cells decreased to 17% compared to control and following 48 h only 1% of cells 
remained alive (Figure 3.13).
HL-60
M 0 %  m 6.25% M 12.50% ii 25%
24hrs 48hrs
Live Apoptotic Dead Live Apoptotic Dead
Figure 3.13: Annexin V-FITC/ PI based on flow cytometry following treatment with PJ (0%, 
6.25%, 12.5% and 25%) for 24 and 48 h on HL-60.Mean ± SEM. * indicates significant 
difference (P < 0.05) vs. untreated control. n= 3.
105
Treatm ent of K562 cell lines with PJ showed a significant decrease in the number of 
live cells and increase in the number of apoptotic cells at all concentrations (6.25%, 
12.5% and 25%) after 24 and 48 h (P < 0.05) (Figure 3.14).
K562
48hrs24hrs
Live Apoptotic Dead Live Apoptotic Dead
Figure 3.14: Annexin V-FITC/ PI based on flow cytometry following treatment with PJ (0%, 
6.25%, 12.5% and 25%) for 24 and 48 h on K562. Mean ± SEM. * indicates significant difference 
(P < 0.05) vs. untreated control. n= 3.
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THP-1 cells were the most resisitant leukaemia cell line, they showed a significant 
decrease in the number of live cells and increase in the number of apoptotic and dead 
cells after all tim e points (P < 0.05). Less than 10% decrease in the number of live cells 
was observed following 6.25% PJ treatm ent for 24 h which increased to 22% following  
48 h (Figure 3.15). Apoptotic cells did not show an increase in the number o f cells 
comparing to control when treated with PJ at concentration 6.25% after 24 h 
incubation, although all other treatm ents induced significant increases in apoptotic 
and dead cell populations (P < 0.05) (Figure 3.15).
THP-1
M 0 %  U  6.25% M 12.50% H 25%
24hrs 48hrs
Live Apoptotic Dead Live Apoptotic Dead
Figure 3.15: Annexin V-FITC/ PI based on flow cytometry following treatment with PJ (0%, 
6.25%, 12.5% and 25%) for 24 and 48 h on THP-1. Mean ± SEM. * indicates significant 
difference (P < 0.05) vs. untreated control. n= 3.
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The non-tumour CD133+ HSCs were less sensitive to PJ treatm ent than the majority of 
the leukamia cell lines (Figure 3.16). Treatm ent with 6.25% PJ did not show a 
significant decrease in the number of live cell and increase in the number of apoptotic 
and dead cells after 24 h (P > 0.05). The highest dose of PJ (25%) failed to induce 50%  
cell death even after 48 h (Figure 3.16).
CD133 HSC
I  0% ■  6.25% U 12.50% H 25%
24hrs 48hrs
Live Apoptotic Dead Live Apoptotic Dead
Figure 3.16: Annexin V-FITC/ PI based on flow cytometry following treatment with PJ (0%, 
6.25%, 12.5% and 25%) for 24 and 48 h on CD133 positive hematopoietic stem cells (non­
tumour HSC). Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. 
n= 3.
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3.4.2 Effect of PJ on Induction of Apoptosis Using DAPI for Morphology 
Assessment
DAPI nuclear stain exhibits normal cells with round, clear edged and uniformly stained. 
In contrast it demonstrates apoptotic cells with irregular edges around the nucleus, 
chromatin condensation in the nucleus, intense staining and with pyknosis increase 
number of nuclear body fragments (Figure 2.6). DAPI morphological analysis showed a 
significant (P < 0.05) increase in the number of apoptotic cells in all 4 lymphoid and 4 
myeloid human leukaemia cell lines in a dose dependent manner following treatment 
with PJ at concentration 6.25%, 12.5% and 25% compared to control with patterns 
confirming the annexin V/PI results (Figure 3.17 to 27). In addition, the percentage of 
apoptotic cells was significantly higher within lymphoid than the myeloid cell lines.
CCRF-CEM cells showed a significant increase in apoptotic population at all doses of PJ 
after 24 and 48 h incubation (Figure 3.17). Similarly, Jurkat cells showed a significant 
(*P < 0.05) rise in the number of apoptotic population at all thee PJ concentrations 
following 24 and 48 h. The lowest dose (6.25%) and highest dose (25%) of PJ have 
shown a 10% increase in the apoptotic cell number following 48 h incubation 
compared with 24 h incubation time (Figure 3.18). Similarly MOLT-3 and SUP-B15 also 
showed significant (P < 0.05) increase in apoptosis following 24 and 48 h incubation 
with PJ (Fig 3.19 and 3.20)
KG-1 cells were the most affected myeloid cell line with 57, 71 and 82 apoptotic cell 
number following 24 h incubation and 71%, 82% and 92% apoptotic cell population 
following 48 h at concentration of PJ 6.25%, 12.5% and 25% respectively (Figure 3.21). 
TFIP-1 was least affected lymphoid cell lines with maximum apoptotic cells of 46% and 
64% at highest dose of PJ following 24 and 48 h incubation respectively (Figure 3.22). 
CD133 demonstrated a significant (P < 0.05) increase in the number of apoptotic cells, 
but it was less than all leukaemia cell lines (Figure 3.23).
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Figure 3.17: (1) Morphological staining analysis of CCRF-CEM with DAPI treated with PJ at 
concentrations 0%, 6.25%, 12.5% and 25% for 24 h. Live cells are indicated by the green arrows, 
and apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells 
determined from DAPI morphological assessment following treatment with PJ at concentration 
0%, 6.25%, 12.5% and 25% for 24 and 48 h. Mean ± SEM. * indicates significant difference (P < 
0.05) vs. untreated control. Scale bar= 25 pm. n= 3.
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Figure 3.18: (1) Morphological staining analysis of Junket with DAPI treated with PJ at 
concentrations 0%, 6.25%, 12.5% and 25% for 24 h. Live cells are indicated by the green arrows, 
and apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells 
determined from DAPI morphological assessment following treatment with PJ at concentration 
0%, 6.25%, 12.5% and 25% for 24 and 48 h. Mean ± SEM. * indicates significant difference (P < 
0.05) vs. untreated control. Scale bar= 25 pm. n= 3.
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Figure 3.19: (1) Morphological staining analysis of MOLT-3 with DAPI treated with PJ at 
concentrations 0%, 6.25%, 12.5% and 25% for 24 h. Live cells are indicated by the green arrows, 
and apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells 
determined from DAPI morphological assessment following treatment with PJ at concentration 
0%, 6.25%, 12.5% and 25% for 24 and 48 h. Mean ± SEM. * indicates significant difference (P < 
0.05) vs. untreated control. Scale bar= 25 pm. n= 3.
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cFigure 3.20: (1) Morphological staining analysis of SUP-B15 with DAPI treated with PJ at 
concentrations 0%, 6.25%, 12.5% and 25% for 24 h. Live cells are indicated by the green arrows, 
and apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells 
determined from DAPI morphological assessment following treatment with PJ at concentration 
0%, 6.25%, 12.5% and 25% for 24 and 48 h. Mean ± SEM. * indicates significant difference (P < 
0.05) vs. untreated control. Scale bar= 25 pm. n= 3.
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Figure 3.21: (1) Morphological staining analysis of KG-la with DAPI treated with PJ at 
concentrations 0%, 6.25%, 12.5% and 25% for 24 h. Live cells are indicated by the green arrows, 
and apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells 
determined from DAPI morphological assessment following treatment with PJ at concentration 
0%, 6.25%, 12.5% and 25% for 24 and 48 h. Mean ± SEM. * indicates significant difference (P < 
0.05) vs. untreated control. Scale bar= 25 pm. n= 3.
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Figure 3.22: (1) Morphological staining analysis of HL-60 with DAPI treated with PJ at 
concentrations 0%, 6.25%, 12.5% and 25% for 24 h. Live cells are indicated by the green arrows, 
and apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells 
determined from DAPI morphological assessment following treatment with PJ at concentration 
0%, 6.25%, 12.5% and 25% for 24 and 48 h. Mean ± SEM. * indicates significant difference (P < 
0.05) vs. untreated control. Scale bar= 25 pm. n= 3.
24 hr 48 hr
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Figure 3.23: (1) Morphological staining analysis of K562 with DAPI treated with PJ at 
concentrations 0%, 6.25%, 12.5% and 25% for 24 h. Live cells are indicated by the green arrows, 
and apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells 
determined from DAPI morphological assessment following treatment with PJ at concentration 
0%, 6.25%, 12.5% and 25% for 24 and 48 h. Mean ± SEM. * indicates significant difference (P < 
0.05) vs. untreated control. Scale bar= 25 pm. n= 3.
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Figure 3.24: (1) Morphological staining analysis of K562 with DAPI treated with PJ at 
concentrations 0%, 6.25%, 12.5% and 25% for 24 h. Live cells are indicated by the green arrows, 
and apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells 
determined from DAPI morphological assessment following treatment with PJ at concentration 
0%, 6.25%, 12.5% and 25% for 24 and 48 h. Mean ± SEM. * indicates significant difference (P < 
0.05) vs. untreated control. Scale bar= 25 pm. n= 3.
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Effect of PJE on induction of apoptosis using DAPI staining 
following 24 hr incubation
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Figure 3.25: Analysis of DAPI staining of apoptotic cell populations normalized to untreated controls 
in 4 lymphoid leukaemia cell lines (CCRF-CEM, JURKAT, MOLT-3, SUP-B15), 4 myeloid leukaemia cell 
lines (KG-la, HL-60, K562, THP-1), and non-tumour hematopoietic stem cells (CD133) following 
treatment PJ for 24 h.
Effect of PJE on induction of apoptosis using DAPI staining 
follwing 48 hr incubation
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Figure 3.26: Analysis of DAPI staining of apoptotic cell populations normalized to untreated controls 
in 4 lymphoid leukaemia cell lines (CCRF-CEM, JURKAT, MOLT-3, SUP-B15), 4 myeloid leukaemia cell 
lines (KG-la, HL-60, K562, THP-1), and non-tumour hematopoietic stem cells (CD133) following 
treatment PJ for 48 h.
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3.4.3 Effect of PJ on Cell Viability
To investigate whether PJ treatment imparts anti-proliferative effects against 
leukaemia cells, the effect of PJ on the growth of these cells was evaluated by the 
trypan blue exclusion assay.
Trypan blue exclusion assay was used based on the countess™ automated cell counter 
to measure the effect of PJ on all leukaemia cell lines and non-tumour haematopoietic 
stem cells on cell viability following 24 and 48 h incubation. In this case the dye is 
normally taken up by viable cells but non-viable cells.
Treatment with PJ at concentrations 6.25%, 12.5% and 25% resulted in a significant 
decrease in the number of viable cells in a dose dependent manner compared to 
untreated cells (0%) following 24h and 48 h incubation in all four human lymphoid 
leukaemia cells (CCRF-CEM, MOLT-3, Jurkat and SUP-B15) and four myeloid leukaemia 
cells (HL-60, THP-1, K562 and KG la) (P < 0.05) (Figure 3.28 to 3.36).
CCRF-CEM and Jurkat showed less than 2% viable cells post treatment with 12.5% and 
25% PJ after only 24 h incubation and there was no significant difference between 24 
and 48 h in the same concentration (Figure 3.27). Other lymphoid cell lines (MOLT-3 
and SUP-B15) were less affected than CCRF-CEM and Jurkat with about 10% of cells 
renaming viable following 25% PJ treatment for 48 h (Figure 3.28. 3.29, and 3.30).
KG-la was the most affected myeloid cell line with 96% decrease in the number of live 
cells following 48 h treatment with 25% PJ (Figure 3.31). In contrast THP-1 was the 
least affected cell lines since it only showed less than 10% decrease in the number of 
live cells at 6.25% PJ following 24 and at highest concentration of PJ 25% following 48 h 
demonstrated less than 80% decrease in the number of live cells compared to control 
(Figure 3.34). 25% PJ failed to inhibit more than 50% of CD133 after 24 h incubation, 
while following 48 h incubation the number of live cells for CD133 showed a decrease 
with about 80% reduction following 25% PJ (Figure 3.35).
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Figure 3.27: Effect of pomegranate juice extract (PJ) on cell viability using trypan exclusion 
assay following 24 and 48 h incubation at 6.25%, 12.5%, and 25% on CCRF-CEM. Average cell 
number of untreated cells was set at 100% and relative number of cells calculated accordingly. 
Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Figure 3.28: Effect of pomegranate juice extract (PJ) on cell viability using trypan exclusion 
assay following 24 and 48 h incubation at 6.25%, 12.5%, and 25% on CCRF-CEM. Average cell 
number of untreated cells was set at 100% and relative number of cells calculated accordingly. 
Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Figure 3.29: Effect of PJ on cell viability using trypan exclusion assay following 24 and 48 h 
incubation at 6.25%, 12.5%, and 25% on MOLT-3. Average cell number of untreated cells was 
set at 100% and relative number of cells calculated accordingly. Mean ± SEM. * indicates 
significant difference (P < 0.05) vs. untreated control. n= 3.
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Figure 3.30: Effect of PJ on cell viability using trypan exclusion assay following 24 and 48 h 
incubation at 6.25%, 12.5%, and 25% on SUP-B15. Average cell number of untreated cells was 
set at 100% and relative number of cells calculated accordingly. Mean ± SEM. * indicates 
significant difference (P < 0.05) vs. untreated control. n= 3.
SUP-B15
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Figure 3.31: Effect of PJ on cell viability using trypan exclusion assay following 24 and 48 h 
incubation at 6.25%, 12.5%, and 25% on KG-la. Average cell number of untreated cells was set 
at 100% and relative number of cells calculated accordingly. Mean ± SEM* indicates significant 
difference (P < 0.05) vs. untreated control. n= 3.
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Figure 3.32: Effect of PJ on cell viability using trypan exclusion assay following 24 and 48 h 
incubation at 6.25%, 12.5%, and 25% on HL-60. Average cell number of untreated cells was set 
at 100% and relative number of cells calculated accordingly. Mean ± SEM. * indicates 
significant difference (P < 0.05) vs. untreated control. n= 3.
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Figure 3.33: Effect of PJ on cell viability using trypan exclusion assay following 24 and 48 h 
incubation at 6.25%, 12.5%, and 25% on K562. Average cell number of untreated cells was set 
at 100% and relative number of cells calculated accordingly. Mean ± SEM. * indicates 
significant difference ( P  <  0.05) vs. untreated control. n= 3.
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Figure 3.34: Effect of PJ on cell viability using trypan exclusion assay following 24 and 48 h 
incubation at 6.25%, 12.5%, and 25% on K562. Average cell number of untreated cells was set 
at 100% and relative number of cells calculated accordingly. Mean ± SEM.* indicates significant 
difference ( P  <  0.05) vs. untreated control. n= 3.
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Figure 3.35: Effect of PJ on cell viability using trypan exclusion assay following 24 and 48 h 
incubation at 6.25%, 12.5%, and 25% on K562. Average cell number of untreated cells was set 
at 100% and relative number of cells calculated accordingly. Mean ± SEM. * indicates 
significant difference (P < 0.05) vs. untreated control. n= 3.
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3.4.4 Effect of PJ on Cell Cycle Using Flow Cytometry
D ifferential effects on cell cycle stage follow ing PJ treatm ent were observed
dependent on cell type investigated and dose and duration of PJ treatm ents (Table 3.3). 
CCRF-CEM cells displayed cell cycle accumulation in S phase, which was significant 
following 6.25% and 25% treatm ents with PJ (Figure 3.36) (P < 0.05). MOLT-3 and SUP- 
615 cells showed a significant (P < 0.05) S phase accumulation at all concentrations of 
PJ (Figure 3.37 and 3.38). Jurkat cells displayed a significant G0/G i phase accumulation 
at 6.25% of PJ and significant (P < 0.05) S phase accumulation at 12.5% and 25% of PJ 
(Figure 3.37). Myeloid cells (K562 and TFIP-1) displayed a significant (P < 0.05) S phase 
accumulation at the higher doses of PJ (Figure 3.42 and 3.43), while KG-la and HL-60 
cells were the only tw o cell lines which displayed a G0/G i  phase accumulation at all 
doses (Figure 3.40 and 3.41).
6.25% 12.5% 25%
CCRF-CEM S S * S *
JURKAT GO/GI* s * S *
MOLT-3 S* s * S *
SUP-B15 S * s * S *
KG-la Go/Gi Go/Gx* G0/Gi*
HL-60 Go/Gi* G0/G i* S *
K562 G0/Gi S * S*
THP-1 S S * S *
Table 3.3: Summary of cell cycle results.
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Figure 3.36: Cell cycle based on flow cytometry using FlowJo software following treatment 
with PJ at concentration 0%, 6.25%, and 12.5% for 24 h incubation on CCRF-CEM. Mean ± SEM. 
* indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Figure 3.37: Cell cycle based on flow cytometry using FlowJo software following treatment
with PJ at concentration 0%, 6.25%, and 12.5% for 24 h incubation on Jurkat. Mean ± SEM*
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Figure 3.38: Cell cycle based on flow cytometry using FlowJo software following treatment 
with PJ at concentration 0%, 6.25%, and 12.5% for 24 h incubation on MOLT-3. Mean ± SEM. * 
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Figure 3.39: Cell cycle based on flow cytometry using FlowJo software following treatment
with PJ at concentration 0%, 6.25%, and 12.5% for 24 h incubation on SUP-B15. Mean ± SEM. *
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Figure 3.40: Cell cycle based on flow cytometry using FlowJo software following treatment 
with PJ at concentration 0%, 6.25%, and 12.5% for 24 h incubation on KG-la. Mean ± SEM. * 
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Figure 3.41: Cell cycle based on flow cytometry using FlowJo software following treatment 
with PJ at concentration 0%, 6.25%, and 12.5% for 24 h incubation on HL-60. Mean ± SEM. 
*Significant difference (P < 0.05) vs. untreated control. n=3.
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Figure 3.42: Cell cycle based on flow cytometry using FlowJo software following treatment 
with PJ at concentration 0%, 6.25%, and 12.5% for 24 h incubation on K562. Mean ± SEM. * 
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Figure 3.43: Cell cycle based on flow cytometry using FlowJo software following treatment
with PJ at concentration 0%, 6.25%, and 12.5% for 24 h incubation on THP-1. Mean ± SEM. *
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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3.4.5 Effect of Isotonic/Osmolarity and pH Changes on Induction of Apoptosis
To ensure the toxic effects observed were due to bioactive agents in the PJ and not as
a result of altered isotonic or osmolarity or decreased pH induced by PJ inclusions, cells 
were treated with equivalent concentrations of distilled water (0%, 6.25%, 12.5% and 
25%) or in adjusted media [ pH of control media = 7.5; pH of PJ at 6.25% = 7.42; pH of 
PJ at 12.5% = 7.42; pH of PJ at 25% = 6.52 ] on two lymphoid cell lines (CCRF-CEM and 
MOLT-3) (Figure 3.44, 3.45, 3.49, and 3.50) and two myeloid cell lines (HL-60 and THP- 
1) (Figure 3.46, 3.47, 3.51, and 3.52) and the non-tumour CD133+ (Figure 3.48 and 
3.53) for 48 h. The majority of cell types investigated showed no significance decrease 
in live cells or increase in the apoptotic or dead cells following inclusion of water 
controls or in altered pH (P < 0.05). A small but significant decrease in live cells was 
observed in THP-1 cells (Figure 3.52) treated with water equivalent to 12.5% and 25% 
PJ, and in CCRF-CEM cells treated with adjusted media to 25% (Figure 3.45). HL-60 cells 
also showed a small significant decrease in the number of live and increased in 
apoptotic cells when treated in adjusted media to 25% (Figure 3.46). However, it is 
noteworthy that these effects were far smaller than those seen following PJ treatment.
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Figure 3.44: Annexin V-FITC/PI g based on flow cytometry. CCRF-CEM treated in pH adjusted 
media for 48 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. 
n= 3.
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Figure 3.45: Annexin V-FITC/PI based on flow cytometry. MOLT-3 treated in pH adjusted media 
for 48 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Figure 3.46: Annexin V-FITC/PI based on flow cytometry. HL-60 treated in pH adjusted media 
for 48 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
THP-1
m  0% rn 6.25% U 12.50% ■  25%
Live Apoptotic Dead
Figure 3.47: Annexin V-FITC/PI based on flow cyotmetry.THP-1 treated in pH adjusted media 
for 48 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Figure 3.48: Annexin V-FITC/PI based on flow cyotmetry.CD133 treated in pH adjusted media 
for 48 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
CCRF-CEM
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Figure 3.49: Annexin V-FITC/PI based on flow cytometry. CCRF-CEM treated in equivalent
concentration of water for 48 h. Mean ± SEM* indicates significant difference (P < 0.05) vs.
untreated control. n= 3.
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Figure 3.50: Annexin V-FITC/PI based on flow cytometry. MOLT-3 treated in with equivalent 
concentration of water for 48 h. Mean ± SEM. *indicates significant difference (P < 0.05) vs. 
untreated control. n= 3.
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Figure 3.51: Annexin V-FITC/PI based on flow cytometry. HL-60 treated in equivalent
concentration of water for 48 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs.
untreated control. n= 3.
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Figure 3.52: Annexin V-FITC/PI based on flow cytometry. THP-1 treated in equivalent 
concentration of water for 48 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. 
untreated control. n= 3.
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Figure 3.53: Annexin V-FITC/PI based on flow cytometry. CD133 treated in equivalent
concentration of water for 48 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs.
untreated control. n= 3.
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3.5 Discussion
This study aimed to investigate the hypothesis that: The effect of pomegranate
extracts and its purified constituents have been investigated previously using cell lines
derived from solid tumours; few, however, have investigated the effect in leukaemia
cells. Khan et al. (2009) investigated the effect of PJ on induction of apoptosis in 2
breast cancer cell lines (SUM 149 and MDA-231), together with non-tumour MCF-7
10A cells, where treatment with PJ induced apoptosis following 72 h selectively within
the 2 tumour cell lines and did not affect the non-tumour MCF-7 cells. Here we also
identified an increased sensitivity to PJ within the majority of leukaemia cell lines
compared to non-tumour HSCs were seen. Together, these studies suggest that
pomegranate extracts could hold promise for selective cancer therapies in subsets of
cancer types. Seeram and his colleagues (2005) showed that both isolated constituents,
such as ellagic acid and punicalagin as well as PJ induced apoptosis in 2 human colon
cell cultures (HT-29 and HCT116). It has also been shown that PJ derived ellagitannins
and urolithins induced apoptosis in colon cancer cell line (HT-29) following 24 h
(Kasimsetty et al, 2010). Induction of apoptosis, in a number of prostate cancer cells
such as PC3 (Albrecht etal, 2004; Malik et al, 2005), DU-145 (Malik et al, 2005; Hong et
al, 2008), LNCaP and LNCaP-AR (Hong et al, 2008), and LAPC4 (Koyoma etal, 2010) has
also been shown. Here, PJ also induced apoptosis in a number of leukaemia cell lines.
Importantly, we have shown that the response to PJ varied between leukaemia cell
lines and the majority was affected to a greater extent than the non-tumour control
cells. The sensitivity to chemotherapy agents often display selective targeting to either
leukaemias of the lymphoid or myeloid origin; for example, phenoxodiol showed
greater toxicity to lymphoid leukaemia than myeloid leukaemia (Herst et al, 2009), as
do extracts from carrot juice (Zaini et al, 2010). Lymphoid leukaemia and myeloid
leukaemia are well known to be caused by abnormalities to differential signalling
pathways; for example, STATs are involved in the pathogenesis of myeloid leukaemia
and act as a target for selective chemotherapy agents such as the tyrosine kinase
inhibitors, which do not show any effect within lymphoid leukaemia (White and Huges,
2009). Thus, it is not surprising to see differential sensitivity patterns between cell lines
derived from myeloid and lymphoid leukaemia's within the current study. Future work
will focus on investigating the molecular mechanisms of PJ on these cell lines to
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elucidate further the molecular targets of PJ and hence identify reasons for the 
selective targeting toward lymphoid leukaemia cell lines.
Interestingly, however, some of the myeloid leukaemia cell lines did show cytotoxic 
effects, suggesting that in certain subtypes of myeloid leukaemia PJ may still be a 
useful therapeutic agent. In addition to induction of apoptosis, cell cycle arrest can be 
a useful target for cancer therapies (Schmitt, 2007).
Here, a dose-dependent arrest of cell cycle at different phases was observed. At low
doses of PJ, the majority of cells showed G0/G i arrest, suggesting induction of
senescence (Schmitt, 2007). G0/G i arrest has been observed previously in a number of
tumour cell lines following PJ treatments; for example, human lung carcinoma A549
cell line treatment with PJ for 72 h resulted in a dose-dependent arrest of cells in Go/Gi
phase of the cell cycle (Khan et al, 2006b). In addition, Kasimsetty et al. (2010)
observed a reduction in S phase and an accumulation of cells in Go/Gi in DU145 colon
cancer cells following PJ treatment (Kasimsetty et al, 2010). This reduction in S phase
and accumulation of cells in Go/Gi was also observed within the higher concentration
of PJ for HL-60 and KG-la cell lines, which were also the most sensitive myeloid cell
lines. Interestingly, these 2 cell lines were the only ones investigated that at this
concentration induced G0/G i arrest; these 2 cell lines show myeloblast morphology
unlike the other 2 myeloid cell lines that appears to affect the cell cycle response. This
may be due to modulation of c-myc expression that is over expressed within HL-60
cells and inhibition of c-myc induces G0/G i cell cycle arrest (Anfossi et al, 1989); thus it
is possible the G0/G i arrest observed here is due to inhibition of c-myc expression. In
all other cell lines and non-tumour HSCs treated with 12.5%, PJ S-phase arrest was
observed, demonstrating again variability between cell lines from different leukaemia
types. This effect has been observed previously in CaCo-2 cells treated with the
pomegranate extracted ellagitannin: punicalagin (Herst et al, 2009). Kasimsetty et al.
(2010) also evaluated the effect of PJ-derived ellagitannins (gallic acid, ellagic acid,
gallagic acid, hexahydroxydiphenic, gallagyldilactone, punicalins, and punicalagins) on
HT-29 colon cells, and once again S-phase arrest was observed. Differential effects on
cell cycle dependent on concentration or duration has been seen in a number of
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studies previously for example, Mertens-Talcott et al. (2003) investigated 3 
polyphenolic compounds (camptothecin, ellagic acid, and quercetin) on a lymphoid 
leukaemia cell line (MOLT-4); they demonstrated Go/Gi arrest following camptothecin 
treatment for 12 h, but this effect was not observed at later time points, whereas 
treatment with a combination of ellagic acid and quercetin showed no effect following 
12 h, but S-phase arrest was observed following 24 h (Mertens-Talcott et al, 2003). S- 
phase arrest can result from 2 main causes, either an artefact of cells undergoing 
apoptosis within G2/M  phase thus reducing their DNA content and accumulating within 
the S-phase peak during cell cycle analysis. Alternatively, agents that alter cell cycle 
expression that control progression though S phase will result in S-phase arrest. This 
has been shown previously in colon cancer cells treated with 2,3- 
dichlorophenoxypropyl, where S-phase arrest was induced by over expression of p21 
(Zhu et a l , 2004) or by affecting agents involved in DNA repair mechanisms such as 
inhibition of Poly(ADPribose) as seen following treatment of RAW 264.7, a macrophage 
cell line with gallotannin (Rapizzi et al, 2004), which could be a mechanism induced by 
pomegranate extracts within our current study.
Within this study, we also investigated the overall effect of PJ on total viable cell 
number, which shows a combined effect of induction of apoptosis and inhibition of 
cellular proliferation, confirming our previous data. Decreased number of viable cells 
has previously been demonstrated following pomegranate extract treatments in a 
number of cancers. Several studies in cell culture and animal models have reported 
inhibition of prostate cancer by PJ (Seeram et al 2005, 2007; Albrecht et al 2004; 
Lansky (1) et al 2005; Malik et al 2005; Sartippour et al., 2008; Retting et al, 2008; 
Hong et al, 2008; Koyoma et al, 2010).
The effects of pomegranate fruit extracts on lung cancer were examined by Khan et al.
(2007b) both in vitro and in vivo, demonstrating that Normal bronchial epithelial cells
(NHBE) and human lung carcinoma A549 cells were treated with pomegranate fruit
extract (50-150 pg/ml) for 72 h, showing significant decrease in cell viability in A549
cells, while treatment of NHBE cells resulted in minimal effects. Based on the results of
this in vitro data, a study carried out in the mouse model showed that oral
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administration of human acceptable dose of PJ extract to athymic mice implemented 
with A549 cells resulted in significant inhibition in progression of tumour growth. 
Human breast cancer cell lines MCF-7 and MB-MDA-231 treated with fermented 
pomegranate resulted in a decrease in cell viability on both cells. In other breast 
cancer cell lines (MDA-231 and SUM-149) pomegranate fruit extract decreased cell 
proliferation following 72 h. In vitro studies pomegranate fruit extract decreased cell 
viability in WA4 mouse mammary cancer cells. Seeram et al. (2005) reported that both 
isolated constituents such as ellagic acid and punicalagin as well as PJ inhibited the 
proliferative effects of HT29 and HCT116 colon tumour cells.
PJ investigated within this study was a total extract of all the polyphenolics and 
anthocyanins together with any other potential bioactive agents, rather than a pure 
fraction this was performed to investigate the effects of combined responses, rather 
than simple individual actions. Pomegranates contain a wide number of potential 
bioactive agents, including hydrolysable tannins (such as punicalin, punicalagin, and 
gallagic), and anthocyanins (such as delphinidin, cyanidin, and pelargonidin), which can 
often act synergistically or indeed inhibit the actions of other agents (Herst et al, 2009; 
Mertens-Talcott etal, 2003).
3.6 Conclusion
This study is the first to investigate the effect of PJ on 8 different leukaemia cell lines in 
addition to normal HSCs; we demonstrated important variations in sensitivity between 
different types of leukaemia cell lines and normal cells. This study suggests that the 
active components from PJ could have potential as agents in the treatment of certain 
leukaemia's, and further work will aim to identify these components.
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compounds
4.1 Introduction
We have previously shown that crude extracts of PJ induce apoptosis and inhibit cell 
cycle in a number of leukaemia cell lines, which demonstrated greater sensitivity than 
non-tumour control cells (Chapter 3) (Dahlawi etal, 2011).
However, to date, the compounds responsible for the anti-leukaemic properties of 
pomegranate remain unknown. PJ contains a number of potential active compounds 
including organic acids, vitamins, sugars, and phenolic components. The phenolic 
components include phenolic acids: principally, hydroxybenzoic acids (such as gallic 
acid and ellagic acid) (Amakura et al, 2000); hydroxycinnamic acids (such as caffeic acid 
and chlorogenic acid) (Elfalleh et al, 2011); anthocyanins, including glycosylated forms 
of cyanidin, delphinidin, and pelargonidin (Fanali et al, 2011; Krueger, 2012); and 
gallotannins and ellagitannins (Amakura et al, 2000). In addition, PJ contains glucose, 
fructose, water, and organic acids (including ascorbic and citric acid) (Krueger, 2012). 
However, the concentration and the contents of these compounds vary due to growing 
region, climate, cultivation practice, and storage conditions (Pande and Akoh 2009; 
Elfalleh et al, 2011; Legua et al, 2012).
Here, we used solid phase extraction (SPE) to fractionate PJ to determine which 
fractions induced apoptosis and cell cycle arrest using two lymphoid and two myeloid 
cell lines, which we previously demonstrated in Chapter 3 were sensitive to crude PJ. 
We assessed the polyphenol composition of the fractions by phenol assay and used 
liquid chromatography mass spectrometry (LC-MS) to identify active compounds 
within fractions of PJ.
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4.2 Materials and Methods
4.2 .1  Sample Preparation and Fraction Separation from  PJ
Solid phase extraction (SPE) using Strata C18E GIGA columns (Phenomenex) were used 
to separate fractions from pomegranate juice extract (PJ). First, the columns were pre­
equilibrated by washing with 50 ml. of acetonitrile, then 50 mL of 0.1% formic 
acid/ultra pure water (v/v) (Sigma) PJ derived from fresh pomegranates (Sainsbury's 
U.K.) prepared as described in section 2.1 were sterile filtered through 0.22 pm syringe 
filter (Invitrogen) and diluted 1:1 with sterile distilled water, then 50 mL of this diluted 
juice was added to the SPE unit. The unbound compounds which passed directly 
though the column were collected (Fraction A: unbound Fraction). Then, 50 mL each of 
ultra-pure water, acetonitrile, acetone, and ethyl acetate were added to the column to 
collect water (Fraction B), acetonitrile (Fraction C), acetone (Fraction D), and ethyl 
acetate (Fraction E) fractions, respectively, as described previously (Zaini et al, 2012) 
(Figure: 4.1). Each fraction was dried using freeze drying (MODULYOD-230 freeze dryer, 
Thermo) at -30 to -80°C for Fractions A and B or dried under a nitrogen stream at room 
temperature for Fractions C, D, and E. The water, unbound, and acetonitrile fractions 
were dissolved in distilled water; the acetone fraction in methanol; and ethyl acetate 
fraction in DMSOto the required dilution (Sigma)).
A B C D E
Figure 4.1: Illustrates fractions generated from PJ using SPE. A: Unbound fraction, B: water 
fraction, C: acetonitrile fraction, D: acetone fraction, and D: ethyl acetate fraction.
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4.2.2 Cell lines and Culture
Four leukaem ia cell lines were obtained from the American Type Culture Collection 
(ATCC; Middlesex, U.K.), which chapter 3 and Dahlawi et al. (2011) demonstrated  
differing sensitivity to PJ. Two lymphoid cell lines: CCRF-CEM and MOLT-3 and tw o  
myeloid cell lines: HL-60 and THP-1 (Section 2.2). Cell lines were maintained and 
cultured in R P M I1640 medium (Invitrogen, Paisley, U.K.) supplemented w ith 10% (v/v) 
foetal bovine serum, 1.5 m m ol/L L-glutamine, and 100 |ig/mL penicillin/streptomycin  
(complete media) in a hum idified atmosphere of 5% C 02 at 37°C.
Cells were seeded in 12-well plates (Fisher Scientific) at a cell density of 0.5 x 106 cells 
per well and treated individually w ith the five fractions (unbound [i.e., compounds 
which passed directly though the column] and fractions eluted w ith w ater, acetonitrile, 
acetone, and ethyl acetate fractions) at equivalent compound weights seen in 0%, 
6.25%, 12.5%, and 25% whole PJ, all treatm ents were performed in triplicate. 
Following treatm ent, cells were investigated for induction of apoptosis and inhibition 
of cell proliferation following 24, 48, and 72 h (Table 4.1).
Cell Titer-Glo* PJ, unbound, water, 6.25%, 12.5%, CCRF-CEM, MOLT- 24, 48
Luminescent Cell acetonitrile, and 25% 3, HL-60, and and 72
Viability Assay acetone, and ethyl 
acetate fractions
THP-1 hr
Cell cycle Acetonitrile fraction 6.25%, 12.5%, 
and 25%
CCRF-CEM, MOLT- 
3, HL-60, and 
THP-1
148 hr
Annexin V-FITC/PI Acetonitrile fraction 6.25%, 12.5%, 
and 25%
CCRF-CEM, MOLT- 
3, HL-60, and 
THP-1
24, 48 
and 72 
hr
NucView™ 488 Acetonitrile fraction 6.25%, 12.5%, CCRF-CEM, MOLT- 24, 48
Caspase-3 substrate 
assay
and 25% 3, HL-60, and 
THP-1
and 72 
hr
Hoechst 33342 and PI Acetonitrile fraction 6.25%, 12.5%, 
and 25%
CCRF-CEM, MOLT- 
3, HL-60, and 
THP-1
24, 48 
and 72 
hr
LC-MS PJ, unbound, water, acetonitrile, acetone, and ethyl acetate fractions
Folin-Ciocalteu
method
PJ, unbound, water, acetonitrile, acetone, and ethyl acetate fractions
Table 4.1: Experimental design for Chapter 4.
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4.2 .3  Cell V iab ility
The effect of SPE fractions (unbound, water, acetonitrile, acetone, and ethyl acetate) 
on the viability of cells was determined by the Cell Titer-Glo* Luminescent Cell Viability 
Assay (Promega) which measures total adenosine triphosphate (ATP) present, 
indicating the number of metabolically active cells as described in section 2.3.2. Cells 
were seeded at 25 x io 4 cells in 100 pL of complete media and treated with each 
fraction at a concentration equivalent to that seen in 0%, 6.25%, 12.5%, and 25% 
whole PJ in white 96-well plate (Fisher Scientific) for 48 h.
4 .2 .4  Annexin V- FITC /P I Flow Cytom etry assay
Annexin V-FITC/PI fluorescein isothiocyanate (FITC) stains were used to detect 
apoptosis based on flow cytometry as described in section 2.4.1. Cells were seeded at 
5 x io 5 cells in 100 pL of complete media and treated with each fraction at a 
concentration equivalent to that seen in 0%, 6.25%, 12.5%, and 25% whole PJ in a 12- 
well plate (Fisher Scientific) for 24,48, and 72 h. Data were recorded from 10,000 cells 
per sample and analyzed using FlowJo software (Tree Star).
4.2 .5  Caspase-3 Activity
NucView™ 488 Caspase-3 substrate (Cambridge Bioscience, Cambridge, U.K.), was 
used for detection of apoptosis based on flow cytomerty as described in section 2.4.3. 
Cells were treated with PJ fractions (unbound, water, acetonitrile (ACN), acetone, and 
ethyl acetate) at concentrations equivalent to their component concentrations seen in 
0-25% whole PJ for 48 h. Data were recorded from 10,000 cells per sample and 
analyzed using FlowJo software (Tree Star, Ashland, OR).
4.2 .6  Hoechst 33342 and Prop idium Iodide (PI) staining
Apoptotic cells can be distinguished from healthy and necrotic cells by certain
morphological features which are an important tool in apoptosis research. These 
features include cell shrinkage, membrane blebbing, chromatin condensation and 
nuclear fragmentation (Kerr et al, 1972, Wyllie et al, 1980, Galluzi et al, 2007). In 
contrast necrotic cells characterised by loss of membrane integrity. Begin with swelling
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of the cytoplasm and mitochondria complete necrosis with cell lysis (Galluzi et al, 
2007). Such features can be observed under a fluorescence microscope using a DNA 
specific dye.
Hoechst 33342 and PI staining technique detects apoptosis based upon fluorescent 
detection for morphological changes in apoptotic cells. Hoechst 33342, is a cell 
permeable DNA stain that is excited by ultraviolet light at around 350 nm and emits 
blue fluorescence at 460 nm. Hoechst 33342 binds preferentially to adenine-thymine 
(A-T) regions of DNA. This stain binds into the minor groove of DNA and exhibits 
distinct fluorescence emission spectra that are dependent on dye base pair ratio. PI 
stain as described previously in section 2.4.1 is a red-fluorescence dye 
(excitation/emission 535/617), which is only permeate to dead cells. The staining 
pattern resulting from the simultaneous use of these dyes makes it possible to 
distinguish normal, apoptotic, and dead (late apoptotic and necrotic) cell populations 
by fluorescence microscopy (Figure 4.3).
4.2.5.1 Methodology
Hoechst 33342 and propidium iodide (PI) staining was used to observe the 
apoptotic/necrotic morphology of HL-60 cells. In brief, 0.25 x io 5 cells/mL were seeded 
into 12-well plates and incubated for 24 h following treatment with the acetonitrile 
fractions at concentrations equivalent to component concentrations seen in 0-25%  
whole PJ. Then, 1 pL of PI (50 pg/mL) and 5 pL of Hoechst 33258 (10 pg/mL) stains 
were added to each well and incubated at 37°C for 15 min. Cells were investigated 
using an Olympus inverted fluorescence microscope at excitation wavelength 350 nm 
and 488 nm dual wavelength filter and images were captured using Q Capture-Pro 8.0 
(UVP Biolmaging Systems, Loughborough, U.K.).
4.2.5.2 Analysis
Cell populations (live, apoptotic & necrotic) were separated into three groups: live cells
displayed low levels of fluorescence and normal morphology; apoptotic cells showed a
higher level of blue fluorescence together with chromatin features of apoptosis, and
dead cells displayed intense red fluorescence (Figure: 4.2). Necrotic cells is also
characterized by high red fluorescence with damaged membranes display, but can be
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differentiated from late apoptotic cells as mentioned in 4.2.6. (Figure4.2). Quantitative 
analysis of cell populations (live, apoptotic and necrotic) was performed based on 
counting 200 randomly-selected cells and the percentage of apoptotic features 
determined for each sample.
Figure 4.2: Analysis of apoptosis of HL-60 cell line using Hoechst and PI staining. Live cells 
indicated by blue arrow, early apoptotic cells indicated by green arrows, dead and late 
apoptotic cell indicated by red arrows, and necrotic cell indicated by purple arrow.
4.2 .6  Cell Cycle
The cell cycle distribution of leukaemia cell lines was measured by DNA content in each 
cell based on flow cytometry using the PI stain as described in section 2.5. Data from 
10,000 cells per sample were recorded and percentages of cells within G0/Gi, S, and 
G2/M  cell cycle phases were determined with Flow Jo software and Waston 
(pragmatic) analysis of cell cycle (Tree Star).
4.2 .7  Liquid Chrom atography Mass Spectrom etry (LC-MS)
4.2.7.1 Methodology
Samples (containing 20 pg gallic acid equivalents [GAE]s by Folin assay) were analyzed 
on a LCQ-DECA system, comprising Surveyor autosampler, pump and photo diode 
array detector (PDAD), and a Thermo-Finnegan mass spectrometer iontrap (Stoke on
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Trent, U.K.). The PDAD scanned three discrete channels at 280, 365, and 520 nm. 
Samples were eluted with a linear gradient of 5% acetonitrile (0.1% formic acid) to 30% 
acetonitrile (0.1% formic acid) on C18 column (Synergi Hydro C18 with polar end 
capping 2.0 mm x 150 mm) (Phenomenex) over 60 min at a rate of 200 pL/min. For 
died fraction samples, the gradient was altered {t = 0, 5% acetonitrile; t = 10 min, 
12.5% acetonitrile; and t = 60 min, 30% acetonitrile) to try to separate the later eluting 
ellagitannins. The LCQ-DECA LC-MS was fitted with an electrospray ionization interface 
and the samples were analyzed in positive and negative ion mode. There were two 
scan events: full scan analysis followed by data-dependent MS/MS of the most intense 
ions. The data-dependant MS/MS used collision energies (source voltage) of 45% in 
wideband activation mode. The MS detector was tuned against cyanidin-3-O-glucoside 
(positive mode) and against ellagic acid (negative mode).
4.2 .8  D eterm ination o f Total Phenolics
The aim of this method was to determine the total polyphenol content in PJ and its 
fractions (unbound, water, acetonitrile, acetone, and ethyl acetate) using Half Strength 
Folin-Ciocalteu method (Singleton etal, 1999; Ainsworth etal, 2007).
Phenolic compounds are oxidized by Folin-Ciocalteu reagent. This reagent is formed 
from a mixture of phosphotungstic acid, H3PW12O40, and phosphomolybdic acid, 
H3PMol2O40, which, after oxidation of the phenols, is reduced to a mixture of blue 
oxides of tungsten, W8023, and molybdenum, Mo8023. The blue colouration 
produced has a maximum absorption in the region of 750 nm, and is proportional to 
the total quantity of phenolic compounds originally present (Ainsworth et al, 2007
4.2.8.1 Methodology
The content of the total phenolics was evaluated by using the Half Strength Folin- 
Ciocalteu method adapted from (Deighton et al. 2000). First, 250 pL Folin-Ciocalteu 
reagent (Sigma) was added to 250 pL of each fraction (unbound, water, acetonitrile, 
acetone, and ethyl acetate) (1% diluted with water) and mixed gently prior to 3 
minutes incubation at room temperature. Then, 250 pL of sodium carbonate solution 
was added to each sample, mixed well, and incubated for 1 h prior to recording at 750
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nm using Ultrospec™ 2100 pro UV/Visible Spectrophotometer (GE Healthcare Life 
Science).
Triplicate samples containing a range of gallic acid contents from 0-500 pg were 
prepared to create standards. Total phenolics were expressed as Gallic Acid 
Equivalents (GAEs).
4.2 .9  Statistical analysis:
Means and standard error of the mean (SEM) were calculated and a Shapiro-Wilke 
test (Stats Direct, Cheshire, U.K.) was used to test whether data followed a normal 
distribution. Data were non-parametric and thus a Kruskal-Wallis test and a Conover- 
Inman post hoc test were used to investigate significant differences. Results were 
considered statistically significant when P < 0.05.
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4.3. Results:
4.3 .1  D ifferential Effects o f Pomegranate Fractions on ATP Levels
W hole PJ induced a dose-dependent inhibition of ATP levels w ithin all four leukaem ia
cell lines (P < 0.05) (Figure: 4.3). The acetonitrile fraction obtained after SPE induced a 
significant decrease in ATP levels (P < 0.05) which showed a non-significant increase in 
cytotoxicity compared to the whole juice extracts mainly at the highest concentrations 
(25%) [P > 0.05) (Figure 4.3). The IC50 values of PJ and acetonitrile fractions for CCRF- 
CEM, MOLT-3, HL-60, and THP-1 cells are illustrated in Table 4.2. Low-dose treatm ents  
of leukaem ia cell lines w ith e ither whole PJ or the acetonitrile fractions demonstrated  
dramatic reduction in ATP levels indicating decreased cell viability following 24 h 
treatm ent (Fig. 4.3). The unbound, water, acetone, and ethyl acetate SPE fractions had 
m inimal effects on any cell line at the doses investigated (concentration equ ivalent to  
those present in 6.25%, 12.5%, and 25% whole PJ treatm ents) (Figure: 4.3).
PJ 4.0% 4.7% 4.3% 7.0%
Acetonitrile
fraction
3.1% 3.9% 3.0% 5.5%
Table 4.2: The IC50 of PJ and acetonitrile fractions on leukaemia cell lines (CCRF-CEM, MOLT-3, 
HL-60, and THP-1) following 24 h treatm ent..
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4.3.2 Effect of Acetonitrile Fraction from Pomegranate Juice on Cell 
Cycle Arrest within Leukaemia Cell Lines
Treatment of leukaemia cells lines with the acetonitrile fraction for 48 h 
demonstrated significant S phase arrest within all four cell lines (P < 0.05) with a 
corresponding significant decrease in cells within Go/Gi and M phases (P < 0.05) 
(Figure. 4.4).
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4.3 .3  Induction o f Apoptosis by Ace ton itrile SPE Fraction from  
Pom egranate Extracts w ith in  Leukaem ia Cell Lines
Acetonitrile fraction induced apoptosis (determined via Annexin V/PI-FITC) in a 
dose-dependent manner in all four leukaemia cell lines following 24, 48, and 72 h 
incubation. Acetonitrile fraction showed a significant decrease in the number of live 
cells with a significant increase in the number of apoptotic and dead cells in CCRF- 
CEM cells at all concentrations following 24, 48, and 72 h (P < 0.05) (Figure 4.5). 
MOLT-3 and HL-60 cells exhibited a slight decrease in the number of live cells with a 
slight increase in the number of apoptotic and dead cells at 6.25% following 24 h 
treatment with acetonitrile fraction. However, following 48 and 72 h both cell lines 
significantly induced apoptosis at all concentrations (P < 0.05) (Figure 4.5 and 4.6). 
THP-1 was the least sensitive among the cell lines investigated, which illustrated 
only slight induction of apoptosis at the highest concentration of 25% following 24 
h treatment. Following 48 and 72 h a significant decrease in the number of live cells 
and a significant increase in the number of live and apoptotic cells at the highest 
two concentrations 12.5% and 25% was seen (P< 0.05) (Figure: 4.6)
Induction of apoptosis by treatment with acetonitrile fraction was confirmed with 
induction of caspase-3 activity in all four cell lines following 24, 48, and 72 h (Figure 
4.7). Results showed the same pattern of sensitivity toward acetonitrile fractions 
when determined with annexin V-FITC/PI (Figure 4.5 and 4.6)
Microscopic examination (Figure 4.8) also demonstrated a marked increase in the 
number of cells displaying apoptotic morphology (such as chromatin condensation 
and fragmentation), in addition to a decrease in the number of live cells displaying 
normal nuclear morphology in CCRF-CEM, MOLT-3, HL-60 and THP-1 cells (Figure 
4.9 and 4.10). Necrotic cells were significantly increased following treatment with 
high concentrations (25%) in most of the cell lines.
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Figure 4.5: Effect of acetonitrile fraction generated by SPE of PJ on induction of apoptosis 
in leukaemia cell lines CCRF-CEM and MOLT-3. Cells treated for 24, 48, and 72 h with 
acetonitrile fraction at concentration equivalent to the concentrations of compounds 
found in 6.25%, 12.5%, and 25% whole PJ. Induction of apoptosis was determined by 
Annexin V-FITC/PI based on flow cytometry analysis. Means ± standard error. * indicates 
significant difference (P < 0.05) vs. untreated control. n= 3.
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, 24 hr 48 hr 72 hr100
Figure 4.6: Effect of acetonitrile fraction generated by SPE of PJ on induction of apoptosis in 
leukaemia cell lines HL-60 and THP-1. Cells treated for 24, 48, and 72 h with acetonitrile 
fraction at concentration equivalent to the concentrations of compounds found in 6.25%, 
12.5%, and 25% whole PJ. Induction of apoptosis was determined by Annexin V-FITC/PI 
based on flow cytometry analysis. Means ± standard error. * indicates significant difference 
(P < 0.05) vs. untreated control. n= 3.
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Figure 4.8: Effect of acetonitrile fraction generated by SFE of PJ on morphology of apoptotic 
cells in HL-60. Cells treated for 48h at concentration 6.25%, 12.5% and 25%. Apoptotic 
morphology was determined by Hoechst 33258 and PI staining using fluorescence microscope 
at magnification of x40.
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Figure 4.9: Percentage of Live, apoptotic, and necrotic in CCRF-CEM and MOLT-3 cells 
determined from Hoechst 33342 and PI morphological assessment following treatment with 
acetonitrile fraction generated by SPE of PJ at concentration 6.25%, 12.5% and 25% for 24. 
Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Figure 4.10: Percentage of Live, apoptotic, and necrotic in HL-60 and THP-1 cells determined 
from Hoechst 33258 and PI morphological assessment following treatment with acetonitrile 
fraction generated by SPE of PJ at concentration 6.25%, 12.5% and 25% for 24. (Mean ± SEM, 
* indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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4.3 .4  Phenolic Content o f SPE Fractions
The acetonitrile fraction generated by SPE had the highest phenol content of 2696.7 pg 
GAE/mL, which was more than double than that seen within whole juice extracts (1236.9 pg 
GAE/mL), whereas the phenol content of other extracts was minor in comparison with 53.5 
pg GAE/mL in the unbound fraction, 148.2 pg GAE/mL in the water fraction, 46.0 pg GAE/mL 
in the acetone fraction, and 5.7 pg GAE/mL in the ethyl acetate fraction (Figure: 4.11). This 
translated to concentrations of phenol content of 6.25% equivalent treatments containing 5.2 
pg/mL GAE within acetonitrile treatments and 2.4 pg/mL GAE within 6.25% treatments within 
whole PJ. Other fractions contained negligible levels of phenols which correlated with no 
observable biological activity.
Estimated Total Level of Phenolic Compound in Pomegranate Juice Fractions
3500
2500
oo 2000
Unbound Water Acetonitrile Acetone Ethyl acetate Juice
Figure 4.11: Estimated total level of phenolic compounds of PJ fractions (unbound, water, 
acetonitrile, acetone, and ethyl acetate) generated by SPE and whole PJ. n=3
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4.3.5 LC-MS of Whole PJ and SPE Fractions
LC-MS was carried out on the whole PJ and each fraction generated from the SPE 
procedure on samples containing 20 pg GAE. Virtually all the material from the 
unbound fraction and the water fraction was not retained and eluted in the column 
wash (data not shown). Previous work has shown that these fractions contain organic 
acids, vitamin C, and sugars. The whole PJ contained peaks characteristic of phenolic 
components previously found in pomegranate (Fischer et al, 2011) and included 
gallotannins, ellagitannins, anthocyanins, and hydroxycinnamic acid derivatives (Figure 
4.12 and Table 4.3). The acetonitrile fraction had the highest intensity of peaks but 
had a similar composition to the whole PJ. The acetone and ethyl acetate fractions 
contained lower amounts of phenolic materials but certain components were 
enhanced in these fractions (Figure 4.12). Comparison of whole PJ and the acetonitrile 
fraction (Figure 4.13) demonstrated that the acetonitrile fraction was enriched in a 
number of ellagitannins, ellagic acid, and hydroxycinnamic acid derivatives over the 
whole PJ (Figure: 4.13 and Table 4.2). However, it was clear that the acetonitrile 
fraction was depleted in anthocyanins compared to whole juice extracts (Figure 4.13) 
but all the anthocyanins in the juice were also present in the acetonitrile fraction but 
were eightfold lower (Figure 4.14 and Table 4.3). The anthocyanins identified within 
both the whole juice extracts and acetonitrile fraction included the characteristic 
glycosylated forms of delphinidin, cyanidin, and pelargonidin (Figure 4.14 and Table 
4.3) found in pomegranate.
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Figure 4.12: LC-MS chromatographs of whole PJ (A) and acetonitrile (B), acetone (C) and ethyl 
acetate fractions (D) from solid phase extraction of PJ LC-MS performed on samples containing 
20 pg GAE/mL by follin assay. LC-MS, liquid chromatography mass spectrometry; PJ, 
pomegranate juice extract; GAE, gallic acid equivalent.
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Figure 4.13: LC-MS chromatographs of whole PJ (Black) and acetonitrile solid phase fraction 
from PJ (Blue) demonstrating peak differences within negative ion mode. *The main peaks in 
juice sample that differ from the ACN fraction. The identities of peaks labelled are described in 
Table 4.2.
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Figure 4.14: LC-MS chromatographs of whole PJ (Black) and acetonitrile solid phase fraction 
from PJ (Blue) demonstrating peak differences within positive ion mode. *The main peaks in 
juice sample that differ from the ACN fraction. The identities of peaks labelled are described in 
Table 4.2.
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1 275 1083 783, 481, 301 Punicalagin
2 275 1569 935, 785, 765 Sanguiin H-10 like isomer
3 275 1569 935, 785, 765 Sanguiin H-10 like isomer
4 280 1569 935, 785, 765 Sanguiin H-10 like isomer
5 275 581 301 EA derivative
6 290 507 327, 315 Methyl EA derivative
7 330 533 353 HCA derivative
A1 520 627+ 303 Delphnidin-3, 5-O-diglucoside
A2 512 611+ 287 Cyanidin-3, 5-O-diglucoside
A3 500 595+ 271 Pelargonidin-3, 5-O-diglucoside
A4 520 465+ 303 Delphnidin-3-O-glucoside
A5 515 449+ 287 Cyanidin-3-O-glucoside
A6 500 433+ 271 Pelargonidin- O-glucoside
Table 4.3: Putative identification of phenolic components.
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4 .4  Discussion
Pomegranates have been postulated by a number of groups worldwide to provide 
bioactive compounds with anti-cancer actions, and have been successfully used in a 
number of randomized clinical trials for prostate cancer (Paller etal, 2012). We 
previously demonstrated in Chapter 3 that crude pomegranate juice extract induced 
apoptosis and inhibited cellular proliferation inducing S phase arrest in leukemia cell 
lines. Here, we used SPE to separate the PJ into fractions and identified that the 
acetonitrile fraction contained the bioactive compounds responsible for induction of 
apoptosis, cell cycle arrest and inhibition of proliferation within leukemia cell lines.
LC-MS analysis confirmed that the PJ contained a mixture of gallotannins, ellagitannins, 
anthocyanins and hydroxycinnamic acid derivatives characteristic of pomegranate 
(Fischer etal, 2011). Importantly most of these components were recovered in the 
acetonitrile fraction with only a small proportion of phenolic components being 
identified in other fractions. The phenolic-enriched acetonitrile fraction was the most 
effective, and this strongly suggests that ellagitanins and other phenolic agents were 
responsible for its bioactive actions. Interestingly, we identified that the active 
acetonitrile fraction to be enriched in ellagitannins, but comparably depleted in 
anthocyanins.
A number of ellagitannins were identified as well as ellagic acid and hydroxycinnamic 
acid derivatives. Ellagitannins extracted from pomegranate have been previously 
shown to induce apoptosis in HL-60 cell lines (Li et al, 2011). We observed similar pro- 
apoptotic affects when we treated this cell line together with other leukemia cell lines 
with the ellagitannin-rich acetonitrile fraction from pomegranate juice. Similarly ellagic 
acid has been shown to induce apoptosis within HL-60 cell lines, together with S Phase 
arrest (Hagiwara etal, 2010). This S Phase arrest mimics that seen here following 
treatment with the acetonitrile fraction, and those seen previously on whole PJ 
(Chapter 3). In contrast, ellagic acid and caffeic acid treatment of normal human 
peripheral blood mononuclear cells inhibited apoptosis induced by hydrogen peroxide 
treatments, suggesting that these compounds have protective effects on these cells 
(Khanduja etal, 2006). This was confirmed in Chapter 3 which showed PJ showed a 
greater toxicity towards leukemia cell lines than non-tumour control cells. This may
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suggests that the ellagitannins within PJ display protection to apoptosis in non-tumour 
cells, but induce apoptosis in tumour cells
Induction of apoptosis by a number of hydroxycinnamic acids have also been seen 
within leukaemia cell lines. Artepillin C, an extract from Brazilian propolis, has been 
shown to induce apoptosis and inhibit DNA synthesis resulting in S Phase arrest 
(Kimoto et al, 2001). Anthocyanins were also found in the acetonitrile fraction from PJ 
although at lower levels than seen in whole PJ. Anthocyanin treatments of leukaemia 
cell lines have also demonstrated inhibition of cell proliferation and induction of 
apoptosis by a number of groups worldwide (Hou etal, 2003, 2005; Katsuzaki etal, 
2003; Fimognari etal, 2004, 2005; Hyun and Chung 2004; Chang etal, 2005; Xia etal, 
2006; Feng et al, 2007; Lee et al, 2009). This could account for some of the apoptosis 
induction within leukaemia cells following treatment with the acetonitrile fraction 
from PJ. However, although treatment of U937 cells (histocytic leukemia cell lines) 
with cyanidin and malvinidin demonstrated G2/M  phase arrest (Hyun and Chung 2004), 
50 % effectiveness was not reached until ~50 pg/mL. The acetonitrile fraction was very 
effective at ~50 pg GAE/mL and the anthocyanin content was less than ~5 % of the 
content. However, the 8-fold depletion in anthocyanin content between PJ and the 
acetonitrile fraction did not reduce effectiveness and this suggests that the actions of 
PJ may not be due to its anthocyanin content.
This study demonstrated that only the acetonitrile fraction demonstrated activity 
towards leukaemia cell lines suggesting the phenolic agents within pomegranate are 
responsible for induction of apoptosis and inhibition of cellular proliferation. The 
relative enrichment of ellagitannins over anthocyanins and the closer agreement on 
affects of cell cycle seen with ellagitannin treatment of leukemia cell lines, suggest that 
ellagitannins may be the major players in the anti-cancer actions of pomegranate. 
However, it is highly probable that a number of compounds found within the 
acetonitrile fraction of PJ interact with each other. Indeed synergistic actions of ellagic 
acid with quercetin and resveratrol have been demonstrated previously in the 
leukemia cell line MOLT4 cells (Mertens-Talcott etal, 2003, 2005; Mertens-Talcott and 
Percival 2005). Seeram et al, (2005) found that individual treatment of human oral, 
colon and prostate cancer cell lines with punicalagin, ellagic acid and total
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pomegranate tannins failed to induce the same toxicity as whole pomegranate extracts 
suggesting these agents either work synergistically or that other minor agents within 
PJ are responsible for the actions of pomegranate (Seeram et al, 2004). Conversely, our 
study demonstrated that treatment of leukaemia cell lines with the acetonitrile 
fraction from pomegranate at concentrations determined to ensure equal 
concentrations of agents (not just phenolics) within the fractions to those in whole PJ 
suggested all the toxicity seen in pomegranate juice was due to the agents seen within 
this acetonitrile fraction. SPE resulted in increased phenolic content of the acetonitrile 
fraction compared to the whole juice, which was not surprising as it is concentrated in 
phenolic compounds due to the loss of sugars and other compounds which are 
extracted in the unbound and water fractions.
Of course upon consumption of pomegranates many of the compounds identified here 
do not enter the blood stream within this form. For example the ellagitannins 
themselves do not enter the bloodstream (Seeram etal, 2004, 2006, 2008; Espin etal, 
2007). As such they cannot be effective directly against leukemic cells in vivo if 
delivered via oral consumption. However these could be delivered via pharmacological 
means. However oral delivery could still provide bioactivity from the ellagitannins as 
the colonic-derived metabolites the urolithins are known to circulate in the blood 
stream (Seeram etal, 2004, 2006, 2008; Espin etal, 2007), accumulate at certain sites 
(Seeram etal, 2007) and are effective against cancer cell lines (Seeram etal, 2007; 
Bialonska etal, 2009; Kasimsetty etal, 2010), and thus could provide the bioactive 
actions of consumed pomegranates. The identification of the compounds responsible 
within pomegranate for the anti-cancer affects will be the next step towards 
understanding the role of pomegranates in cancer therapeutics.
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5. Anti-proliferative 
pomegranate pure compounds in
leukaemia cell line
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5.1 Introduction
Dietary chemoprevention of cancer is increasingly considered as being an important 
way to reduce the risk of cancer. In the last decade pomegranate has shown promise 
in the prevention of cancers, as has been demonstrated in studies with extracts and/or 
isolated bioactive compounds (Lansky and Newman, 2007; Dahlawi et al, 2011, 
Dahlawi et al, 2013, Viladomiu et al, 2013). PJ is a rich source of many compounds 
belonging to different chemical classes including, organic acid and phenolic 
compounds such as: phenolic acids; anthocyanins; flavonoids; anthocyanins, and 
ellagitannins, which have been discussed previously (3.1.2.3) (Lansky and Newman, 
2007; Viuda-Marrots et al, 2010; Viladomiu et al, 2013). However, the chemical 
composition of pomegranate can vary depending on the cultivar, growing region, 
climate, maturity and storage conditions and plant components (Poyrazoglu et al, 
2002; Barzegar et al, 2004; Fadvi et al, 2005).
This study tested the hypothesis that: compounds found in the PJ have growth 
inhibitory properties that contribute to their protection against survival and growth of 
cancers.
5.2 Objective
The objective of this study was to examine the effect on cell viability of a number of 
pure compounds that were either identified in the acetonitrile fraction of PJ (chapter 
3) (Dahlawi et al, 2013); were present in the other fractions of PJ or have been 
identified as PJ components in previous studies (Lansky and Newman, 2007, Fischer 
et al, 2011, Viladomiu et al, 2013). The effects of the selected compounds were 
studied on ATP levels in four human leukaemia cell lines and non-tumour HSCs.
Twenty six compounds (Table 5.1) representing the different classes of compounds 
found in PJ were screened. These included: organic acids; hydroxybenzoic acids; 
hydroxybenzoic acids; falavan-3-ols; ellagitannins; amino acids; indoleamines; and 
anthocyanins. This would enable the identification of the most active compounds in PJ 
for further investigation.
170
Chemical class Compound name Compound structure References
Organic acid Citric acid (Sigma) O H
)
Poyrazoglu et 
al. (2002).
Organic acid Malic acid (Sigma)
0 „  H
O H OH
Poyrazoglu et 
al. (2002).
Organic acid Tartaric acid 
(Sigma)
0 .  H
O H OH
Poyrazoglu et 
al. (2002).
Organic acid Fumaric acid 
(Sigma)
OH
O H
Poyrazoglu et 
al. (2002).
Organic acid Succinic acid 
(Sigma)
Poyrazoglu et 
al. (2002).
Organic acid Ascorbic acid 
(Sigma)
.OH
H„
O *  H
P rO H  OH
Lansky and 
Newman, 2007
Hydroxybenzoic Gallic acid (Sigma) 
acid V 0H
HO^  'OH
OH
Amakura et al. 
(2000b), Huang 
etal. (2005), 
Gomez-Caravaca 
et al. (2013).
Hydroxybenzoic Ellagic acid
acid (Sigma)
O H
O H
Amakura et al. 
(2000), Gill et 
al.(2000), Wang 
et al. (2005), 
Gomez- 
Caravaca et al. 
(2013).
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Table (continued)
Hydroxycinnamic
acid
Caffeic acid 
(Sigma)
H O
O H
Artik (1998), 
Amakura et 
al.{2000a)
O
Hydroxycinnamic
acid
p-cumaric acid O H Artik (1998), 
Amakura et 
al.(2000a).
Cyclitol carboxylic 
acid
Quinic acid 
(Sigma)
Artik (1998), 
Amakura et 
al.(2000a)
O H
Flavan-3-ols catechin 
(Enzo Life 
Science)
de Pascual- 
Teresa et 
al.{2000), 
Gomez- 
Caravaca eto l. 
(2013).
Flavan-3-ols Epicatechin (Enzo 
Life Science)
HO
de Pascual- 
Teresa et 
al.(2000), 
Gomez- 
Caravaca et al. 
(2013).
Flavan-3-ols Epigalocatechin 
3-gallate (EGCG) 
(Enzo Life 
Science)
,OH
HO. ‘O H
.OH
‘O H
de Pascual- 
Teresa et 
al.(2000).
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Table (continued)
Chemical class Compound name Compound structure References
Flavonols Quercetin (Sigma) Artik (1998); 
Caravaca et 
al. (2013).
Flavonols Rutin
(Enzo Life 
Science)
Ellagitannins Punicalagin
(Sigma)
Gill et 
al.(2000), 
Gomez- 
Caravaca et 
al. (2013). 
Dahlawi et 
al.( 2013).
Amino acids Proline
(Sigma)
Velioglu et al. 
(1997).
Amino acids Valine
(Sigma)
Franciosi
(1980).
Amino acids Methionine
(Sigma)
Franciosi
(1980).
Artik (1998).
Indoleamines Tryptamine
(Enzo Life 
Science)
Badria (2002).
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Table (continued)
Indoleamines
Chemical class Compound name
Serotonin 
(Enzo Life 
Science)
Compound structure
HO NH-
References
Badria (2002).
Indoleamines Melatonin 
(Enzo Life 
Science)
O Badria (2002).
N H 'H ,C O ,
H
CH3
Anthocyanidins Delphinidin
(Extrasynthese)
OH
.OH
HO,
OH
OH
OH
Hernandez et 
al.( 1999), Gill 
e ta l.(2000), 
Mousavinejad 
et a I.(2009), 
Gomez- 
Caravaca et al. 
(2013). Dahlawi 
et al.(2013)
Anthocyanidins Cyanidin
(Extrasynthese)
O H
•OH
HO,
'O H
OH
Hernandez et 
al.( 1999), Gill 
et al.(2000), 
Mousavinejad 
et al.(2009), 
Gomez- 
Caravaca e ta l. 
(2013). Dahlawi 
et al. (2013).
Anthocyanidins Pelargonidin
(Extrasynthese)
.O H
H O ,
‘O H
O H
Hernandez et 
al. (1999), Gill 
et al.(2000), 
Mousavinejad 
et al.(2009), 
Gomez- 
Caravaca et al. 
(2013). Dahlawi 
et al. (2013).
Table 5.1: Summarised pomegranate compounds found in PJ and their chemical structure.
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5.3 Material and Methods
5.3.1 Cell Culture
Four leukaemia cell lines were obtained from the American Type Culture Collection 
(ATCC; Middlesex, U.K.), which have previously described to have demonstrated 
differing sensitivity to PJ (Chapter 3) (Dahlawi et al, 2011) and the acetonitrile fraction 
(Chapter 4) (Dahlawi et al, 2013). They included two lymphoid cell lines: CCRF-CEM, 
and MOLT-3, and two myeloid cell lines: HL-60 and THP-1 (Section 2.2). These cell lines 
were maintained and cultured in RPMI 1640 medium (Invitrogen, Paisley, U.K.) 
supplemented with 10% (v/v) foetal bovine serum, 1.5 mmol/L L-glutamine, and 100 
pg/mL penicillin/streptomycin (complete media) in a humidified atmosphere of 5% C02 
at 37°C.
5.3.2 Treatm ent o f Cells
Cells were seeded at 25 x  104 cells in 100 pL of complete media and treated with each 
compound (Table 5.1) at concentrations: 0,10, 25, 50, and 100 pM in white 96-well 
plates (Fisher Scientific) for 24 and 48 h. The IC50 values were then determined, 
following assessment of cell viability using Cell Titer-Glo* Luminescent Cell Viability 
Assay (Promega) (Section 2.3.2)(Table 5.2).
Cell Titer-Glo* 26 pure 10, 25, 50, and CCRF-CEM, MOLT-3, 24 and 48
Luminescent Cell compounds 100 pM HL-60, and THP-1 hr
Viability Assay (Table 5.1)
Table 5.2: Experiemental design for Chapter 5.
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5.4 Results:
5.4.1 Effect o f Pom egranate Compounds in Leukaem ia Cell Lines; on ATP 
Levels as an Ind icator o f Total V iable Cells
5.4.1.1 Organic acids:
The effects of the organic acids: citric acid; malic acid; tartaric acid; fumaric acid; 
succininc acid and ascorbic acid were investigated on four leukaemia cell lines to 
determine potential bioactive actions affecting cell viability and proliferation, 
determined via measuring total ATP levels as an indication of number of metabolically 
active cells.
5.4.1.1.1 Citric Acid:
Citric acid did not significantly inhibit ATP levels, in any of the four leukaemia cell lines 
investigated following 24 h. However after 48 h, a significant inhibition of ATP levels 
was observed at the two highest concentrations (50 and 100 pM) in CCRF-CEM cells. 
Citric acid failed to cause a 50% reduction in ATP in all four cell lines following 24 and 
48 h (Figure 5.1) and no IC5o value could be determined.
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Citric acid 24 hr
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Figure 5.1: Effect of citric acid on cell proliferation at concentrations 0 ,10 , 25, 50, and 100 pM 
in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. * 
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.1.2 Malic Acid:
Malic acid did not significantly inhibit ATP levels in any of the four leukaem ia cell line 
investigated and failed to cause a 50% reduction in ATP in each of the four cell lines 
follow ing 24 and 48 h (Figure 5.2).
2 100+*co 90uo 80*->T3 70OJ
T5E>_
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os 40
> 30JV
CL 20
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¥
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-♦-CCRF-CEM -MOLT-3 HL-60 -THP-1
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Figure 5.2: Effect of malic acid on cell proliferation at concentrations 0,10, 25, 50, and 100 pM 
in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. * 
indicates significant difference (P < 0.05)
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5.4.1.1.3 Tartaric Acid:
Tartaric acid did not significantly inh ib it ATP levels in any o f the fou r leukaemia cell 
lines investigated fo llow ing 24 and 48 h (P > 0.05). As a result, it failed to  cause a 50% 
reduction in ATP in all fou r cell lines fo llow ing 24 and 48 h (Figure 5.3).
Tartaric acid 24hr
-♦-CCRF-CEM -Sf-MOLT-3 - i HL-60  THP-1
0 1 1 01  ioo $■
8 90
3  80 
13 70N^  60
I  50
J  40
§ 30
-  2 0  o.
1 0
10040 50 60 70 80 900 1 0 2 0 30
Concen tration ( |iM )
Tartaric acid 48hr
— n o
~  100
90 
80 
70 
60 
50 
40 
« 30
CL
5
2 0
1 0
0
CCRF-CEM -MOLT-3 HL-60 -THP-1
1 0 2 0
—l—
5030 40  60 70
Concen tration ( |iM )
80 90 100
Figure 5.3: Effect of Tartaric acid on cell proliferation at concentrations 0, 10, 25, 50, and 100 
pM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.1.4 Fumaric Acid:
Fumaric acid did not significantly inh ib it ATP levels in each o f the  fou r leukaemia cell 
line investigated fo llow ing 24 h [ P  >  0.05). Following 48 h, fum aric acid significantly 
inh ib ited ATP levels in CCRF-CEM cells only at the highest tw o  concentrations (50 and 
100 |iM ) ( P  <  0.05). However, it failed to  cause a 50% reduction in ATP in any o f the 
fou r cell lines fo llow ing 24 and 48 h (Figure 5.4).
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Figure 5.4: Effect of Fumaric acid on cell proliferation at concentrations 0, 10, 25, 50, and 100 
pM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.1.5 Succininc Acid:
Succininc acid did not significantly inhibit ATP levels in any of the four leukaem ia cell 
lines investigated follow ing 24 h (P > 0.05). Following 48 h, succininc acid significantly 
inhibited ATP levels in CCRF-CEM cells only follow ing treatm ent w ith 25, 50, and 100 
pM  (P < 0.05). However, it failed to cause a 50% reduction in ATP in all cell lines 
follow ing 24 and 48 h (Figure 5.5).
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Figure 5.5: Effect of succinic acid on cell proliferation at concentrations 0, 10, 25, 50, and 100 
pM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.1.6 Ascorbic Acid:
Ascorbic acid showed significant inhibition on ATP levels in CCRF-CEM cells follow ing 
stimulation w ith 25, 50, and 100 pM in a dose-dependent manner follow ing 24 and 48  
h treatm ents (P < 0.05). The remaining cell lines, displayed no significant inhibition of 
ATP levels follow ing 24 and 48 h treatm ents (P > 0.05). Ascorbic acid caused 50%  
reduction in ATP levels in CCRF-CEM cells only (Figure 5.6) and the IC50 values follow ing 
24 and 48 h treatm ents w ere 61 and 57 pM , respectively (Figure 5.6).
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Figure 5.6: Effect of ascorbic acid on cell proliferation at concentrations 0 ,10 , 25, 50, and 100 
pM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.2 Phenolic Acids
A number of phenolic acid groups are found within pomegranates including: 
hydroxybenzoic acids and Hydroxycinnamic Acids which were investigated here for 
their potential bioactive actions on leukaemia cell lines.
5.4.1.2.1 Hydroxybenzoic Acids
The effects of the hydroxybenzoic acids: Gallic acid and ellagic acid were investigated 
on four leukaemia cell lines to determine potential bioactive actions affecting cell 
viability and proliferation, determined via measuring total ATP levels as an indication 
of number of metabolically active cells.
5.4.1.2.1.1 Gallic Acid
Gallic acid significantly inhibited ATP levels in all four leukaemia cell lines (CCRF-CEM, 
MOLT-3, HL-60 and THP-1) with differing sensitivity (P < 0.05) following 24 and 48 h 
treatments. However, it only caused a 50% reduction in ATP in CCRF-CEM, MOLT-3, 
and HL-60 cells following 24 and 48 h treatments. Gallic acid IC5o values for CCRF-CEM, 
MOLT-3, and HL-60 cells were 17 pM following 24 h treatment. Following 48 h, the 
IC50 of gallic acid was 14 pM for CCRF-CEM and 15 pM for MOLT-3 and HL-60 was 
(Figure 5.7).
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Figure 5.7: Effect of gallic acid on cell proliferation at concentrations 0 ,10, 25, 50, and 100 pM 
in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error, * 
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.2.1.2 Ellagic Acid
Ellagic acid significantly inhibited ATP levels in all four leukaemia cell lines (CCRF-CEM, 
MOLT-3, HL-60 and THP-1) with different sensitivity following 24 and 48 h (P < 0.05). 
However, it only caused a 50% reduction in ATP in MOLT-3 cells following 24 h 
treatments at a concentration of 98 pM. Following 48 h ellagic acid caused a 50% 
reduction in ATP in all four leukaemia cell lines. The IC50of gallic acid for CCRF-CEM, 
MOLT-3, HL-60, and THP-1 cells were 40, 32, 91, and 94 pM, respectively (Figure 5.8).
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Figure 5.8: Effect of ellagic acid on cell proliferation at concentrations 0, 10, 25, 50, and 100 
pM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.2.2 Hydroxycinnamic Acids
The effects of the hydroxycinnamic acids: caffeic acid and p-cumaric were investigated 
on four leukaemia cell lines to determine potential bioactive actions affecting cell 
viability and proliferation, determined via measuring total ATP levels as an indication 
of number of metabolically active cells.
5.4.1.2.2.1 Caffeic Acid
Caffeic acid significantly inhibited ATP levels in all four cell lines, with greater 
sensitivity being shown by CCRF-CEM at 24 and 48 h (P < 0.05). CCRF-CEM was the only 
cell line to show a 50% reduction in ATP levels, with an IC50 value of 61 and 57 pM, at 
24 and 48 h respectively (Figure 5.9).
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Figure 5.9: Effect of caffeic acid on cell proliferation at concentrations 0, 10, 25, 50, and 100 
pM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.2.2.2 p-cuamric Acid:
p-cuamric acid significantly inhibited ATP levels in the CCRF-CEM cells follow ing 24 and 
48 h treatm ent. However, it failed to cause a 50% reduction in ATP in any of the cell 
lines investigated follow ing 24 and 48 h treatm ents (Figure 5.10).
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Figure 5.10: Effect of p-cuamric acid on cell proliferation at concentrations 0, 10, 25, 50, and 
lOOpM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. 
ATP levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide 
indication of live cell numbers. ATP levels normalized to controls and presented as means ± 
standard error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.3 Cyclitol Carboxylic Acid
The effects of the cyclitol carboxylic acid: Quinin acid was investigated on four 
leukaem ia cell lines to determ ine potential bioactive actions affecting cell viability and 
proliferation, determ ined via measuring total ATP levels as an indication of number of 
metabolically active cells.
5.4.1.3.1 Quinin Acid:
Quinine acid showed no significant effect on ATP levels in any of the four leukaem ia 
cell lines investigated, at 24 and 48 h treatm ents (P < 0.05). As a result, it failed to 
cause a 50% reduction in ATP in all four cell lines follow ing 24 and 48 h (Figure 5.11).
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Figure 5.11: Effect of quinic acid on cell proliferation at concentrations 0, 10, 25, 50, and 100 
pM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.4 Flavan-3-ols
The effects of the Flavan-3-ols: catechin, epicatechin and EGCG were investigated on 
four leukaemia cell lines to determine potential bioactive actions affecting cell viability 
and proliferation, determined via measuring total ATP levels as an indication of 
number of metabolically active cells.
5.4.1.4.1 Catechin
Catechin showed no significant effect on ATP levels in any of the four leukaemia cell 
lines following 24 h treatment (P < 0.05). Following 48 h treatment, there was a 
significant effect on inhibition of ATP levels in CCRF-CEM, MOLT-3, and HL-60 cells 
following treatment with the highest two concentrations (50 and 100 pM) (P < 0.05). 
However, catechin failed to cause a 50% reduction in ATP in all four cell lines following 
24 and 48 h (Figure 5.12).
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Figure 5.12: Effect of catechin on cell proliferation at concentrations 0 ,10 , 25, 50, and 100 |iM  
in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. * 
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.4.2 Epicatechin
Epicatechin treatm ent significantly inhibited ATP levels in all four leukaem ia cell lines 
with d ifferent sensitivity follow ing 24 and 48 h treatm ents (P < 0.05). However, 
epicatechin failed to cause a 50% reduction in ATP in each cell lines at 24 and 48 h 
(Figure 5.13).
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Figure 5.13: Effect of epicatechin on cell proliferation at concentrations 10, 25, 50, and 100 pM 
in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. * 
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.4.1 Epigallocatechin Gallate (EGCG)
Epigallocatechin gallate (EGCG) treatm ent of CCRF-CEM, MOLT-3, HL-60, and THP-1 
cells resulted in a significant inhibition of ATP levels follow ing 24 and 48 h incubation 
(P < 0.05) (Figure 5.14). Following 24 h treatm ent, EGCG caused a 50% reduction in ATP 
in CCRF-CEM, MOLT-3, and HL-60 cells at concentrations of 17, 21, and 19 pM  
respectively. At 48 h there was a 50% reduction in ATP in the THP-1 cells. The IC50 
values at 48 h post-treatm ent w ith EGCG for CCRF-CEM, MOLT-3, HL-60 and THP-1 
cells were 9 ,1 5 ,1 3 , and 84 pM , respectively (Figure 5.14).
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Figure 5.14: Effect of EGCG on cell proliferation at concentrations 10, 25, 50, and 100 pM in 
CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. * 
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.5 Flavanoids
The effects of the Flavanoids: Quercetin and rutin were investigated on four leukaemia 
cell lines to determine potential bioactive actions affecting cell viability and 
proliferation, determined via measuring total ATP levels as an indication of number of 
metabolically active cells.
5.3.1.5.1 Quercetin
Quercetin treatment of CCRF-CEM, MOLT-3, HL-60, and TFIP-1 cells resulted in a 
significant inhibition of ATP levels following 24 and 48 h incubation (P < 0.05). The IC50  
values at 24 h post-treatment for quercetin in CCRF-CEM, MOLT-3, HL-60, and THP-1 
cells were 25, 50, 43, 23 pM, respectively. At 48 h treatment, the IC50 values for CCRF- 
CEM, MOLT-3, HL-60, and THP-1 cells were 14.5, 29, 22.5, and 20.5 pM, respectively 
(Figure 5.15).
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Figure 5.15: Effect of quercetin on cell proliferation at concentrations 0, 10, 25, 50, and 100 
|iM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.5.2 Rutin
Rutin did not significantly affect the ATP levels in all four leukaem ia cell lines follow ing 
24 h treatm ent (P > 0.05). Rutin treatm ent to CCRF-CEM and HL-60 cells resulted in a 
significant reduction in ATP levels follow ing 48 h treatm ent (P < 0.05). However, rutin 
failed to cause a 50% reduction in ATP in any of the cell lines (Figure 5.16).
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Figure 5.16: Effect of rutin on cell proliferation at concentrations 0, 10, 25, 50, and 100 pM in 
CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. * 
indicates significant difference [P < 0.05) vs. untreated control. n= 3.
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5.4.1.6 Ellagitannins
The effects of the ellagitannins: Punicalagin was investigated on four leukaemia cell 
lines to determine potential bioactive actions affecting cell viability and proliferation, 
determined via measuring total ATP levels as an indication of number of metabolically 
active cells.
5.4.1.6.1 Punicalagin
Punicalagin treatment of CCRF-CEM, MOLT-3, HL-60, and THP-1 cells resulted in a 
significant reduction in ATP levels following 24 and 48 h incubation (P < 0.05). The IC50  
values at 24 h post-treatment with punicalagin for CCRF-CEM, MOLT-3, HL-60, and 
THP-1 cells were 11, 19, 17, 6 8  pM, respectively. Following 48 h treatment, the IC50  
values of punicalagin for CCRF-CEM, MOLT-3, HL-60, and THP-1 cells were 9, 14, 14, 
and 39 pM, respectively (Figure 5.17).
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Figure 5.17: Effect of punicalagin on cell proliferation at concentrations 0, 10, 25, 50, and 100 
pM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.7 Am ino acids
The effects of the amino acids: proline; valine and methionine were investigated on 
four leukaemia cell lines to determine potential bioactive actions affecting cell viability 
and proliferation, determined via measuring total ATP levels as an indication of 
number of metabolically active cells.
5.4.1.7.1 Proline
Proline did not significantly reduce ATP levels, and failed to cause a 50% reduction in 
ATP in any of the four leukaemia cell lines investigated following 24 and 48 h 
treatments (P > 0.05) (Figure 5.18).
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Figure 5.18: Effect of proline on cell proliferation at concentrations 0, 10, 25, 50, and 100 pM 
in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. * 
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.7.2 Valine
Valine did not significantly reduce ATP levels, and failed to cause a 50% reduction in 
ATP in any of the four leukaem ia cell lines investigated follow ing 24 and 48 h 
treatm ents (P > 0.05) (Figure 5.19).
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Figure 5.19: Effect of valine on cell proliferation at concentrations 0,10, 25, 50, and 100 pM in 
CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. * 
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.7.3 M eth ion ine
M eth ion ine showed no significant effect on inhibition of ATP levels and failed to cause 
a 50% reduction in ATP in any of the four leukaem ia cell lines follow ing 24 and 48 h 
treatm ents (P > 0.05) (Figure 5.20).
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Figure 5.20: Effect of methionine on cell proliferation at concentrations 0, 10, 25, 50, and 100 
pM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.8 Indoleamines
The effects of the indoleamines: tryptamine; Serotonin and Melatonin were 
investigated on four leukaemia cell lines to determine potential bioactive actions 
affecting cell viability and proliferation, determined via measuring total ATP levels as 
an indication of number of metabolically active cells.
5.4.1.8.1 Tryptamine
Tryptamine showed no significant effect on inhibition of ATP levels and failed to cause 
a 50% decrease in ATP in any of the four leukaemia cell lines following 24 and 48 h 
treatments (P > 0.05) (Figure 5.21).
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Figure 5.21: Effect of tryptamine on cell proliferation at concentrations 0, 10, 25, 50, and 100 
pM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.8.2 Serotonin
Serotonin showed significant inhibition of ATP levels in CCRF-CEM cells follow ing 24 h 
treatm ent at concentrations of 50 and 100 pM  and in MOLT-3 cells treatm ent at 
concentration of 100 |iM  (P < 0.05). In contrast, serotonin showed no significant effect 
on ATP levels in any of the four leukaem ia cell lines follow ing 48 h treatm ent (P > 0.05) 
(Figure 5.22).
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Figure 5.22: Effect of serotonin on cell proliferation at concentrations 0, 10, 25, 50, and 100 
pM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.8.3 Melaton in
Melaton in showed significant inhibition of ATP levels follow ing 24 and 48 h treatm ent 
in the CCRF-CEM, MOLT-3, and HL-60 cell lines (P < 0.05). However, it failed to cause a 
50% decrease in ATP in any of the four leukaem ia cell lines (Figure 5.23).
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Figure 5.23: Effect of melatonin on cell proliferation at concentrations 0, 10, 25, 50, and 100 
pM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.1.9 Anthocyanins
The effects of the anthocyanins: delphinidin, cyaniding and pelargonidin were 
investigated on four leukaemia cell lines to determine potential bioactive actions 
affecting cell viability and proliferation, determined via measuring total ATP levels as 
an indication of number of metabolically active cells.
5.4.1.9.1 Delphinidin
Delphinidin significantly inhibited ATP levels in all four leukaemia cell lines investigated 
following 24 and 48 h treatment (P < 0.05). The IC50 values of delphinidin for CCRF-CEM, 
MOLT-3, HL-60, and THP-1 cells following 24 h treatments were 56, 67, 64, and 83 pM, 
respectively. Following 48 h, the IC50 values of delphinidin for CCRF-CEM, MOLT-3, HL- 
60, and THP-1 were 42, 65, 60, and 78 pM, respectively (Figure 5.24).
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Figure 5.24: Effect of delphinidin on cell proliferation at concentrations 0, 10, 25, 50, and 100 
pM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P< 0.05) vs. untreated control. n= 3.
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5.4.1.9.2 Cyanidin
Cyanidin significantly inhibited ATP levels in all four leukaemia cell lines following 24 
and 48 h treatment (P < 0.05). The IC50 values of cyanidin for CCRF-CEM, MOLT-3, HL- 
60, and THP-1 cells following 24 h treatments were 56, 67, 64, and 83 pM, respectively. 
Following 48 h, the IC50 values of cyanidin for CCRF-CEM, MOLT-3, HL-60, and THP-1 
cells were 42, 65, 60, and 78 pM, respectively (Figure 5.25).
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Figure 5.25: Effect of cyanidin on cell proliferation at concentrations 0 ,10 , 25, 50, and 100 pM 
in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. * 
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.3.1.9.3 Pelargonidin
Pelargonidin significantly inhibited ATP levels in all four leukaem ia cell lines follow ing  
24 and 48 h treatm ent (P < 0.05). Punicalagin showed sim ilar IC50 value of 81 pM  for 
each cell line at 24 h treatm ent. At 48 h, the IC50 values of pelargonidin for CCRF-CEM, 
MOLT-3, HL-60, and THP-1 cells were 69, 77, 74, and 82 pM , respectively (Figure 5.26).
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Figure 5.26: Effect of pelargonidin on cell proliferation at concentrations 0,10, 25, 50, and 100 
pM in CCRF-CEM, MOLT-3, HL-60, and THP-1 leukaemia cell lines following 24 and 48 h. ATP 
levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication 
of live cell numbers. ATP levels normalized to controls and presented as means ± standard 
error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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5.4.2 Sum mary of Results
Twenty six naturally occurring pomegranate compounds exhibited selective anti­
cancer activity towards the leukaem ia cell lines: CCRF-CEM, MOLT-3, HL-60, and THP-1 
follow ing 24 and 48 h treatm ent. Only 7 out of 26 compounds induced a 50% reduction 
in ATP levels in 3 or more leukaem ia cell lines (Table 5.3).
H B j l H
Organic acid
Citric acid 24 h NR NR NR NR48 h NR NR NR NR
Malic acid 24 h NR NR NR
NR
48 h NR NR NR NR
Tartaric acid 24 h NR NR NR
NR
48 h NR NR NR NR
Fumaric acid 24 h NR NR NR
NR
48 h NR NR NR NR
Succinic acid 24 h NR NR NR NR48 h NR NR NR NR
Ascorbic acid 24 h 61 pM NR NR NR48 h 57 pM NR NR NR
Hydroxy benzoic 
acid
Gallic acid 24 h 17 pM 17 pM 17 pM NR48 h 14 pM 15 pM 15 pM NR
Ellagic acid 24 h NR 98 pM NR NR48 h 40 pM 32 pM 91 pM 94 pM
Hydroxycinnamic
acid
Caffeic acid 24 h 68 pM NR NR
NR
48 h 64 pM NR NR NR
p-cumaric
acid
24 h NR NR NR NR
48 h NR NR NR NR
Cyclitol 
carboxylic acid Quinic acid
24 h NR NR NR NR
48 h NR NR NR NR
Flavan-3-ols
Catechin 24 h NR NR NR NR48 h NR NR NR NR
Epicatechin 24 h NR NR NR NR48 h NR NR NR NR
EGCG 24 h 17 pM 21 pM 19 pM NR pM48 h 9 pM 15 pM 13 pM 84 pM
Fiavonols
Quercetin 24 h 25 pM 50 pM 43 pM 23 pM48 h 14.5 pM 29 pM 22.5 pM 20.5 pM
Rutin 24 h NR NR NR NR48 h NR NR NR NR
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Table (continued)
Ellagitannins Punicalagin 24 h 11 pM 19 pM 17 pM 68 pM48 h 9 pM 14 pM 14 pM 39 pM
Amino acids
Proline 24 h NR NR NR
NR
48 h NR NR NR NR
Valine 24 h NR NR NR
NR
48 h NR NR NR NR
Methionine 24 h NR NR NR NR48 h NR NR NR NR
Tryptamine 24 h NR NR NR NR48 h NR NR NR NR
Indoleamines
Serotonin 24 h NR NR NR
NR
48 h NR NR NR NR
Melatonin 24 h NR NR NR NR48 h NR NR NR NR
Anthocyanins
Delphinidin 24 h 18.5 pM 17 pM 15 pM
76 pM
48 h 18 pM 16 pM 14 pM 31 pM
Cyanidin 24 h 56 67 64
83
48 h 42 65 60 78
Pelargonidin
1
24 h 81 pM 81 pM 81 pM 83 pM
48 h 69 pM 77 pM 74 pM 82 pM
Table 5.3: IC50 values of compounds found in PJ in CCRF-CEM, MOLT-3, HL-60, and THP-1 
leukaemia cells following 24 and 48 h treatments. NR= 1C 50 not reached.
5.4.3 Anti-proliferative effect o f Pom egranate Compounds in Non- 
Tum our CD133+ HSCs
The 7 compounds that were found to cause 50% reduction in ATP in the four studied 
leukaem ia cell lines were tested on the non-tumour CD133 + HSCs. Those compounds 
selected for analysis were delphinidin, cyanidin, pelargonidin, gallic acid, quercetin, 
EGCG, and punicalagin.
The non-tumour CD133+ cells less sensitive than the majority of leukaem ia cell lines at 
all treatm ent doses at follow ing 24 and 48 h (Figure 5.27). The exception was THP-1 
cells when treated w ith gallic acid. Following 24 h treatm ent w ith gallic acid treatm en t 
at 100 pM  34% and 40% decrease in ATP levels was observed in THP-1 and CD133+ cells 
respectively. Following 48 h, gallic acid showed 40% and 52% inhibition in cell 
proliferation in THP-1 and CD133 + HSCs cells (Figure 5.27)
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Figure 5.27: Effect of delphinidin, cyanidin, pelargonidin, gallic acid, quercetin, EGCG, and 
punicalagin on cell proliferation at concentrations 0, 10, 25, 50, and 100 pM in non-tumour 
HSC (CD133) following 24 and 48 h. ATP levels investigated using Cell Titer-Glo® Luminescent 
Cell Viability Assay to provide indication of live cell numbers. ATP levels normalized to controls 
and presented as means ± standard error. * indicates significant difference (P < 0.05) vs. 
untreated control. n= 3.
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5.4 Discussion
The results demonstrated that 7 out of the 26 compounds found in PJ (Table 5.1): 
EGCG; ellagic acid; gallic acid; quercetin; delphinidin; cyanidin; pelargonidin; and 
punicalagin; caused a 50% reduction in ATP in leukaemia cell lines (CCRF-CEM, MOLT-3, 
HL-60, and THP-1). All the Organic acids, amino acids, and indoleamines compounds 
failed to cause a 50% reduction in ATP levels in the four leukaemia cell lines, following 
24 and 48 h treatments. Suggesting that these compounds are inactive compounds 
and would not be of use in the treatment of leukaemia, and as such are not discussed 
further.
5.4.1 Phenolic Acids
The phenolic acids present in PJ are divided into two major groups: hydroxycinnamic 
acids and hydroxybenzoic acid, based on arrangement of the benzene ring, benzoic 
acids and cinnamic acids groups (Kim et al, 2006). These are classified as 
hydroxycinnamic acids including: caffeic acid and p-cumaric acid and hydroxybenzoic 
acids, which include: ellagic and gallic acids. Despite the hydroxycinnamic acid: caffeic 
acid, exhibiting inhibitory effects in CCRF-CEM cells, with IC50 value 68 and 64 pM 
following 24 and 48 h treatments, respectively. It failed to display 50% decrease in ATP 
levels in MOLT-3, HL-60, and THP-1 cells. Indicating that caffeic acid showed selective 
inhibition of ATP levels against leukaemia cell lines. This agrees with the work of 
Hudson et ol. (2000) who showed the anti-proliferative effect of caffeic acid in breast 
cancer cell lines (MCF-7, MDA-MB-468, and HBL-100). They showed that there was a 
decrease in cell proliferation in MCF-7 and MDA-MB-468 cells, but not in HBL-100 cells. 
Other hydroxycinnamic acids such as p-cumaric have also failed to show an inhibition 
of cell proliferation in breast (MCF-7, MDA-MB-468, and HBL-100) (Hudson et al, 2009), 
colon (SW-480 and HT-29) (Hudson et al, 2009), and hepatoma cell lines (Yagazaki et al, 
2000), which support our findings that the hydroxycinnamic acids are selective 
towards certain cancerous cell lines.
The hydroxybenzoic acids were more effective, inhibiting ATP levels in all four 
leukaemia cell lines to a greater extent than hydroxycinnamic acids. This has been seen 
in previous studies (Lapidot et al, 2002; Guang-Jian et al, 2012). Gallic acid was shown 
to cause a 50% reduction in ATP levels in all leukaemia cell lines, except THP-1. 
Generally THP-1 was the least sensitive cell line compared to other leukemic cells
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when tested against PJ (Chapter 3) (Dahlawi et al, 2011), and the acetonitrile fraction 
(Chapter 4) (Dahlawi et al, 2013) and most of the pure PJ compounds investigated here. 
Gallic acid is widely used as an antioxidant in the food industry and was shown to 
exhibit a variety of pharmacological and biological activities, including anti-cancer 
properties. Previous work by Reddy et al. (2012) showed that gallic acid inhibited cell 
growth in the breast cancer cell line (MDA-MB-231), CML cell line (K562), and colon 
cancer cell line (COLO-205). The anti-cancer effect of gallic acid has also been 
demonstrated in two lung cancer cells (Calu-6 and A549), where gallic acid dose- 
dependently decreased the growth of Calu-6 and A549 cells following 24 h treatment 
(Park and You, 2010). In addition to gallic acid, ellagic acid was expressed in the 
acetonitrile fraction from PJ (Chapter 4) (Dahlawi et al, 2013), and here gallic acid 
significantly inhibited ATP following 24 and 48 h treatments. Mertens-Talcott et al. 
(2003) reported that treatment with ellagic acid resulted in a reduction of cell 
proliferation in the leukaemia cell line: MOLT-4. The anti-proliferative effect of ellagic 
acid was shown in several cancers cell lines including pancreatic (MIA PaCa-2; PANC-1; 
SW460 and SW620) (Seeram et al, 2005), prostate (RWPE-1; 22Rvl, DU-145, and PC3) 
(Seeram et al, 2005; Lansky (1) et al, 2005) and colon (HT-29 and HCT116) (Seeram et 
al, 2005) cells.
5.4.2 Flavan-3-ols
Flavan-3-ol compounds found in PJ were tested for their effect on viable cell number 
by measuring ATP levels of CCRF-CEM, MOLT-3, and HL-60 cell lines. Differential effects 
were seen where EGCG showed the most potent effects over catechin and epicatechin. 
Although catechin and epicatechin illustrated significant inhibitory effect on cell 
proliferation, they failed to induce a 50% decrease in ATP levels following 24 and 48 h 
treatments. Suggesting that the number of hydroxyl groups on the B ring and galloyl 
groups could be critical for EGCG inhibitory effects. Consistent with our results, Guang- 
Jian et al (2012) reported that EGCG has more potent anti-proliferative effect than 
catechin and epicatechin in two colorectal cancer cells (HCT-16 and SW-480). Similarly 
Yang et al (1998) indicated that EGCG inhibited growth of the lung cancer cell line 
(H441) and colon cancer cell line (HT-29), whilst epicatechin and catechin were less 
effective. Chung et al (2001) also showed that epicatechin had limited effects on 
prostate cancer cells (DU145) while EGCG demonstrated significant growth
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suppression. However, EGCG has been shown to be the most abundant and bioactive 
Flavan-3-ol compounds in green tea for cancer chemoprevention (Stuart et al, 2006). 
EGCG has been shown to induce inhibition of cell growth in breast cancer cells (MDA- 
MB-231) (Thangapazham et al, 2007) and (MCF-7) (Tang et al, 2006) and prostate 
cancer cells (LnCap) (Hastak et al, 2005). In leukaemia, a study demonstrated a 
reduction in U937 and K562 cell number in response to treatment with EGCG 
(Nakazato et al, 2007).
5.4.3 Flavanoids
Quercetin and rutin belong to a class of polyphenolic flavanoid compounds. Both 
compounds are structurally similar; quercetin is termed the aglycone form of rutin. In 
rutin the hydrogen of the R-3 hydroxyl group is replaced by a disaccharide. Here, 
quercetin significantly inhibited ATP levels in all four leukaemia cell lines displaying 
50% decrease in ATP levels. Interestingly, this study showed that quercetin has more 
potent inhibition in ATP levels in THP-1 cells with an IC50 value of 23 pM which was 
lower than other the cell lines: CCRF-CEM, MOLT-3, and HL-60, with IC5o values 25, 50, 
and 43 pM, respectively. This contradicts the sensitivity order seen following whole PJ, 
and fractions studied previously (Chapter 3 and 4) (Dahlawi et al, 2011; Dahlawi et al, 
2013) suggesting quercetin is less likely to be the major compounds from PJ. Quercetin 
exerts anti-proliferative effects in vitro on cancer cell lines of diverse lineages, 
including breast cancer cells; MCF-7 (Chou et al, 2010; Choi et al, 2001), MDA-MB-231 
(Chien et al, 2009; Jeong et al, 2009 ), SK-Br3 (Jeong et al, 2009), and MDA-MB-453 
(Jeong et al, 2009), colon cancer cells: HT29 (Kim et al, 2005) and Caco-2 (Van Erk et al, 
2004), and prostate cancer cells: PC-3 (Vijayababu et al, 2005; Aalinkeel et al, 2008); 
DU-145 and LNCap (Aalinkeel et al, 2008). In leukaemia cells quercetin has also been 
shown to inhibit cellular proliferation in cell lines including: K562, Jurkat, HL-60, U937, 
K562 (Kawahara et al, 2009; Mahbub et al, 2013), and MOLT-4 (Mertens-Talcott et al, 
2003). Here, Rutin, a glycoside of quercetin, inhibited ATP levels in CCRF-CEM, MOLT-3, 
and HL-60 following 48 h treatment, but failed to display 50% decrease in ATP in all 
four leukaemia cell lines. Suggesting the sugar molecule may suppress the inhibitory 
effect of flavonoids toward leukaemia cell lines tested. Similarly, Kim et al (2005) 
reported that only quercetin was effective in inhibiting growth of colon cancer cells 
(HT-29) growth, but the glycoside rutin did not inhibit HT-29 cell growth. Kunts et al,
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(1999) determined the growth inhibitory activity of various flavonoids, including 
quercetin and rutin, in two colon cancer cells (HT-29 and Caco-2) after 27 h of 
exposure to concentrations between 25 pM to 250 pM. Both quercetin and rutin 
inhibited the growth of intestinal cell lines. The IC5o values of quercetin for HT-29 and 
Caco-2 were 85 and 96 pM, respectively. Whereas, the IC5o value of rutin for HT-29 and 
Caco-2 were approximately 136 pM in both cell lines, indicating that quercetin has 
stronger inhibitory effect than rutin. Kim et a l (2005) also reported that quercetin was 
only effective in inhibiting growth of colon cancer cells (HT-29), but the glycoside rutin 
did not inhibit HT-29 cell growth. Lu et al, (2008) found that quercetin, not rutin, 
inhibited growth of human ovarian cancer cell line (OVAR-3).
5.4 .4  Ellagitannins
Punicalagin is unique to pomegranate and is part of a family of ellagitannins (Tyagi et al, 
2012). Punicalagin, which is the largest polyphenol, having a molecular weight of 1084, 
is reported to be the major component responsible for PJ antioxidant properties (Gil et 
al, 2000). Punicalagin was evaluated for its anti-proliferative activity against colon 
cancer cells (SW460, SW620, HT-29, and HCT116) and prostate cancer cells (RWPE-1 
and 22Rvl), demonstrating inhibition of cell proliferation in a dose-dependent manner 
in all cell lines tested (Saleem et al, 2002). Here, punicalagin showed induction in 
inhibition of ATP levels in all four leukaemia cell lines (CCRF-CEM, MOLT-3, HL-60, and 
THP-1) following 24 and 48 h. Punicalagin was one of the most abundant compounds 
indicated in the effective fraction (acetonitrile fraction) showing a decrease in cell 
proliferation and induction of apoptosis against leukaemia cell lines (CCRF-CEM, MOLT- 
3, HL-60, and THP-1) (Dahlawi et al, 2013) (Chapter 3). Thus suggesting that 
punicalagin may play an important role in the efficacy of PJ toward leukaemia cells.
5.4.5 Anthocyanins
Anthocyanins are one of the groups of compounds which were detected in the 
acetonitrile fraction (Dahlawi et al, 2013) (Chapter 3). Anthocyanins are considered the 
largest and most important group of fiavonoids present in PJ, which give the juice its 
red colour (Lansky and Newman, 2006; Afaq et al, 2005). Studies have proposed that 
anthocyanins are the major phytochemical group responsible for the observed anti- 
cancerous effects. Anthocyanins in the form of rich-extracts from fruits and vegetables 
have shown anti-proliferative activity toward various cancer cell types in
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vitro.(Rodrogo et al, 2006; Seeram et al, 2006; Chen et al, 2005; Reddy et al, 2005 
Zhang et al, 2008). Pure anthocyanins were also tested for inhibition towards the 
growth of cancer cell lines. Katsube et al (2003) found that delphinidin, cyanidin, and 
pelargonidin showed anti-proliferative effects in human colon cancer cells (HCT116). 
Cyanidin and delphinidin showed concentration-dependent growth inhibition in 
human hepatoma cells (HepG2). The estimated IC50values of cyanidin and delphinidin 
were 18.4 and 10.8 pM, respectively (Yeh and Yen, 2005). Anthocyanins, delphinidin 
3-O-P -D-glucoside and cyanidin 3-O-P-D-glucoside, from black bean seed coat and red 
grape skin, respectively, displayed strong inhibitory effect against human leukaemia 
cells (MOLT-4) (Katsuba et al, 2003). Here, we found that delphinidin, cyanidin and 
pelargonidin induced 50% inhibition in ATP levels in all four leukaemia cell lines (CCRF- 
CEM, MOLT-3, HL-60, and THP-1) following 24 and 48 h treatments. Delphinidin 
exerted the greatest inhibition among cyanidin and pelargonidin on all leukaemia cell 
lines, suggesting that anthocyanins appear to be affected by their chemical structures.
5.4.6 Tum our Cell Selectively
This study investigated the effects of pure compounds found in pomegranate on ATP 
levels in leukaemic cells. ATP levels were used as an indication of total viable cells and 
thus compounds resulting in decreased ATP levels could indicate agents which could 
either inhibit proliferation or induce cell death or both within leukaemia cell lines. 
Demonstrating that delphinidin, cyanidin, pelargonidin, gallic acid, quercetin, and 
punicalagin illustrated bioactivity against four leukaemia cell lines (CCRF-CEM, MOLT-3, 
HL-60, and THP-1). Interestingly, less bioactivity was observed in non-tumour cells 
(CD133) when treated with concentrations showing significant cytotoxicity in tumour 
cells, suggesting a selective cytotoxicity against leukaemia cells. Selective inhibition of 
proliferation in carcinoma cells of anthocyanins has been shown previously (Zhao et al, 
2004; Ozbay and Nahta, 2011). Several studies have shown that inhibition of cell 
proliferation by anthocyanins or anthocyanins-rich extracts was more pronounced in 
carcinoma cells than non-tumour cells. Zhao et al. (2004) found that anthocyanin 
extracts inhibited the growth of colon cancer cells (HT-29) with little effects on normal 
colonic cell growth when added to the media in the same concentrations. In another 
study, although, cyanidin-3-O-P-glucopyranoside decreased cell proliferation in both 
transformed (Jurkat cells) and non-transformed (human lymphocytes) T cells, normal T
214
cells were much less sensitive to this effect that non-transformed cells. Ozbay and 
Nahta (2011) examined cell proliferation in response to delphinidin in 7 breast cancer 
cell lines (HCC1806, MDA231, MDA468, SKBR3, MDA453, BT474, and MCF-7) in 
addition to non-transformed breast epithelial cell line (MCF10A). In contrast to the 
majority of breast cancer cell lines, proliferation of non-transformed breast epithelial 
cell line (MCF10A) was not significantly inhibited by delphinidin except at the highest 
concentration. Gallic acid has been shown to inhibit the proliferation of pancreatic 
cancer cells (CFPAC-1 and MiaPaca-2) in a time and dose-dependent manner. 
Remarkably, when compared with normal human cells HL-7702, gallic acid exhibited 
selective cytotoxicity for cancer cells (Liu Z et al, 2012). Polyphenolic compounds in 
green tea, including EGCG, have been widely studied since they showed selective 
cytotoxicity to cancerous cells and not to normal cells. Ahmed et al, 1997 reported that 
delphinidin significantly decreased cell viability of human epidermal carcinoma cell line 
(A431) with little toxicity to normal human epidermal keratinocytes (NHEKs). The 
flavonoid quercetin exhibited selective toxicity, since it has been shown that quercetin 
significantly inhibited the growth of highly aggressive PC-3 cell line and the moderately 
aggressive DU-145 prostate cancer cell line, but did not affect the less aggressive 
LNCap prostate cancer cell or normal BG-9 fibroblast cell line (Nair et al, 2004). 
Together these studies and the findings of this study suggest natural polyphenols 
display selective targeting towards tumour cell lines over normal cells and thus may 
provide better selective therapies for cancers.
5 .5  Conclusion
Among the 26 naturally occurring pomegranate compounds investigated, only seven 
compounds: delphinidin; cyanidin; pelargonidin; EGCG; gallic acid; ellagic acid; 
quercetin; and punicalagin; induced 50% decrease in ATP levels in the studied 
leukaemia cell lines. Of these active components only gallic acid and quercetin were 
not found previously in the acetonitrile fraction of PJ when analysed by MS analysis, 
which was shown to induce apoptosis in the studied leukaemia cell lines (Chapter 4) 
(Dahlawi et al, 2013). Future work will investigate the effect of these active 
components on leukaemia cell lines to investigate the ability to induce apoptosis and 
cell cycle arrest and indicate potential activities on inhibition of proliferation or 
induction off cell death.
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6. Impact of Anthocyanins Chemical 
Structure on Induction of apoptosis and 
Inhibition of cell Proliferation in 
Leukameia cell lines
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6 .1  In tro d u c tio n
Previously it was identified that the anthocyanins are one of most potent compounds 
at decreasing ATP levels in leukaemia cells.
6.1.1 Chem istry o f Anthocyanins
Anthocyanins (in Greek anthos means flower, and kyanos means blue), are the largest 
group of water-soluble pigments in the plant kingdom (Kong et al, 2003). They belong 
to the class of flavonoid compounds and are commonly known as plant polyphenols 
(Kong et al, 2003). In contrast to other flavonoids, the anthocyanins carry a positive 
charge in acidic solutions (Mazza, 1995). Major sources of anthocyanins are 
pomegranate, berries and other fruits and the anthocyanins give them their red, blue 
or purple colours. Colour differences between anthocyanins are mainly determined by 
substitution pattern of the B ring of the glycon, the pattern of the glycosylation, and 
the degree and nature of esterification of the sugars with aliphatic or aromatic acids, 
and the presence of co-pigments (Mazza and Brouillard, 1990). One distinctive 
characteristic of anthocyanins is that they undergo reversible molecular 
transformations with changes in pH. Many anthocyanins are red in very acidic 
conditions and turn blue as the pH is increased (Mazza and Miniati, 1993).
The glycon or de-glycosylated forms of anthocyanins are known as anthocyanidins. 
Anthocyanidins are polyhydroxy and polymethoxy derivatives of 2-phenylbenzoprylium 
or flavylium salts differ in the number and position of their hydroxyl and methoxyl 
groups on the B ring (Figure 6.1). There are 27 known anthocyanidins present in nature 
(Harborne and Williams, 2001), the six most common anthocyanidins are cyanidin, 
pelargonidin, delphinidin, malvidin, pentunidin, and peonidin (Harborne and Williams, 
2001; Kong et al, 2003).
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Figure 6.1: Basic chemical structure of common anthocyanidins.
The glycosides of the three non-methylated anthocyanidins (cyanidin, delphinidin, and 
pelargonidin) are the most widespread in nature being present in 80% of pigmented 
leaves, 69% of fruits and 50% of flowers (Kong et al, 2003) and w ere identified w ith in 
Aceton itrile fraction of PJ (Chapter 4) (Dahlaw i et al, 2013). The distribution of the six 
most common anthocyanidins in edible parts of plants are summarised in table 6.2.
Anthocyanidins rarely occur in the ir free form in nature because of the ir high reactivity, 
but are normally glycosylated w ith one or more sugar components which enhance 
the ir stability and solubility (Clifford, 2000; Giusti and Wrolstad, 2003). The most 
common sugar components which link to the anthocyanins are glucose, galactose, 
rhamnose, xylose, and arabinose (Kong et al, 2003). Anthocyanins can be glycosylated 
w ith one or more sugar units, typically up to 3, w ith some rare exceptions (Kong et al, 
2003). The sugar components of anthocyanins are usually conjugated to the C3- 
hydroxyl group in the anthocyanidins C ring and C5 position of the A ring. Less common 
sites of glycosylations are the C7 position, and in rare cases glycosylation has been 
reported on the B ring (Kong et al, 2003). Several hundred anthocyanin structures are 
known to varying in: the basic anthocyanidin structure; the number o f hydroxyl 
groups; the nature and the number of sugars attached to the molecule; the position of
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this attachment; and the nature and number of aliphatic or aromatic acids attached to  
the sugars in the molecule. However, the most predom inant anthocyanin is cyanidin-3- 
glucoside (Figure 6.1) (Mazza and M iniati, 1993).
Cyanidin 50%
Delphinidin 12%
Pelargonidin 12%
Petunidin 12%
Peonidin 7%
Malvinidin 7%
Table 6.1: Illustrates distribution of the six most common anthocyanidins in edible parts of 
plants (Kong et al, 2003).
6.1.2 Anthocyanins Found in Pom egranate Juice
Pomegranate juice is known to be a major source of phenolic compounds, where  
anthocyanins are thought to be the most important. The main anthocyanins found in 
the acetonitrile fraction (Chapter 4) and found in other studies are: Cyanidin-3- 
gluocside; cyanidin 3,5-O-diglucosides; delphinidin-3-gluocside; delph in id in -3,5-0- 
diglucosides; pelargonidin-3-gluocside and pelargonidin-3,5-0-diglucosides (Hernandez 
et al, 1999; Reed et al, 2005). Delphinidin has hydroxyl groups at 3', 4', and 5', cyanidin 
at 3' and 4' positions in the B-ring. However, pelargonidin has no orthohydroxyl 
substitution (Figure 6.1).
6.1.3 Anthocyanins Bioactivity
In recent years a number of studies have shown that anthocyanins exhibited a w ide 
range of biological and pharmacological benefits such as an ti-in flam m atory (Wang and 
Mazza, 2002; Youdim et al, 2002), anti-m icrobial (Pisha and Pezzuto, 1994) and 
improvement of vision (M atsum oto et al, 2003) and neuroprotective effects (Youdim 
et al, 2002). In addition, anthocyanins have exhibited a variety of effect on cells, blood 
vessels (Andriambelson et al, 1998; M artin et al, 2003) and platelets that may reduce 
the risk of coronary heart disease (Renaud & Lorgeril 1992). They have also been found 
to act as antioxidants, in colon (Renis et al, 2008), breast (Olsson et al, 2004; Singletary 
et al, 2007), liver (Shish et al, 2007), leukaem ic (Dai et al, 2009) and brain cell lines in 
vitro (Hogan et al, 2010). In these culture systems, anthocyanins have shown multiple
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anti-toxic and anti-carcinogenic effects, and directly scavenged reactive oxygen species 
(ROS) (Singletary et al, 2007). Some studies reported that the glycosidic forms show a 
decrease in the antioxidant capacity when compared w ith the corresponding aglycon 
(Rice-Evans et al, 1996; Satue-Gracia et al, 1997; Tsuda et al, 1994).
Pure anthocyanins and anthocyanidins, or in the form of m ixtures have demonstrated  
anti-proliferative and anti-apoptotic effects in breast, colon, oesophageal, uterus and 
prostate cancer cells (Table 6.2). Studies in human leukaem ia cells have also shown 
they had a pro-apoptotic and anti-proliferative activity (Table 6.2). This has been 
confirmed in a number of animal models (Kang et al, 2003; Chen et al, 2005; Stoner et 
al, 2007).
Prostate cancer
Androgen 
refractory human 
PCa 22Rnul cells
Delphinidin -Inhibit cell proliferation 
-G2/M  phase cell cycle arrest 
-cleaved Poly(ADP-ribose) polymerase; 
increased Bax and Bcl-2 expression; increased 
caspase-3 and caspase-9 activity, NF k B 
signalling
Hafeez et al 
(2008b)
Human PC3 cells Delphinidin -Inhibit cell growth 
-G2/M  phase cell cycle arrest 
Induced apoptosis (Phosphatidylserine 
exposure), cleaved poly(ADPribose) 
polymerase, increased Bax and decreased Bcl- 
2 expression, increased caspase-3 and caspase- 
9 activity, NF k B signalling
Hafeez et al 
(2008a)
Human androgen- 
dependent 
LNCaP cells and 
PC-3 cells
Anthocyanin 
fraction from 
Potatoes
- Inhibit cell growth
- DNA fragmentation, cleaved poly(ADP-ribose) 
polymerase, cleaved caspase-3 and cleaved 
caspase-9 proteins and increased Bax 
expression,
Reddivari, et 
al (2007)
Uterus cancer
Human HeLa S3 
cells
Delphinidin - Decreased cell viability
- S phase cell cycle arrest
- DNA fragmentation, phosphatidylserine 
exposure, mitochondrial membrane 
potential, poly(ADP-ribose) 
polymerase cleavage.
Lazze, et al 
(2004)
Esophageal 
cancer cells
Rat highly 
tumuorigenic 
RE-149 DHD cells
Freeze-dried
black
raspberries
Cyanidin-3-O-
rutinoside
- Inhibited cell proliferation
- Caspase-3 and caspase-7 activity
Z ikri, e ta l 
(2009)
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Table (continued)
Hepatic cancer 
cells
Human
hepatocellular 
carcinoma 
PLC/PRF/5 cells
Anthocyanins 
from the 
berries
- decreased cell viability 
-DNA fragmentation, Bcl-2 expression, 
Bax translocation, caspase-3 activity, 
cytochrome c release
Longo, et al 
(2008)
Human HepG2 
cells
Cyanidin,
delphinidin,
malvidin
- Inhibited cell proliferation
-DNA fragmentation and caspase-3 activity.
Yeh and Yen 
(2005)
Human hepatoma 
Hep3B
Anthocyanins
extracts
- Inhibited cell proliferation
- Go/Gi phase cell cycle arrest 
-Induced apoptosis and decreased anti- 
apoptotic proteins (Bcl-2, xlAP, clAP-1, and 
clAP-2
M am m ary cancer 
cells
Hormone- 
responsive 
human MCF-7 
cells
Bilberry extract - Inhibited cell proliferation
- G2/M  phase cell cycle arrest
- DNA fragmentation
Nguyen, et 
al (2010)
Rat mammary 
carcinoma cells 
from
imethylbenz[a] 
anthracene- 
induced tumours 
in female c-Ha- ras 
transgenic rats
Cyanidin 3 -0  b- 
d -glucoside
- Inhibited cell viability
- DNA fragmentation, increased caspase-3 
cleavage.
Fukamachi, 
et al (2008)
Human estrogen 
dependent/ 
aromatase 
positive MCF-7and 
cells and MDAMB- 
231 cells
Freeze-dried 
Jamun 
( Eugenia 
jam bolana ) 
fruit extract
- Inhibited cell proliferation
- DNA fragmentation
Li, et al 
(2009).
Human EGFR 
positive 
AU-565 cells
Delphinidin - Inhibited cell viability
- DNA fragmentation, phosphatidylserine 
exposure, cleaved poly(ADP-ribose) 
polymerase, increased expression of Bax and 
down regulation of Bcl-2 expression, increased 
caspase-3 activity
Afaq, et al 
(2008).
Human HS578T 
cells
Cyanidin -3- 
glucoside, 
Peonidin 3- 
glucoside
- Inhibited cell viability
- G2/M  phase cell cycle arrest.
- Induced apoptosis, caspase-3 activity, cleaved 
poly (ADP-ribose) polymerase.
Chen, et al 
(2005).
Leukaemia cells
Human
promyelocytic 
HL-60 cells
Isolated 
anthocyanins 
from 
Euterpe 
oleracea Mart
- Decreased cell viability
- increased caspase-3 activity
Del Pozo- 
Insfran, et al 
(2007)
Human
promyelocytic HL- 
60 cells 
Human acute 
leukaemia T 
Jurkat cells
Cyanidin 3-0- b
glucopyranosid
e
- Induced apoptosis Fimognari et 
al. (2004)
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Table (continued)
Human
promyelocytic 
HL-60 cells
Delphinidin 3- 
sambubioside
- Inhibited cell proliferation 
-Induced apoptosis, increased caspase-3, 
caspase-8 and caspase-9 activity; induced 
mitochondrial membrane potential, 
cytochrome crelease, Bid truncation.
Hou e ta l 
(2005)
Human
promyelocytic 
HL-60 cells
Bilberry extract, 
malvidin, 
delphinidin, 
cyaniding
- Induced apoptosis Katsube et 
al (2003).
Human acute 
leukaemia T 
MOLT-4 cells 
Human Burkitt 
lymphoma Daudi 
cells
Human T 
leukaemia CCRF- 
CEM cells
Cyanidin-3-
rutinoside
- Induced apoptosis feng et al 
(2007).
Human acute 
leukaemia 
T MOLT-4 cells
Delphinidin3-0- 
3 -D-glucoside 
petunidin 3-0-3  
-D-glucoside, 
malvidin 3-0  -3 
-D-glucoside, 
cyanidin 3- 0  - 
3 -D-glucoside
- Inhibited cell growth.
- Induced apoptosis
Katsuzaki et 
al (2003)
Human U937 cells Anthocyanins 
isolated from 
Vitis coignetiae
- Inhibited cell proliferation
- Induced mitochondrial membrane potential; 
down-regulated of Bcl-2 expression and up 
regulated of Bax expression; increased caspase- 
3,
caspase-8 and caspase-9 activity; inhibitor of 
apoptosis protein (IAP) activity; cleaved 
poly(ADP-ribose) polymerase; and induced 
truncated Bid translocation
Lee et al 
(2009).
Human U937 cells Cyanidin,
malvidin
- inhibited cell proliferation
- G2/M  phase cell cycle arrest
- Induced apoptosis.
Hyun and
Chung
(2004).
Colon cancer cells
Human
adenocarcinoma 
Caco-2 cells
Cabernet
Sauvignon
anthocyanin
extract
- Inhibited cell proliferation
- Increased Caspase-3 activity
Forester
and
Waterhouse
(2010).
Human
adenocarcinoma 
Caco-2 cells
Grape extract, 
anthocyanin 
fraction from 
grape extract
- Inhibited cell proliferation
- Induced apoptosis
Yi (1) e ta l 
(2005)a
Human
adenocarcinoma 
Caco-2 cells 
HT-29 cells
Anthocyanin 
fraction from 
blueberry 
extract
- Inhibited cell proliferation
- Induced apoptosis
Yi (2) et al 
(2005) b
Human HCT-116 
cells
Delphinidin - Decreased cell viability
- G2/M  phase cell cycle arrest
- Induced apoptosis, cleavage of PARP, 
activation of caspases-3, -8, and -9, increase in
Yun e ta l 
(2009)
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Table (continued)
Human
adenocarcinoma 
HT-29 cells
Anthocyanin 
fraction from 
Georgia-grown 
blueberries
- Induced apoptosis and increased caspase-3 
activity
Srivastava 
et al (2007)
Gastric cells
Human
adenocarcinoma 
AGS cells
Malvinidin - Inhibited cell proliferation Shih e ta l 
(2005).
Table 6.2: Impact of anthocyanins in different cancer models in term of induction of apoptosis 
inhibition of cell proliferation and cell cycle
6.2 Objective
The aim of this study was to compare the effective properties of anthocyanins found in 
PJ to understand the relationship between anthocyanin chemical structures and their 
effects on inhibition of cell proliferation and induction of apoptosis in leukaemia cell 
lines.
6.3 Material and Methods
6.3.1 Cell Culture
Four leukaemia cell lines were obtained from the American Type Culture Collection 
(ATCC; Middlesex, U.K.), which previously demonstrated differing sensitivities to PJ 
(Chapter 3) (Dahlawi et al, 2011) and the acetonitrile fraction of PJ (chapter 4) 
(Dahlawi et al, 2013). Two lymphoid cell lines: CCRF-CEM, and MOLT-3, and two 
myeloid cell lines: HL-60 and THP-1 were included in this study. Cell lines were 
maintained and cultured in RPMI 1640 medium (Invitrogen, Paisley, U.K.) 
supplemented with 10% (v/v) foetal bovine serum, 1.5 mmol/L L-glutamine, and 100 
|ig/mL penicillin/streptomycin (complete media) in a humidified atmosphere of 5% C02 
at 37°C (Section 2.2).
6.3.2 Treatm ent of Cells
Cell lines were treated with: Cyanidin; cyanidin 3-glucoside; cyanidin 3,5-diglucosides; 
delphinidin; delphinidin 3-glucoside; delphinidin 3,5-diglucosides; pelargonidin; 
pelargonidin 3-glucoside and pelargonidin 3,5-diglucosides at concentrations between 
0 - 100 pM for 24 h. All compounds were purchased from Extrasynthese and were 
dissolved in 100% methanol. Following treatments, induction of apoptosis and cell
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cycle arrest was determ ined and mechanisms of apoptosis induction by delphinidin 
investigated (Table 6.3).
Cell Titer-Glo* Cyanidin; cyanidin 3- 0,10, 25, CCRF-CEM, 24 hr
Luminescent Cell glucoside; cyanidin 3,5- 50, and 100 MOLT-3, HL-
Viability Assay diglucosides; delphinidin; 
delphinidin 3-gluocside; 
delphinidin 3,5-diglucosides; 
pelargonidin; pelargonidin 
3-glucoside and 
pelargonidin 3,5- 
diglucosides
pM 60, and THP-1
Annexin V-FITC/PI Cyanidin; cyanidin 3- 
gluocside; cyanidin 3,5- 
diglucosides; delphinidin; 
delphinidin 3-gluocside; 
delphinidin 3,5-diglucosides; 
pelargonidin; pelargonidin 
3-gluocside and 
pelargonidin 3,5- 
diglucosides
0,10, 25, 
50, 75, and 
100 pM
CCRF-CEM, 
MOLT-3, HL- 
60, and THP-1
24 hr
NucView™ 488 Cyanidin; cyanidin 3- 0,10, 25, CCRF-CEM, 24 hr
Caspase-3 substrate gluocside; cyanidin 3,5- 50, 75, and MOLT-3, HL-
assay diglucosides; delphinidin; 
delphinidin 3-gluocside; 
delphinidin 3,5-diglucosides; 
pelargonidin; pelargonidin 
3-gluocside and 
pelargonidin 3,5- 
diglucosides
100 pM 60, and THP-1
DAPI staining Delphinidin 0, 25, 50, 
100 pM
CCRF-CEM, 
MOLT-3, HL- 
60, and THP-1
24 hr
Cell cycle Delphinidin 0, 25, 50, 
100 pM
CCRF-CEM, 
MOLT-3, HL- 
60, and THP-1
24 hr
The Caspase-8 and 9 
Glo™ Assays
Delphinidin 50 pM MOLT-3 and 
HL-60
3, 6, 
and 24 
hr
ICC (Cytochrome C 
and SMAC/ Diablo)
Delphinidin 50 pM MOLT-3 and 
HL-60
3/ 6, 
and 24 
hr
qRT-PCR (Bax, Bad, 
Bcl-2, and Bcl-xl
Delphinidin 50 pM MOLT-3 and 
HL-60
6 hr
Table 6.3: Experiemntal design for chapter 6.
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6.3.3 Cell Viability
The effect of cyanidin, cyanidin 3-gluocoside, cyanidin 3,5-diglucosides, delphinidin, 
delphinidin 3-gluocoside, delphinidin 3,5-diglucosides, pelargonidin, pelargonidin 3- 
gluocside and pelargonidin 3,5-diglucosides on cell viability was determined by the Cell 
Titer-Glo* Luminescent Cell Viability Assay as described previously (2.3.2). Cells were 
seeded at 25 x 104 cells in 100 pL of complete media and treated with each compound 
at 0,10, 25, 50, and 100 pM, in white 96-well plates (Fisher Scientific) for 24 h.
6.3 .4  Annexin V - FITC /P I Flow Cytom etry Assay
Annexin V-FITC/PI and flow cytometry were used to detect levels of apoptosis as 
described previously (section 2.4.1). Cells were seeded at 5 x 10s cells in 100 pL of 
complete media and treated with cyanidin, cyanidin 3-gluocside, cyanidin 3,5- 
diglucosides, delphinidin, delphinidin 3-gluocside, delphinidin 3,5-diglucosides, 
pelargonidin, pelargonidin 3-gluocside and pelargonidin 3,5-diglucosides at 
concentration of 0,10, 25, 50, 75, and 100 pM in 12-weli plate (Fisher Scientific) for 24 
h. Data were recorded from 10,000 cells per sample and analyzed using FlowJo 
software (Tree Star).
6.3.5 Caspase-3 Activ ity
NucView™ 488 Caspase-3 substrate assay (Cambridge Bioscience) and flow cytometry 
were used to determine induction of caspase-3 (Section 2.4.3). Cells were treated with 
cyanidin, delphinidin, and pelargonidin at concentrations of 0 ,10 , 25, 50, 75, and 100 
pM for 24 h. Data were recorded from 10,000 cells per sample and analyzed using 
FlowJo software (Tree Star, Ashland, OR).
6.3.6 DAPI Stain
Following treatment with delphinidin at concentrations of 0, 25, 50,100 pM for 24 h at 
a cell density of 5xl04 per well, cells were stained with DAPI to observe apoptotic 
morphology changes (Section 2.4.2). Cells were investigated using Olympus BX60 
fluorescence microscope using UV light at excitation wavelength 350 nm. Quantitative 
analysis of cell populations (live & apoptotic) was performed based on counting of 200
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randomly-selected cells and the percentage of apoptotic features determ ined for each 
sample.
6.3.7 Cell Cycle
The cell cycle distribution of leukaem ia cell lines was measured by flow  cytom etry in PI 
stained cells (Section 2.5). Cells were treated w ith delphinidin at concentrations 0, 25, 
50, and 100 pM  for 24 h. Data from 10,000 cells per sample w ere recorded and 
percentages of cells with in G0/G i, S, and G2/M  cell cycle phase were determ ined w ith 
FlowJo software and Waston (pragmatic) analysis of cell cycle (Tree Star).
6.3.8 Caspase-8 and -9
The Caspase-Glo™ Assays use the lum inogenic caspase-8 tetrapeptide substrate (Z- 
LETD-am inoluciferin) or caspase-9 tetrapeptide substrate (Z-LEHD-am inoluciferin) and 
a stable luciferase in proprietary buffers. In the absence of active caspases, the caspase 
substrates do not produce light. Upon cleavage o f the substrates by the respective 
caspases, am inoluciferin is liberated and can contribute to the generation of light in a 
lum inescence reaction (Figure 6.2). The resulting lum inescent signal is directly 
proportional to the amount of caspase activity present in the sample. Figure 6.2:
H
Luciferase 
M g 2+ *
Light
Figure 6.2: Caspase-8 or -9 cleavage of the proluminogenic substrates containing LETD or LEHD, 
respectively. Following caspase cleavage, a substrate for luciferase (aminoluciferin) is released, 
resulting in the luciferase reaction and production of light.
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6.3.8.1 Methodology
Cells were plated at a cell density of 2.5xl04 cells per well in a white 96 well culture 
plate and then treated with 50 pM delphinidin for 3,6 and 24 h. Following treatment 
Caspase-8 and 9 activity was measured by using Caspase-Glo™ 8 and 9 assays as per 
manufactures industry. MG-132 (30 pi) inhibitor was added to Caspase-Glo™ 8 and 9 
reagents to reduce nonspecific background activity. One hundred microliters of 
Caspase-Glo™ 8 and 9 reagents were added to each sample, mixed well for 30 seconds 
on an orbital shaker at 400 rpm. The plate was allowed to incubate at room 
temperature for 1 h prior to luminescence detection using Wallac 1420 luminescence 
detector (PerkinElmer, Waltham, USA). Control wells were prepared containing 
medium and treatments without cells to obtain a value for background luminescence.
6.3.8.2 Analysis
Background readings were subtracted from all test measurements. The average 
luminescence readings were calculated and all treated samples were normalized to 
controls.
6.3.8.3 Statistical Analysis:
Average and Standard error of the mean (SEM) were calculated and Stats Direct was 
used to test whether data followed a normal distribution using a Shapiro Wilke test. 
Data did not follow a normal distribution, thus Kruskal-Wallis and Connover-lnman 
post hoc tests were used to investigate significant differences. Results were considered 
statistically significant when P < 0.05.
6.3.9 Im m unocytochem istry
Immunocytochemistry (ICC) is a method used to identify the presence of a specific 
protein within cells by using a specific antibody, which binds to it and allows 
visualization and examination of the target protein under the light microscope. Here 
we used an indirect method for ICC (Figure 6.3) to detect the expression of 
cytochrome C and SMAC/Diablo using specific antibodies (Table 6.4).
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Diaminobenzidine (DAB) oxidised 
to brown participate
Secondary antibodv
Primary antibody
Target antigen
Avidin-Biotin-
peroxidase
Complex
(ABC)
Figure 6.3: Illustration of the indirect method of immunocytochemistry.
Description Dilution Species reactivity
Cytochrome C mouse monoclonal 1: 200
Human
abl3575)
(Abeam,
SMAC/ Diablo rabbit monoclonal 1:100
human
ab32023)
(Abeam
Table 6.4: The source and dilution factors used for the primary antibodies.
6.3.9.1 M ethod
Following trea tm en t o f MOLT-3 and HL-60 cells w ith  50 pM delphinid in, cells were 
incubated fo r 3, 6 and 24 h and cells were then transferred to  eppendorf tubes and 
centrifuged fo r 5 m inutes at 400 g at 4°C. The supernatant was removed, and cells 
washed in 100 pi DPBS and resuspended in 100 pi 4 %  (w /v) paraformaldehyde/DPBS 
and stored at 4°C fo r 20 minutes. Cells were then washed w ith  DPBS and 40,000 cells /  
slide were transferred to  slides via a 20 m inute cytospin at 1000 rpm (Shandon 
Cytospin 3 Centrifuge) (Thermo Fisher Scientific). Samples were air dried and then 
washed in IMS fo r 5 minutes. To block any endogenous peroxidase activ ity w ith in  the  
cells, a hydrogen peroxidase (H20 2) block (containing 9 mL 30% H20 2, 291 IMS and 5
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drops of HCL) was applied for 30 m inutes followed by 5 m inutes wash in deionized 
w ater and tw o washes in IX  TBS (Tris Buffered Saline) (20 m M  Tris base (Fisher 
Sceintific) 150 m M  NaCI (Fisher Scientific) pH 7.6) for 5 m inutes. In a hum id chamber, 
100 pi of proteinase K (10 pg/mL) was applied to each slide to lightly digest the cellular 
membrane to retrieve the antigens. Slides were then washed in triplicate w ith IX  TBS 
for 5 m inutes. The serum of the secondary antibodies at 25% v /v  in 1% w /v  BSA in PBS 
was freshly prepared and added to each slide and incubated for 45 m inutes at RT. The 
primary antibodies (Table 6.4) were prepared w ith suitable serum species and 100 pi 
was added in a humid chamber and incubated overnight at 4°C.
Following overnight incubation, cytospins were washed w ith IX  TBS three times for 5 
m inutes and secondary antibodies (Table 6.5) were added and incubated for 30 
m inutes at RT followed by 5 m inutes wash with IX  TBS in triplicate. A drop o f Avidin- 
Biotin-peroxidase Complex (ABC) was added to each slide for 30 m inutes in the wet 
box on the orbital shaker followed by 5 m inutes wash in triplicate w ith IX  TBS. Then 
3,3'-D iam inobenzid ine (DAB) was added for 20 m inutes at RT followed by 5 m inutes 
washing in running tap water. Slides were counterstained in haematoxylin for 45 
seconds then washed in running tap w ater for 5 m inutes. Finally, cells were  
dehydrated in IMS and cleared in Sub-X prior to mounting in pertex.
Description Dilution
Cytochrome C rabbit anti-mouse 1:400 Abeam
(Ab 87032)
SMAC/ Diablo goat anti-rabbit 1:300 Abeam
(Ab 97049)
Table 6.5: The source and dilution factors used for the secondary antibodies.
6.3.9.2 Analysis
Slides were exam ined using Olympus light microscope (X100). Images w ere captured 
using Q Capture Pro 8.0 (UVP Biolmaging Systems). Quantitative analysis of cells 
(active and non-active) (Figure 6.4) was performed based on counting of 200 randomly 
selected cells and the percentage of cells with active staining determ ined for each 
sample (untreated control cells and cells treated w ith delphinidin).
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Figure 6.4: Illustrates analysis of cytochrome C expression in HL-60 cells following treatment 
with delphinidin for 3 h using Olympus light microscope (X100). Cells were divided into two 
groups: active and non-active. Active cells indicated by red arrows. Non-active cells indicated
by green arrows.
6.3.9.3 Statistical Analysis
Average and Standard error of the mean (SEM) was calculated and Shapiro Wilke test 
using Stats Direct was used to analyse whether data followed a normal distribution. 
Data did not follow a normal distribution, thus a Kruskal-Wallis and Connover-lnman 
post hoc test was used to investigate statistical significance. Results of treated cells 
were normalized to the control (untreated cells) where control = 100%. Results were 
considered statistically significant when P < 0.05.
6.3.10 Q uantitative Real T ime Polymerase Chain Reaction (qRT-PCR)
Real-time PCR (Figure 6.5) is widely used to detect and quantify gene expression. It
involves reverse transcription (RT) of mRNA into cDNA followed by PCR to amplify a 
specific target cDNA molecule, which is quantified in real-time by the accumulation of 
fluorescence after each amplification cycle (Orlando et al, 1998, Bustin, 2000).
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S tep:l:
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and 3' ends of 
taqMan probe
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quenched.
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Forward primer
3 '
5'
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ft . Probe
3 '
3 '
5 '
Reverse primer
5 '
3 '
5'
5'
3 '
5*
Step:3
During each 
extension cycle, Taq 
polymerase cleaves 
the reporter dye 
from the probe.
Step:4
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from the quencher, 
the reporter dye 
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flourescence.
Cleavage
s
3 '
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5'
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3 '
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Figure 6.5: Illustration of how TaqMan reagent works. Modified from Applied Biosysytems.
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As amplification proceeds, the fluorescence amplification is captured by the 
instrument after every cycle, and is translated in a RT-PCR graph. With RT-PCR there 
are three amplification stages: 1) lag phase; 2) exponential; 3) plateau (Figure 6.6). In 
the exponential phase, the reagents are in abundance and the PCR products double 
every cycle. In the plateau phase, the reagents are depleted and PCR reaction stops. 
RT-PCR focuses on the exponential phase because it provides the most precise and 
accurate data for quantitation. Within the exponential phase, a threshold is set, the 
PCR cycle at which the sample reaches this threshold is called cycle threshold (Ct). The 
Ct value is used in downstream quantitation and depends on the amount of target, the 
larger the amount of template in the reaction the fewer amplification cycles to form a 
significant fluorescent signal. In contrast a small amount of target will require more 
amplification cycles for the fluorescent signal to generate a detectable fluorescence 
signal (Figure 6.6).
Plateau
phase0.90
0.80
0.70 Sample
0.60 Exponential D AHphaseThreshold0.50
0.40
0.30
No Template0.20 Baseline
0.10
0.00 0 35 405 10 15 20 25 30
Figure 6.6: Illustrates qRT-PCR amplification plot.
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6.3.10.1 Methodology
6.3.10.1.1 RNA Extraction
Following treatment with 50 pM of delphinidin on two leukaemia cell lines (MOLT-3 
and HL-60), cell number was determined using an Invitrogen Countess automated cell 
counter (Invitrogen) incorporating Trypan Blue (Sigma) to distinguish live and dead 
cells (Section 2.3.1). Cell suspension aliquots containing 1 x 105 live cells were 
transferred to RNase free 1.5mL tubes and centrifuged at 400g for 10 minutes to 
recover cells. Supernatant was removed and the remaining cell pellet re-suspended in 
lmL Trizol (Ambion) and incubated at room temperature for 5 minutes. Chloroform 
(Sigma) was added at a rate of 200pL per tube; samples were mixed by vortexing for 
15 seconds and incubated at room temperature for 3 minutes prior to centrifugation 
at 12,000g for 15 minutes at 4°C. Following centrifugation the upper aqueous phase 
(RNA containing) was removed to a fresh 1.5mL tube and 500pL isopropanol (Sigma) 
added. RNA samples were incubated for 10 minutes at room temperature and then at - 
80°C for 1 hour to precipitate RNA. Samples were thawed on ice and centrifuged at 
12,000g for 30 minutes at 4°C to collect RNA precipitate. The resulting cell pellet was 
resuspended in 500 pL of 80% ethanol and centrifuged at 7,500 g for 15 minutes. Then 
samples were air dried on ice for 30 minutes. RNA samples were eluted in 14 pL sterile 
deionized water and used immediately for cDNA synthesis.
6.3.10.1.2 cDNA Synthesis
RNA samples were converted to cDNA using Moloney Murine Leukaemia Virus (MMLV) 
reverse transcriptase (Biolin) prior to carrying out real-time quantitative polymerase 
chain reaction (qPCR). Fourteen microliters of RNA samples were incubated at 60°C 
for 5 minutes to denature RNA. RT mastermix was added immediately at a rate of 36 
pL per 14 pL RNA sample (Table 6.6).
Deoxynucleotide triphosphates 
40mM (Biolin)
(dNTPs) 1.5 pL
Random Hexamers (AB) 1.0 pL
Bioscript 5x RT Buffer (Biolin) 5.0 pL
Bioscript RT Enzyme (Biolin) 0.5 pL
Sterile distilled H20 28 pL
36.0 pL
Table 6.6: RT Mastermix.
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Samples were incubated at 42°C for 1 h to perm it cDNA synthesis, then 10 m inutes at 
80°C to inactivate RT enzyme. cDNA samples were diluted 1:10 by addition of sterile 
deionised w ater and stored at -20°C for use in qPCR.
6.3.10.1.3 qPCR CDNA from Directly Extracted HL-60 and MOLT-3 cells
Taqman PCR was performed on cDNA samples from directly extracted HL-60 and 
MOLT-3 cells. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), was used in all 
experiments to  normalise for variations in total RNA in each sample.
2 pL sample cDNA was loaded in duplicate into 96-well FAST PCR plates (Applied 
Biosystems). Real-Time PCR masterm ix was added at a rate of 8 pL per well (Table 6.7).
Taqman Gene Expression Assay 0.5 pL
2x Taqman Fast MasterM ix (Applied 5.0 pL
Biosystems)
Sterile deionised water 2.5 pL
8.0 pL
Table 6.7: Real-Time PCR Mastermix.
Separate reaction masterm ixes were prepared and loaded for galyceradehyde 3- 
phosphate dehyrogensae (GAPDH) and each target gene assay. Plates w ere sealed w ith  
adhesive film and ran on an Applied Biosystems, StepOnePlus Real-Time PCR machine 
on FAST programme incorporating 50 cycles of denaturation at 95°C for 1 second 
followed by annealing and extension at 60°C for 20 seconds.
6.3.10.4 Analysis of qRT-PCR
Real-time PCR data is expressed as an amplification plot (Figure 6.6) for each individual 
target detected. Baseline was set 2 cycles prior to  the first visible amplification  
individually for each target detected. Thresholds were set w ith in the exponential 
phase of the amplification plot and maintained across all samples investigated. 
Measured CT values were then exported to an excel file where analysis by 2 AACT 
method (Livak and Schm ittgen, 2001) was performed to determ ine target mRNA 
expression relative to internal reference gene and basal expression. Briefly analysis 
was performed by: Arithmetical mean C^values of internal reference gene and target 
gene sample duplicates were calculated.
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Arithmetical mean of the 2 internal reference genes was calculated to generate 'mean 
reference' value for each sample.
ACr values were calculated using the equation:
ACT -  CT (target) - Crimean reference)
Arithmetical mean ACr and standard error of the mean (ACrSE) for each triplicate data 
set (untreated control and treatment group) was calculated
AACr values were calculated using the equation:
ACr = CT (target) - Crimean reference)
Target gene expression, relative to internal reference gene and basal expression was 
calculated using the equation:
Relative gene expression = 2 * ACr
Relative gene expression was represented graphically and error bars representing 
standard error of ACT values for each triplicate data set were calculated using the 
equations:
Positive Error Bar = 2 ,‘ACT+tSE) - 2'iicr 
Negative Error Bar = 2‘ic r- 2 ,‘Acr‘ ' 'SE)
6.3.10.3 Statistical Analysis
In order to perform statistical analysis on RT-PCR data, 2~“ CT was calculated for each 
sample and control versus treated groups compared using a Mann Whitney U test. 
Results were considered statistically significant when P < 0.05. To generate error bar to 
control data, eah control replicate is normalized against control average to enable 
spread of data to be show as error bars.
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6.4 Results
6.4.1 Effect o f Anthocyanid ins and Anthocyanins on ATP Levels as an 
Ind icator of Total V iable Cells
To test whether anthocyanidins and anthocyanins found in PJ are effective in 
suppressing ATP levels of human leukaemia cell lines, the effects on ATP levels were 
investigated to indicate potential action on inhibiting proliferation or induction of 
apoptosis of cyanidin, cyanidin-3-O-gluocside, cyanidin-3,5-0-diglucosides, delphinidin, 
delphinidin-3-O-gluocside, delphinidin-3,5-0-diglucosides, pelargonidin, pelargonidin- 
3-O-gluocside and pelargonidin-3,5-0-diglucosides on CCRF-CEM, MOLT-3, HL-60 and 
THP-1 cells.
Delphinidin, Delphinidn-3-O-glucoside, and delphinidin-3,5-di-0-glucose significantly (P 
< 0.05) inhibited ATP levels in CCRF-CEM cells at all concentrations (10, 25, 50,100 pM) 
in a dose-dependent manner following 24 h treatment. The IC50 values of delphinidin, 
delphinidn-3-O-glucoside, and delphinidin-3,5-di-0-glucose for CCRF-CEM cells at 24 h 
treatments were 20, 35, and 41 pM respectively (Figure 6.7) (Table 6.8).
CCRF-CEM 24 hr
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Figure 6.7: Effect of Delphinidin, Delphinidn-3-Oglucoside, and delphinidin-3,5-di-0-glucose on 
ATP levels proliferation at concentrations 10, 25, 50, andlOO pM on CCRF-CEM leukaemia cell 
line. ATP levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide 
indication of live cell numbers. ATP levels normalized to controls and presented as means ± 
standard error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Delphinidin and delphinidn-3-O-glucoside treatment in MOLT-3 cells resulted in a 
significant [P < 0.05) inhibition of ATP levels at all concentrations (10 to 100 pM) in a 
dose-dependent manner, while delphinidin-3,5-di-0-glucose showed significant (P < 
0.05) decrease in ATP levels only at 25, 50, 100 pM. The IC50 values at 24 h post 
treatment with delphinidin, delphinidn-3-0 glucoside, and delphinidin-3,5-di-0-glucose 
for MOLT-3 cells were 17, 34, 44 pM respectively (Figure 6.8) (Table 6.8).
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Figure 6.8: Effect of Delphinidin, Delphinidn-3-Oglucoside, and delphinidin-3,5-di-0-glucose on 
ATP levels at concentrations 10, 25, 50, and 100 pM on MOLT-3 leukaemia cell line. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. * 
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Delphinidin, Delphinidn-3-O-glucoside, and delphinidin-3,5-di-0-glucose significantly (P 
< 0.05) inhibited ATP levels in HL-60 cells at all concentrations (10, 25, 50,100 pM) in a 
dose-dependent manner following 24 h treatment. The IC50 values of delphinidin, 
Delphinidn-3-0-glucoside,and delphinidin-3,5-di-0-glucose for HL-60 cells at 24 h 
treatments were 16,19, and 34pM respectively (Figure 6.9 ) (Table 6.8).
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Figure 6.9: Effect of Delphinidin, Delphinidn-3-0-glucoside, and delphinidin-3,5-di-0-glucose 
on ATP levels at concentrations 10, 25, 50, and 100 pM on HL-60 leukaemia cell line. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. * 
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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The ATP levels in THP-1 cells was also significantly (P < 0.05) inhibited in a dose- 
dependent manner by delphinidin, delphinidin-3-O-glucoside, and delph inid in-3,5-d i- 
O-glucose follow ing 24 h treatm ent. The IC50 values of delphinin, delph inid in-3-O- 
glucoside, and delph inid in-3,5-d i-0-glucose for THP-1 cells was found to be 38, 63, and 
74 pM respectively (Figure 6.10) (Table 6.8).
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Figure 6.10: Effect of Delphinidin, Delphinidn-3-O-glucoside, and delphinidin-3,5-di-0-glucose 
on ATP levels at concentrations 10, 25, 50, and 100 pM on THP-1 leukaemia cell line. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. 
* indicates significant difference (P < 0.05) vs. untreated control. n= 3.
239
Cyanidin and cyanidin-3-O-glucoside significantly (P < 0.05) inhibited ATP levels in 
CCRF-CEM cells at all concentrations (10, 25, 50, and 100 pM ) in a dose-dependent 
manner follow ing 24 h treatm ent. The IC50 values of cyanidin and cyanidin-3-O- 
glucoside for CCRF-CEM cells at 24 h were 75 and 87 pM  respectively. Although 
cyanid in-3,5-d i-0-glucose exhibited a significant decrease in ATP levels of CCRF-CEM 
cells, it failed to  display 50% growth inhibition (Figure 6.11) (Table 6.8).
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Figure 6.11: Effect of cyanidin, cyanidin-3-O-glucoside, and cyanidin -3,5-di-O-glucose on ATP 
levels at concentrations 10, 25, 50, and 100 pM on CCRF-CEM leukaemia cell line. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. 
* indicates significant difference (P< 0.05) vs. untreated control. n= 3.
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Cyanidin and cyanidin-3-O-glucoside significantly (P < 0.05) inhibited ATP levels in 
MOLT-3 cells at all concentrations (10, 25, 50, and 100 pM ) in a dose-dependent 
manner follow ing 24 h treatm ent. The IC50 values of cyanidin and cyanidin-3-O- 
glucoside for MOLT-3 cells were 67 and 88 pM  respectively. Although cyanidin -3,5-d i- 
O-glucose showed significant decrease in ATP in MOLT-3 cells at 50 and 100 pM , it 
failed to display 50% growth inhibition (Figure 6.12) (Table 6.8).
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Figure 6.12: Effect of cyanidin, cyanidin-3-O-glucoside, and cyanidin -3,5-di-O-glucose on ATP 
levels at concentrations 10, 25, 50, and 100 pM on MOLT-3 leukaemia cell line. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. 
* indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Cyanidin significantly (P < 0.05) inhibited ATP levels in HL-60 cells at all concentrations 
(10, 25, 50, 100 pM ) in a dose-dependent manner, while cyanidin-3-O-glucoside 
displayed significant (P < 0.05) decrease at 25, 50, and 100 pM  follow ing 24 h 
treatm ent. The IC50 values cyanidin and cyanidin-3-O-glucoside for HL-60 cells were 64 
and 70 pM , respectively. Cyanidin-3,5-di-0-glucose showed a decrease in ATP in HL-60 
cells at the highest tw o concentrations (50 and 100 pM ), but not significantly and 
failed to display 50% growth inhibition (Figure 6.13) (Table 6.8).
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Figure 6.13: Effect of cyanidin, cyanidin-3-O-glucoside, and cyanidin -3,5-di-O-glucose on ATP 
levels at concentrations 10, 25, 50, and 100 pM on HL-60 leukaemia cell line. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. 
* indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Cyanidin significantly ( P  < 0.05) inhibited ATP levels in THP-1 cells at all concentrations 
(10, 25, 50, 100 pM ) in a dose-dependent manner, while cyanidin-3-O-glucoside 
displayed significant ( P  < 0.05) decrease at 25, 50, and 100 pM fo llow ing 24 h 
treatm ent. The IC50 values o f cyanidin and cyanidin-3-O-glucoside fo r THP-1 cells were 
83 and 90 pM , respectively. Cyanidin -3,5-di-O-glucose showed only a significant 
decrease in ATP levels in THP-1 cells at highest concentration (100 pM), and failed to  
display 50% growth inh ib ition (Figure 6.14) (Table 6.8).
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Figure 6.14: Effect of cyanidin, cyanidin-3-O-glucoside, and cyanidin -3,5-di-O-glucose on ATP 
levels at concentrations 10, 25, 50, and 100 pM on THP-1 leukaemia cell line. ATP levels 
investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide indication of live 
cell numbers. ATP levels normalized to controls and presented as means ± standard error. 
* indicates significant difference ( P <  0.05) vs. untreated control. n= 3.
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Pelargonidin and pelargonidin-3-O-glucoside significantly (P< 0.05) inhibited ATP levels 
in CCRF-CEM cells at 10, 25, 50, 100 pM in a dose-dependent manner (P< 0.05), while 
pelargonidin -3,5-di-O-glucose did not show a significant (P > 0.05) decrease at all 
concentrations following 24 h treatment. Pelargonidin induced IC50in CCRF-CEM cells 
at 81 pM. In contrast, pelargonidin-3-O-glucoside and pelargonidin-3,5-di-0-glucose 
failed to display 50% decrease in ATP levels in CCRF-CEM cells (Figure 6.15) (Table 6.8).
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Figure 6.15: Effect of pelargonidin, pelargonidin-3-O-glucoside, and pelargonidin -3,5-di-O- 
glucose on ATP levels at concentrations 10, 25, 50, and 100 pM on CCRF-CEM leukaemia cell 
line. ATP levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide 
indication of live cell numbers. ATP levels normalized to controls and presented as means ± 
standard error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Pelargonidin and pelargonidin-3-O-glucoside significantly (P < 0.05) inhibited ATP levels 
in MOLT-3 cells at 25, 50, 100 pM in a dose-dependent manner, while pelargonidin-
3,5-di-O-glucose showed significant decrease at only 50 and 100 pM following 24 h 
treatment (P < 0.05). Pelargonidin induced IC50in MOLT-3 cells at 83 pM. In contrast, 
pelargonidin-3-O-glucoside and pelargonidin-3-O-glucoside failed to display 50% 
decrease in ATP levels in MOLT-3 cells (Figure 6.16) (Table 6.8).
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Figure 6.16: Effect of pelargonidin, pelargonidin-3-0-glucoside, and pelargonidin -3,5-di-O- 
glucose on ATP levels at concentrations 10, 25, 50, and 100 pM on MOLT-3 leukaemia cell line. 
ATP levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide 
indication of live cell numbers. ATP levels normalized to controls and presented as means ± 
standard error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Pelargonidin and pelargonidin-3-O-glucoside significantly (P<  0.05) inhibited ATP levels 
in HL-60 cells at 25, 50 and 100 pM  in a dose-dependent manner, wh ile pelargonidin -
3,5-di-O-glucose did not show a significant (P < 0.05) decrease at all concentrations 
follow ing 24 h treatm ent. Pelargonidin and pelargonidin-3-O-glucoside displayed IC5o 
against HL-60 cells at 81 and 98 pM . In contrast, pelargonidin -3,5-di-O-glucose failed 
to display 50% decrease in ATP levels in HL-60 cells (Figure 6.17) (Table 6.8).
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Figure 6.17: Effect of pelargonidin, pelargonidin-3-O-glucoside, and pelargonidin -3,5-di-O- 
glucose on ATP levels at concentrations 10, 25, 50, and 100 pM on HL-60 leukaemia cell line. 
ATP levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide 
indication of live cell numbers. ATP levels normalized to controls and presented as means ± 
standard error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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Pelargonidin and pelargonidin-3-O-glucoside significantly (P < 0.05) inhibited ATP levels 
in THP-1 cells at 10, 25, 50, 100 pM in a dose-dependent manner, while pelargonidin -
3,5-di-O-glucose did not show significant decrease at any concentration following 24 h 
treatment (P > 0.05). Pelargonidin displayed IC50 against THP-1 cells of 83 pM. In 
contrast, pelargonidin-3-O-glucoside and pelargonidin-3-O-glucoside failed to display 
50% decrease in ATP levels in THP-1 cells (Figure 6.18) (Table 6.8).
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Figure 6.18: Effect of pelargonidin, pelargonidin-3-O-glucoside, and pelargonidin -3,5-di-O- 
glucose on ATP levels at concentrations 10, 25, 50, and 100 pM on THP-1 leukaemia cell line. 
ATP levels investigated using Cell Titer-Glo® Luminescent Cell Viability Assay to provide 
indication of live cell numbers. ATP levels normalized to controls and presented as means ± 
standard error. * indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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w a r n
Delphinidin 20 pM 17 pM 16 pM 38 pM
Delphinidn-3-O-
glucoside 35 pM 34 pM 19 pM 63 pM
Delphinidin-3,5-
O-diglucosie 41 pM 44 pM 34 pM 74 pM
Cyanidin 57 pM 67 pM 64 pM 83 pM
Cyanidin-3-O-
glucoside 87 pM 88 pM 70 pM 90 pM
Cyanidin-3,5-0-
diglucosie NR NR NR NR
Pelargonidin 81 pM 83 pM 81 pM 83 pM
Pelargonidin-3-
O-glucoside NR NR 98 pM NR
Pelargonidin-
3,5-O-diglucosie NR NR NR NR
Table 6.8: The IC50 of anthocyanins and anthocyanidins on leukaemia cell lines (CCRF-CEM,
MOLT-3, HL-60, and THP-1) following 24 h treatment. NR= not reached.
6.4.2 Effect o f anthocyanidins and anthocyanins found in PJ on induction  
of cell death
Delphinidin, delphinidn-3-O-glucoside, and delphinidin-3,5-di-0-glucose showed a 
significant (P < 0.05) increase in the number of apoptotic and dead cells and significant 
{P < 0.05) decrease in the number of live cells in CCRF-CEM, MOLT-3 (Figure 6.19), HL- 
60, and THP-1 cells (Figure 6.20) with different sensitivity between these cells 
following 24 h treatment. Delphinidin exhibited potent induction of apoptosis in all 
cells compared to delphinidn-3-O-glucoside, and delphinidin-3,5-di-0-glucose which 
had less effect on the induction of apoptosis (P > 0.05).
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Figure 6.19: Annexin V-FITC/ PI based on flow cytometry following treatment with delphinidin, 
delphinidn-3-0-glucoside, and delphinidin-3,5-di-0-glucose (0, 10, 25, 50, 75, and 100 pM) for 
24 h on CCRF-CEM and MOLT-3. * indicates significant difference (P < 0.05) vs. untreated 
control. n= 3.
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Figure 6.20: Annexin V-FI1C/ PI based on flow cytometry following treatment with delphinidin, 
delphinidn-3-O-glucoside, and delphinidin-3,5-di-0-glucose (0, 10, 25, 50, 75, and 100 pM) for 
24 h on HL-60 and THP-1 Mean ± SEM. * indicates significant difference (P < 0.05) vs. 
untreated control. n= 3.
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Cyanidin, cyanidin-3-O-glucoside, and cyanidin -3,5-di-O-glucose showed a significant 
increase in the number of apoptotic and dead cells and significant decrease in the 
number of live cells in CCRF-CEM cells following 24 h treatment (P < 0.05) (Figure 6.21). 
Cyanidin illustrated potent induction of apoptosis compared to cyanidin-3-O-glucoside 
and cyanidin-3,5-di-0-glucose on CCRF-CEM cells. Cyanidin induced apoptosis in MOLT- 
3 (Figure 6.21) and HL-60 cells (Figure 6.22), while cyanidin treatment of THP-1 cells 
failed to induce apoptosis. Cyanidin-3-O-glucoside and cyanidin -3,5-di-O-glucose did 
not show any effect on induction of apoptosis in MOLT-3, HL-60, and THP-1 cells 
(Figure 6.21 and 6.22).
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Figure 6.21: Annexin V-FITC/ PI based on flow cytometry following treatment with cyanidin, 
cyanidin-3-O-glucoside, and cyanidin-3,5-di-0-glucose (0, 10, 25, 50, 75, and 100 pM) for 24 h 
on CCRF-CEM and MOLT-3. Mean ± SEM. * indicates significant difference (P < 0.05) vs. 
untreated control. n= 3.
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Figure 6.22: Analysis of Annexin V-FITC/ PI based on flow cytometry following treatment with 
cyanidin, cyanidin-3-O-glucoside, and cyanidin-3,5-di-0-glucose (0,10, 25, 50, 75, and 100 |iM) 
for 24 h on HL-60 and THP-1. Mean ± SEM. * indicates significant difference (P < 0.05) vs. 
untreated control. n= 3.
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Pelargonidin slightly induced apoptosis, but this failed to reach significance in CCRF- 
CEM, MOLT-3, and HL-60 cells, and failed to induce apoptosis on THP-1 cells (Figure 
6.23 and 6.24). Pelargonidin, Pelargonidin-3-O-glucoside, and pelargon id in-3,5-d i-0- 
glucose did not show any effect on induction of apoptosis in any of the cells lines 
investigated (Figure 6.23 and 6.24).
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Figure 6.23: Annexin V-FITC/ PI based on flow cytometry following treatment with 
pelargonidin, pelargonidin -3-0-glucoside, and pelargonidin-3,5-di-0-glucose (0, 10, 25, 50, 75, 
and 100 pM) for 24 h on CCRF-CEM and MOLT-3. Mean ± SEM. * indicates significant 
difference (P < 0.05) vs. untreated control. n= 3.
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Figure 6.24: Annexin V-FITC/ PI based on flow cytometry following treatment with 
pelargonidin, pelargonidin -3-0-glucoside, and pelargonidin-3,5-di-0-glucose (0,10, 25, 50, 75, 
and 100 pM) for 24 h on HL-60 and THP-1. Mean ± SEM. * indicates significant difference (P < 
0.05) vs. untreated control. n= 3.
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6.4.3 Effect o f Anthocyanid ins (Delphinid in, Cyanidin, and Pelargon id in) 
on Caspase-3 Activ ity
Caspase- 3 activation plays a central role during the apoptotic process. Induction of 
apoptosis by treatment with delphinidin, cyanidin, and pelargonidin was confirmed 
with induction of caspase-3 activity in all four cell lines following 24 h. In CCRF-CEM, 
MOLT-3, and HL-60 cells a significant increase in the number of cells with active 
caspase-3 was observed at concentrations 25, 50, 75 and 100 pM delphinidin (P £ 
0.05). While, in THP-1 the number of cells with active caspase-3 was observed at 
concentrations 50, 75, and 100 pM delphinidin, with no significant effect seen 
following 25 pM treatment with delphinidin (P £ 0.05) (Figure 6.25).
Cyanidin induced apoptosis with different sensitivity in CCRF-CEM, MOLT-3, HL-60and 
THP-1 cells, cyanidin failed to induce apoptosis at all concentrations (Figure 6.25). 
Pelargonidin failed to induce apoptosis in all four leukaemia cell lines (Figure 6.25).
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Figure 6.25: Effect of delphinidin, cyanidin, and pelargonidin on caspase-3 activation in four 
leukaemia cell lines (CCRF-CEM, MOLT-3, HL-60, and THP-1). Cells treated for 24 at 
concentrations 10, 25, 50 and 100 pM. Caspase-3 activation was determined by NucView™ 488 
Caspase-3 substrate based on flow cytometry analysis. Mean ± SEM. * indicates significant 
difference (P < 0.05) vs. untreated control. n= 3.
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6.4 .4  Effect o f Delph inid in on Induction o f Apoptosis Using DAPI for  
M orphology Assessment
To confirm the results of annexin V/PI-FITC and caspase-3 activity, we examined the 
effect of delphinidin on leukaemia cell lines (CCRF-CEM, MOLT-3, HL-60, and THP-1) on 
apoptotic morphological using DAPI stain at concentrations (25, 50, and 100 pM) 
following 24 h treatments.
In all cell lines, untreated cells (0 pM) exhibited intact cells, but delphinidin-treated 
cells showed significant nuclear fragmentation, which is a typical marker of apoptosis. 
The induction of apoptosis cell death was accompanied by characteristic morphology 
and structural changes, including a condensed and fragmented nuclear structure and 
decreased cell size (Figure 6.27 and 6.29).
Differential responses between cells lines was observed following delphinidin 
treatment at different concentrations as was observed with annexin V-FITC /PI and 
caspase-3 activity assessment. Treatment of CCRF-CEM and HL-60 cells with 
delphinidin resulted in a significant increase in the number of apoptotic cells at all 
concentrations 25, 50, and 100 pM (Figure 6.26 and 6.28), while in MOLT-3 and THP-1 
cells a significant increase in the number of apoptotic cells was only observed following
50 and 100 pM (P < 0.05) (Figure 6.27 and 6.29).
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Figure 6.26: (1) Morphological staining analysis of CCRF-CEM with DAPI treated with 
delphinidin 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and 
apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells determined 
from DAPI morphological assessment following treatment with delphinidin at concentration 25, 
50, and 100 pM for 24 h. * indicates significant difference (P < 0.05) vs. untreated control. 
Scale bar = 12.5 pm. n= 3.
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Figure 6.27: (1) Morphological staining analysis of MOLT-3 with DAPI treated with delphinidin 
25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and apoptotic cells 
are indicated by the red arrows. (2) Percentage of apoptotic cells determined from DAPI 
morphological assessment following treatment with delphinidin at concentration 25, 50, and 
100 pM for 24 h. * indicates significant difference (P < 0.05) vs. untreated control. Scale bar =
12.5 pm.n= 3.
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Figure 6.28: (1) Morphological staining analysis of HL-60 with DAPI treated with delphinidin 25, 
50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and apoptotic cells are 
indicated by the red arrows. (2) Percentage of apoptotic cells determined from DAPI 
morphological assessment following treatment with delphinidin at concentration 25, 50, and 
100 pM for 24 h. * indicates significant difference (P < 0.05) vs. untreated control. Scale bar =
12.5 pm. n= 3.
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Figure 6.29: (1) Morphological staining analysis of THP-1 with DAPI treated with delphinidin 25, 
50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and apoptotic cells are 
indicated by the red arrows. (2) Percentage of apoptotic cells determined from DAPI 
morphological assessment following treatment with delphinidin at concentration 25, 50, and 
100 pM for 24 h. * indicates significant difference (P < 0.05) vs. untreated control. Scale bar = 
12.5 pm. n= 3.
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6.4.5 Effect o f Delph inid in on Cell Cycle Arrest w ith in  Leukaem ia Cell 
Lines
To evaluate the effect of delphinidin treatment on the distribution of cells in phases of 
cell cycle, DNA cell cycle analysis by flow cytometry was performed. Delphinidin 
treatment at concentrations 25, 50, and 100 pM resulted in a dose-dependent 
accumulation of cells in S phase, in all leukaemia cell lines (CCRF-CEM, MOLT-3, HL-60, 
and THP-1).
CCRF-CEM cells showed a significant accumulation of cells in S phase, and a significant 
(P < 0.05) decrease in the Go/Gi phase, at all delphinidin concentrations (25, 50, and
100 pM) at 24 h (Figure 6.30). MOLT-3 cells exhibited similar pattern as CCRF-CEM cells, 
however, the significant accumulation of cells at S phase was only seen at 
concentrations of 50 and 100 pM of delphinidin following 24 h treatments (Figure
6.30). The myeloid cell lines HL-60 and THP-1, showed a significant (P £ 0.05)
accumulation of cells in S phase corresponding with a decrease in the Go/Gi and M 
phases following treatment with delphinidin for 24 h (Figure 6.30).
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6.4 .6  Effect o f Delph inid in on Activities of Caspase-8 and -9 in HL-60 and 
MOLT-3
In order to determine whether delphinidin activated the intrinsic or extrinsic pathway levels 
of caspase-8 and -9 were determined using Caspase-Glo™ 8 and 9 assays. In HL-60 cells, 
there was a significant time-dependent increase in caspase-8 and -9 when treated with 25 
and 50 pM (Figure 6.31). There was at least a 2-fold increase in caspase-8 and -9 activity 
between 3 and 6 h incubation. After 24 h, there was a decrease in both caspse-8 and -9 
(Figure 6.31).
In MOLT-3 cells, delphinidin failed to stimulate both caspase-8 and -9, at 3 h incubation. At 6 
h, there was increase in caspase-8 and -9 activity but was only following treatment with 25 
pM concentration. When a 50 pM of delphinidin treatment was used more than 3.5 fold 
increase in both caspases. At 24 h, a decrease in both caspases was observed (Figure 6.32).
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Figure 6.31: Effect of delphinidin on activation of caspase-8 (A) and caspase-9 (B). HL-60 cells were 
treated with delphinidin at concentration 25 and 50 pM for 3, 6, and 24 h. Caspase-8 and -9 activities 
were investigated using Caspase-Glo™ 8 and 9 Assays. Level of both caspases activites normalized to 
control and presented as means ± standard error. * indicates significant difference (P < 0.05) vs. 
untreated control. n= 3.
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Figure 6.32: Effect of delphinidin on activation of caspase-8 (A) and caspase-9 (B). MOLT-3 cells 
were treated with delphinidin at concentration 25 and 50 pM for 3, 6, and 24 h. Caspase-8 and -9 
activities were investigated using Caspase-Glo™ 8 and 9 Assays. Level of both caspases activities 
normalized to control and presented as means ± standard error. * indicates significant difference (P 
< 0.05) vs. untreated control. n= 3.
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6.4 .7  Effect o f Delph inid in on Expression o f Cytochrome C in HL-60 and 
MOLT-3 Cells
Cytochrome c is normally expressed in the cells binding to the inner membrane of the 
mitochondria. In response to pro-apoptotic stimuli it is released from the mitochondria to 
the cytosol. Thus, when using a specific antibody it is possible to demonstrate the 
expression, and translocation of cytochrome c as a dark brown staining. In cells with inactive 
cytochrome c this appears as a pale brown colour.
The number of cells displaying active cytochrome c was significantly (P < 0.05) increased in 
HL-60 cells following 3, 6, and 24 h in a dose dependent manner (Figure 6.33 and 6.37). In 
MOLT-3 cells the number of active cytochrome c cells was significantly (P < 0.05) increased 
after 6 and 24 h treatment, with 50 pM delphinidin (Figure 6.34 and 6.37).
6.4.8 Effect o f Delph inid in on Expression o f Sm ac/Diablo in HL-60 and MOLT- 
3 Cells
Smac/Diablo is a mitochondrial pro-apoptotic protein, which is found in an inactive form 
within normal cells, within active cells an increased intensity was seen indicating the release 
from the mitochondrial membrane.
Smac/Diablo immunopositivity was also significantly increased following 3, 6, and 24 h 
treatment with 50 pM of delphinidin (P< 0.05). At 6 h, there was a 44% increase in 
Smac/Diablo activity, this was greater than that seen in controls and the earlier 1 and 3 h 
time points (Figure 6.35 and 6.38). In MOLT-3 cells the number of active Smac/Diablo cells 
was also significantly increased after 6 and 24 h treatment with 50 pM delphinidin (Figure 
6.36 and 6.38) (P < 0.05).
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Figure 6.37: Percentage of active cytochrome C in HL-60 and MOLT-3 cells determined from 
ICC morphological assessment following treatment with delphinidin at 50 pM for 3, 6, and 24 h 
normalized to untreated controls. Mean ± SEM. * indicates significant difference (P < 0.05) vs. 
untreated control. n= 3.
Delphinidin
MOLT-3HL-60
3 hr 6 hr 24 hr 3 hr 6 hr 24 hr
Incubation tim e
Figure 6.38: Percentage of active Smac/DIABLO in HL-60 and MOLT-3 cells determined from 
ICC morphological assessment following treatment with delphinidin at 50 pM for 3, 6, and 24 h 
normalized to untreated controls. Mean ± SEM. * indicates significant difference (P < 0.05) vs. 
untreated control. n= 3.
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6.4.9 Effect o f Delph inid in on the Expression o f Pro-Apoptotic Proteins 
(BAX and BAD) and Anti-Apoptotic Proteins (Bcl-2 and Bcl-xl)
The effect of delphinidin on the mRNA expression of pro-apoptotic proteins (BAX and
BAD) and anti-apoptotic proteins (Bcl-2 and Bcl-xl) on two leukaemia cell lines (HL-60 
and MOLT-3) was investigated. Delphinidin (50 pM) up-regulated the mRNA expression 
of Bax and Bad (4.6-fold and 4.4-fold respectively) on HL-60 cells following 6 h 
treatment. In addition, mRNA expression for Bcl-2 and Bcl-xl were significantly down- 
regulated (6.2-fold and 6.6-fold respectively) in HL-60 cells following treatment with 50 
pM delphinidin for 6 h (Figure 6.39).
Similarly in MOLT-3 cells treatment with delphinidin (50 pM) resulted in up-regulated 
of the mRNA expression of BAX and BAD (4.1-fold and 3.5-fold respectively) and down- 
regulated the mRNA expression of Bcl-2 and Bcl-xl (5.8-fold and 5.6-fold respectively) 
following 6 h treatment (Figure 6.40).
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Figure 6.39: Effect of delphinidin (50 pM) on the mRNA expression of pro-apoptotic protein 
(BAX and BAD) and anti-apoptotic proteins (Bcl-2 and Bcl-xl) on HL-60 leukaemia cells following 
6 h treatment. The result of untreated cells was normalized to 1. Results were significant to 
the control sample when P < 0.05. n= 3.
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Figure 6.40: Effect of delphinidin (50 pM) on the mRNA expression of pro-apoptotic protein 
(BAX and BAD) and anti-apoptotic proteins (Bcl-2 and Bcl-xl) on MOLT-3 leukaemia cells 
following 6 h treatment. The result of untreated cells was normalized to 1. Results were 
significant to the control sample when P < 0.05. n= 3.
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6.5 Discussion:
This study showed for the first time that delphinidin, cyanidin, and pelargonidin, were 
capable of reducing ATP levels in all four leukaemia cell lines investigated.
Delphinidin was the most potent anthocyanins studied, suggesting that its ortho- 
hydroxyphenyl structure is critical for its activity. Consistent with our results Katsube et 
al, (2003) demonstrated that anthocyanidins could reduce cell proliferation of HCT116 
colon cell line. Their anti-proliferative effects in order of effectiveness were: 
delphinidin > cyanidin > peonidin > pelargonidin > malvinidin in HCT116 cells. Similarly, 
six anthocyanidins were shown to inhibit TPA-induced JB6 mouse epidermal cell 
transformation and AP-1 transcription activity (Hou et al, 2004. Delphinidin was shown 
to be the most effective having a greater activity than petunidin, cyanidin, pelargonidin, 
malvinidin, and peonidin (Hou et al, 2004). It was concluded that the ortho- 
dihydroxyphenyl structure at the B-ring found in delphinidin was essential for 
apoptosis (Hou et al, 2003). Meiers et al. (2001) reported that cyanidin and
delphinidin contain hydroxyl groups, whilst malvinidin did not. Cyanidin and 
delphinidin induced higher inhibitory effects on the growth of human vulva carcinoma 
cell line A431 in vitro (Meiers et al, 2001).
6.5.1 Delphinid in is the  most active Anthocyanin on Leukaem ia Cells
Delphinidin showed the greatest induction of apoptosis compared with cyanidin and
pelargonidin in all four leukaemia cell lines (CCRF-CEM, MOLT-3, HL-60, and THP-1). 
However, there was differential sensitivity shown between them. Similarly delphinidin 
induced apoptosis in HepG2 cells more effectively than cyanidin (Yeh and Yen, 2005). 
Delphinidin has also been shown to induce apoptosis in different cancer cell lines 
including breast (AU-565 cells) (Afaq et al, 2008); prostate (PC3 cells (Hafeez et al, 
2008a) and PCa 22Rnul cells (Hafeez et al, 2008b)); colon (HCT-116 cells) (Yun et al, 
2009); liver (HepG2 cells) (Yeh and Yen, 2005); uterus (Hela S3 cells) (Lazze et al, 2004) 
and leukaemia (HL-60 cells).
Here, cyanidin inhibited cell proliferation in all four leukaemia cell lines (CCRF-CEM,
MOLT-3, HL-60, and THP-1), but only induced apoptosis in CCRF-CEM, MOLT-3, and HL-
60 at high concentrations and failed to induce apoptosis in THP-1 cells. Several studies
have reported that cyanidin in different forms (cyanidn-rutinoside, cyanidin-3-O-p-
glucopyranoside and cyanidin-3-O-p-D-glucopyranoside) induced apoptosis in
275
oesophageal (Zikri et al, 2009) liver (Longo et al, 2008), and 6 leukaemia cell lines: (HL- 
60 (Feng et al, 2007; Fimograni et al, 2004); MOLT-4 (Katsuzaki et al, 2003); U937 
(Hyun and Chung, 2004) and Jurkat cells (Fimognari et al, 2004)). In contrast Annalucia 
et al, (2004) demonstrated cyanidin-3-O-P-glucopyranoside failed to induce apoptosis 
but did decrease cellular proliferation.
Pelargonidin failed to induce apoptosis in all four leukaemia cell lines. Similarly, Katsub 
et al (2003) reported that pelargonidin failed to induce apoptosis in colon cancer cells 
HCT-116 (Katsub et al, 2003). Yeh and Yen (2005) showed that delphinidin and cyanidin 
induced apoptosis in HepG2 cells whilst pelargonidin did not induce apoptosis.
6.5 .2  Effect o f Sugar Molecules
This study showed that the anthocyanidins exhibited greater anti-proliferative and pro- 
apoptotic effects than their glycosylated counterparts: the anthocyanins. Shish et al 
(2005) also reported that cyanidin and pelargonidin show stronger inhibitory effects on 
human gastric adenocarcinoma than their glycosidic forms: cyanidin-3-glucose and 
pelargonidin-3-glucose. The current study also showed the number of glucoside groups 
affected their activity, with mono-glycoside being more potent inhibitors of cellular 
proliferation and inducers of apoptosis than di-glycosides. This result agrees with 
previous work (Chapter 5), which showed that rutin illustrated less inhibitory effect on 
ATP levels that its aglycon form, quercetin. This data suggests that glycosilation of the 
anthrocyanins inhibit their biological activities. Few studies have been conducted to 
investigate the relationship between structure and function of glycosylated 
anthocyanins. Jing et al. (2008) studied the relationship between chemical 
characteristics of anthocyanins and their biological activity. Demonstrating that 
anthocyanins with structure properties of mono-glycoside were stronger inhibitors of 
cell proliferation in HT-29 colon cells than their tri-glycosylated counterparts (Jing et al, 
200). Similarly it has been found that cyanidin and pelargonidin showed greater anti­
proliferative capabilities than cyanidn-3-glucoside and pelargonidin-3-glucose on 
human gastric adenocarcinoma AGS cells (Shish et al, 2005). Koide et al. (1997) 
reported that an extract containing mostly cyanidin-glucoside and cyanidin- 
rhamnoside was more effective in suppressing the HCT15 colon cells growth in vitro 
than the extract rich in cyanidin-rhamnoside, suggesting that anthocyanin chemical 
structure has an effect on inhibiting cell growth (Koide et al, 1997).
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The results indicated that potency of cancer chemoprevention of anthocyanins 
including inhibition of ATP levels and induction of apoptosis is associated with the 
number of hydroxyl groups on the B-ring and sugar units. These factors have also been 
reported to have an effect on antioxidant activity which plays an important role in 
cancer treatment (Kahkonen and Heinonen, 2002). Noda et al (2002) reported that 
delphinidin has more potent antioxidant activity than cyanidin and pelargonidin. In 
addition, studies suggest that glycosidic forms generally display a decrease in the 
antioxidant capacity when compared with the corresponding aglycon. This may due to 
the steric hindrance conferred by the bulky sugars (Satue-Garcia et al, 1997; Tsuda et 
al, 1994).
Delphinidin was the most potent compound inhibiting cell proliferation and inducing 
apoptosis in a dose dependent manner to a greater extent than cyanidin and 
pelargonidin and thus was selected for further investigation.
6.5.3 Regulation o f Cell Cycle by Delphinid in
Studies have shown the involvement of cell cycle regulation in inhibiting cell growth. 
Here, delphinidin treatment of CCRF-CEM, MOLT-3, HL-60 and THP-1 cells resulted in 
arrest of cells in S phase. Similarly, Lazze, et al., (2004) showed that exposure of human 
uterus cancer cells (Hela S3) to delphinidin caused S phase arrest. Whilst G2/M  phase 
arrest has been shown in breast cancer cells (MCF-7) (Nguyen et al, 2010; Chen et al, 
2005) and (HS578T), and colon cancer cells (HCT-116) (Yun et al, 2009). Previously S 
phase arrest was also observed following treatment with PJ (Chapter 3) (Dahlawi et al, 
2011) and acetonitrile fractions (Chapter 4) (Dahlawi et al, 2013) in the same cell lines 
tested here, indicating that delphinidin may be one of the major components in PJ.
6.5 .4  M olecular Mechanism of Apoptosis Induction by Delph inid in
Here, caspase-3 activity was increased in all four leukaemia cell lines following
treatment with delphinidin. This finding is supported by the work of Hou et al. (2005)
who showed that treatment with delphinidin-3-sambubioside at a concentration of
100 pM induced caspase-3 activity in human promyelocytic HL-60 cells. Delphinidin has
also been shown to induce caspase-3 in human colon (HCT-116) (Yun et al, 2009),
breast (Human EGFR positive AU-565) (Afaq et al, 2008), and prostate (Androgen
refractory human PCa 22Rnu 1) (Hafeez et al, 2008b), (PC3), and (human androgen-
dependent LNCaP) (Hafeez et al, 2008b) cancer cell lines.
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Delphinidin was shown here to induce activation of both caspase-8 and -9 in MOLT-3 
and HL-60 cells, suggesting activation of both intrinsic and extrinsic apoptosis 
pathways by delphinidin. This has also been reported in delphinidin-3-sambubioside 
treated HL-60 cells (Hou et al, 2005) and delphinidin treated colon cancer cells (HCT- 
116) (Yun etal, 2009). In addition the current study showed that delphinidin treatment 
increased the expression of cytochrome c in HL-60 and MOLT-3 cells. Consistent with 
our results, Hou et al (2005) reported that cytochrome c release was observed in HL-60 
cells following treatment with delphinidin-3-sambubioside. Release of cytochrome c 
was also observed in leukaemia cells (HL-60) and in hepatic cancer cells (PLC/PRF/5) 
following treatment with a mixture of anthocyanins (Change et al, 2005; Longo et al, 
2008).
In addition, delphinidin treatment of MOLT-3 and HL-60 cells caused release of 
Smac/Diablo from the mitochondria. Khan et al. (2008) found that flavonoid treatment, 
fisetin, resulted in inhibition of IAP and induction of apoptosis via Smac/Diablo in 
prostate cancer cells (LNCaP).
A decrease in Bcl-2 and Bcl-XI and an increase in Bax and Bad mRNA in MOLT-3 and HL- 
60 cells following treatment with delphinidin was also seen further supporting the 
activation of the intrinsic pathway of apoptosis.
The activation of both intrinsic and extrinsic apoptosis by delphinidin has also been 
shown in breast cancer cells (MCF-7) Kue et al, (2004). Together with studies showing 
intrinsic and extrinsic apoptosis by anthocyanins extracted from different fruits 
(Change etal, 2005; Reddivari etal, 2007).
6 .6  Conclusion
Anthocyanins activity was found to be dependent on the ortho-hydroxyphenyl 
structure and the most potent glycosidic form of the anthocyanins with proliferation 
and apoptosis effects seen in anthocyanins with greatest hydroxyl groups and least 
glycosidic form, namely delphinidin. Delphinidin induced apoptosis through intrinsic 
and extrinsic pathways. Suggesting that delphinidin may have potential for use as a 
chemotherapeutic agent against leukaemia.
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7. Induction of apoptos
arrest following stimulation with EGCG, 
Gallic acid, guerticin and punicalagin.
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7 .1  In tro d u c tio n
Pomegranates have been shown to be a rich source of a wide of variety of bioactive 
compounds amongst these compounds, EGCG; gallic acid; quercetin and punicalagin 
were identified as demonstrating potent decreases in ATP levels in leukaemia cell lines 
(Chapter 5). To determine whether the decrease in ATP levels by these compounds 
was due to apoptosis or cell cycle arrest these agents were investigated further.
EGCG is a a falavn-3-ol and is the major polyphenolic agent in green tea, which has 
been shown to have potential as a chemopreventive agent for a number of cancers 
(Cimino et al, 2012). Previously EGCG was shown to be the most potent compound 
among other flavan-3-ol agents tested (Chapter 5). In vitro EGCG induces apoptosis 
and cell cycle arrest in many cancer cells without affecting normal cells (Paschtka et al, 
1998; Ahmad et al, 2000; Ahn et al, 2003; Salucci et al, 2002; Hastak et al, 2005; 
hangapazham et al, 2007; Tang et al, 2007; Adhami et al, 2007), although to date there 
are limited studies on its effects on leukaemia cells.
Quercetin is a flavonol and is found in a variety of fruits and vegetables (Chen et al, 
2007). Numerous reports on the potential anti-cancer effects of quercetin have been 
published (Nair et al, 2004; Vijayababu et al, 2005; Granado-Serrano et al, 2006; Jeong 
et al, 2009; Chien et al, 2009; Jung et al, 2010; Jung et al, 2010). The cancer-preventive 
effects have been attributed to cell cycle arrest, inhibition of proliferation and 
induction of apoptosis (Nair et al, 2004; Vijayababu et al, 2005; Granado-Serrano et al, 
2006; Jeong et al, 2009; Chien et al, 2009; Jung et al, 2010; Jung et al, 2010).
Gallic acid is a naturally occurring plant phenolic acid, and has been reported to have 
potential anti-cancer activities (Weng and Yen 2012). In vitro and in vivo studies using 
gallic acid have shown anti-cancer activities in several types of cancer cell lines 
including: colon, lung, and prostate cancer cell lines (Yoshioka et a l 2000; Veluri et al, 
2006; Ji et al, 2009). In addition gallic acid displays selectivity towards tumour cells 
with lower toxicitiy seen in normal cells (Veluri et al, 2006; Bernhaus et al, 2009). 
Gallic acid can induce apoptosis and results in cell cycle arrest (Kaur et al, 2009; You 
and Park, 2010; Ou et al. 2010; Locatelli et al, 2012).
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Punicalagin, anellagitannins is found in pomegranates, strawberries, raspberries, 
almonds, and walnuts (Amakura et al, 2000; Clifford and Scalbert, 2000). In PJ, 
punicalagin is believed to be responsible for more than 50% of its antioxidant activity 
(Gil et al, 2000). Our previous work (Chapter 4) (Dahlawi et al, 2013) has identified 
punicalagin as one of the most abundant compounds within acetonitrile fraction, and 
we have shown it induces a potent inhibition of ATP levels indicating decreases in live 
cell numbers (Chapter 5). However, to date, few studies have investigated the effect of 
punicalagin as pure agent in cancer cell lines (Larrosa et al, 2005; Seeram et al, 2005).
The present chapter will focus on the potential chemopreventive activities of EGCG, 
quercetin, gallic acid and punicalagin. Testing the hypothesis that: these agents induce 
apoptosis and cell cycle arrest in leukaemia cell lines.
7.2 Materials and Methods
7.2.1 Cell Culture
Four leukaemia cell lines were used in this study. These were selected as they were 
shown to have sensitivity to PJ (Dahlawi et al, 2011) (chapter 3) and to the acetonitrile 
fraction of PJ (Dahlawi et al, 2013) (Chapter 4). They included two lymphoid cell lines: 
CCRF-CEM and MOLT-3 and two myeloid cell lines: HL-60 and THP-1. Cell lines were 
maintained and cultured in RPMI 1640 medium (Invitrogen, Paisley, U.K.) 
supplemented with 10% (v/v) foetal bovine serum, 1.5 mmol/L L-glutamine, and 100 
pg/mL penicillin/streptomycin (complete media) in a humidified atmosphere of 5% C02 
at 37°C.
7.2.2 T reatm ent o f Cells
Cells were treated with EGCG, gallic acid, quercetin, and punicalagin at dose of 0 -1 0 0  
pM for 24 h and induction of apoptosis and cell cycle arrest investigated (Table 7.1).
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Annexin V-FITC/PI EGCG, gallic acid, 0,10, 25, 50, CCRF-CEM, MOLT- 24 hr
quercetin, and 75, and 100 pM 3, HL-60, and
punicalagin THP-1
NucView™ 488 EGCG, gallic acid, 0,10, 25, 50, CCRF-CEM, MOLT- 24 hr
Caspase-3 substrate quercetin, and 75, and 100 pM 3, HL-60, and
assay punicalagin THP-1
DAPi staining EGCG, gallic acid, 0, 25, 50,100 CCRF-CEM, MOLT- 24 hr
quercetin, and pM 3, HL-60, and
punicalagin THP-1
Cell cycle EGCG, gallic acid, 0, 25, 50,100 CCRF-CEM, MOLT- 24 hr
quercetin, and pM 3, HL-60, and
punicalagin THP-1
Table 7.1: Experimental deighn for chapter 7.
7.2.3 Annexin V- FITC /P I Flow Cytometry Assay
Flow cytometry of Annexin V-FITC /PI was used to detect apoptosis as described 
previously (section 2.4.1). Cells were seeded at 5 x 105 cells in 1 ml of complete media 
in a 6-well plate (Fisher Scientific) and treated with EGCG, gallic acid, quercetin, and 
punicalagin at a concentration of 0, 10, 25, 50, 75, and 100 pM for 24 h. Data were 
recorded from 10,000 cells per sample and analyzed using FlowJo software (Tree Star).
7.2.4 Caspase-3 Activ ity
NucView™ 488 Caspase-3 substrate was used to detect caspase-3 activity as described 
in section 2.4.3. Cells were treated with EGCG, gallic acid, quercetin, and punicalagin at 
concentrations 0, 10, 25, 50, 75, and 100 pM for 24 h. Data were recorded from 10,000 
cells per sample and analyzed using FlowJo software (Tree Star).
7.2.5 DAPI Stain
Following treatment with EGCG, gallic acid, quercetin, and punicalagin at 
concentrations of 0, 25, 50, 100 for 24 h at cell density 5xl04 cells per well, cells were 
stained with DAPI to observe apoptotic morphology as described previously (section 
2.4.2). Cells were examined using an Olympus BX60 fluorescence microscope using UV 
light at excitation wavelength 350 nm. Quantitative analysis of cell populations (live & 
apoptotic) was performed based on counting of 200 randomly-selected cells and the 
percentage of apoptotic features determined for each sample.
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7.2.6 Cell Cycle
The cell cycle distribution of leukaemia cell lines was measured by the DNA contents in 
each cell based on flow cytometry using PI stain as described previously in section 2.5. 
Cells were treated with EGCG, gallic acid, quercetin, and punicalagin at concentrations 
of 0 25, 50, and 100 pM for 24 h. Data from 10,000 cells per sample were recorded and 
percentages of cells within Go/Gi, S, and G2/M  cell cycle phase were determined with 
FlowJo software and Waston (pragmatic) analysis of cell cycle (Tree Star).
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7.3 Results
7.3.1 EGCG
7.3.1.1 Effect of EGCG on Induction of Apoptosis
7.3.1.1.1 Annexin V-FITC/PI Based on Flow Cytometry
EGCG treatment of CCRF-CEM, MOLT-3, HL-60, and THP-1 cells resulted in a significant 
increase in the number of apoptotic and dead cells and a decrease in the number of 
live cells following 24 h incubation at concentrations: 25, 50, 75, and 100 pM (P < 0.05). 
At the lowest concentration (10 pM) of EGCG no significant induction of apoptosis was 
observed in all four cell lines. THP-1 was the least sensitive among the cell lines 
investigated, which illustrated only slight decrease in the number of live cells and 
increase in the number of apoptotic and dead cells (Figure 7.1).
EGCG
KtOuM H lO u M  U 25U M  M 50uM  tof 75uM  M lOOuM
CCRF-CEM
Figure 7.1: Annexin V-FITC/ PI based on flow cytometry following treatment with EGCG (0, 10, 
25, 50, 75, and 100 pM) for 24 h on CCRF-CEM, MOLT-3, HL-60, and THP-1. Mean ± SEM. * 
indicates significant difference (P < 0.05) vs. untreated control. n= 3.
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7.3.1.1.2 Caspase-3 Activity:
EGCG at treatment dose of 25, 50, 75, and 100 pM significantly increased caspase-3 
activity in all four leukaemia cell lines (CCRF-CEM, MOLT-3, HL-60 and THP-1) with 
different sensitivity following 24 h treatment (P < 0.05). In CCRF-CEM cells, following 
100 pM of EGCG caspase-3 activity was increased to 98% of cells positive as compared 
to 8% in untreated controls cells. In HL-60 and MOLT-3 cells caspase-3 activity was 
increased to 88% and 78% of cells positive respectively. THP-1 cells were the least 
sensitive cell lines, with only 16% of cells positive for caspase-3 activity following 100 
pM of EGCG for 24 h compared to 7.5% in control cells (Figure 7.2).
EGCG
HOuM i f  lO uM  ■  25uM  i f  50uM  M 75uM  l IOOu M
CCRF-CEM MOLT-3 HL-60 THP-1
Figure 7.2: Effect of EGCG on caspase-3 activation in four leukaemia cell lines (CCRF-CEM, 
MOLT-3, HL-60, and THP-1). Cells treated for 24 at concentrations 10, 25, 50, 75 and 100 pM. 
Caspase-3 activation was determined by NucView™ 488 Caspase-3 substrate based on flow 
cytometry analysis. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated 
control. n= 3.
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7.3.1.1.3 DAPI for Morphological Assessment:
The EGCG-treated cells showed significant increase in the number of apoptotic cells in 
all four leukaemia cell lines tested (CCRF-CEM, MOLT-3, HL-60, and THP-1) at all 
concentrations 25, 50 ,100  pM following 24 h treatment (P < 0.05) (Figure 7.3-7.6).
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Figure 7.3: (1) DAPI Morphological staining analysis of CCRF-CEM with DAPI treated with EGCG 
at concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, 
and apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells 
determined from DAPI morphological assessment following treatment with delphinidin at 25, 
50, and 100 pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. 
untreated control. Scale bar= 12.5 pm. n= 3.
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MOLT-3
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Figure 7.4: (1) Morphological staining analysis of MOLT-3 with DAPI treated with EGCG at 
concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and 
apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells determined 
from DAPI morphological assessment following treatment with delphinidin at 25, 50, and 100 
pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. 
Scale bar= 12.5 pm. n= 3.
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HL-60
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Figure 7.5: (1) Morphological staining analysis of HL-60 with DAPI treated with EGCG at 
concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and 
apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells determined 
from DAPI morphological assessment following treatment with delphinidin at 25, 50, and 100 
pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. 
Scale bar= 12.5 pm. n= 3.
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Figure 7.6: (1) Morphological staining analysis of THP-1 with DAPI treated with EGCG at 
concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and 
apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells determined 
from DAPI morphological assessment following treatment with delphinidin at 25, 50, and 100 
pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. 
Scale bar= 12.5 pm. n= 3.
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7.3 .1 .2  Effect o f EGCG on Cell Cycle:
EGCG showed significant accumulation of cells in Go/Gi phase corresponding with a 
significant decrease in S and M phases in CCRF-CEM, MOLT-3, and HL-60 cell lines 
following 24 h treatment with concentration of 25, 50, and 100 pM (P < 0.05) (Figure 
7.7). In THP-1 cells Go/Gi phase arrest was observed, but this failed to reach 
significance (P > 0.05) (Figure 7.7).
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1
7.3.2 Gallic acid
7.3.2.1 Effect of Gallic Acid on Induction of Apoptosis
7.3.2.1.1 Annexin V-FITC/PI Based on Flow Cytometry
Gallic acid treatm ent of CCRF-CEM, MOLT-3, HL-60, and THP-1 cells resulted in a 
significant increase in the number of apoptotic and dead cells and decrease in the  
number of live cells follow ing 24 h incubation at concentrations: 25, 50, 75, and 100 
pM  (P < 0.05). At the lowest concentration (10 pM ) of gallic acid no significant 
induction of apoptosis was observed in all four cell lines (P > 0.05) (Figure 7.8). THP-1 
was the least sensitive among the cell lines investigated, which illustrated significant 
decrease in the number of live cells and increase in the number of apoptotic and dead 
cells at concentration 50, 75, and 100 pM , but the effects seen were lower than that 
observed in the other cell lines (Figure 7.8).
Gallic acid
WOuM i l lO u M  M 25uM  H  5 0 u M  m 75uM  M lOOuM
M O L T -3
Figure 7.8: Annexin V-FITC/ PI based on flow cytometry following treatment with gallic acid (0, 
10, 25, 50, 75, and 100 pM) for 24 h on CCRF-CEM, MOLT-3, HL-60, and THP-1. Mean ± SEM. * 
indicates significant difference [P < 0.05) vs. untreated control. n= 3.
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7.3.2.1.2 Caspase-3 Activity:
Gallic acid showed a significant increase in caspase-3 activity in CCRF-CEM, MOLT-3, 
and HL-60 cells, but failed to induce apoptosis in THP-1 cells (P < 0.05) (Figure 7.9).
Gallic acid
U  OuM fci lO liM  fit 25uM  U  50uM  u  75uM  u lOOuM
CCRF-CEM MOLT-3 HL-60 THP-1
Figure 7.9: Effect of gallic acid on caspase-3 activation in four leukaemia cell lines (CCRF-CEM, 
MOLT-3, HL-60, and THP-1). Cells treated for 24 at concentrations of 10, 25, 50, 75 and 100 pM. 
Caspase-3 activation was determined by NucView™ 488 Caspase-3 substrate assay based on 
flow cytometry analysis. Mean ± SEM. Mean ± SEM. * indicates significant difference (P < 0.05) 
vs. untreated control. n= 3.
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7.3.1.1.3 DAPI for Morphological Assessment:
Gallic acid showed a significant increase the number of apoptotic cells at all 
concentrations in CCRF-CEM and HL-60 cells following 24 h treatment (P < 0.05) (Figure 
7.10-7.11). In MOLT-3, a significant increase in the number of apoptotic cells was 
observed at 50 and 100 pM. THP-1 cells were the least sensitive with only a small but 
significant increase in the number of apoptotic cells at high concentration 100 pM 
following 24 h treatment (P < 0.05) (Figure 7.13).
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Figure 7.10: (1) Morphological staining analysis of CCRF-CEM with DAPI treated with gallic acid 
at concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, 
and apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells 
determined from DAPI morphological assessment following treatment with delphinidin at 25, 
50, and 100 pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. 
untreated control. Scale bar= 12.5 pm. n= 3.
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Figure 7.11: (1) Morphological staining analysis of MOLT-3 with DAPI treated with gallic acid at 
concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and 
apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells determined 
from DAPI morphological assessment following treatment with delphinidin at 25, 50, and 100 
pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. 
Scale bar= 12.5 pm. n= 3.
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Figure 7.12: (1) Morphological staining analysis of HL-60 with DAPI treated with gallic acid at 
concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and 
apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells determined 
from DAPI morphological assessment following treatment with delphinidin at 25, 50, and 100 
pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. 
Scale bar= 12.5 pm. n= 3.
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Figure 7.13: (1) Morphological staining analysis of THP-1 with DAPI treated with gallic acid at 
concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and 
apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells determined 
from DAPI morphological assessment following treatment with delphinidin at 25, 50, and 100 
pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. 
Scale bar= 12.5 pm. n= 3.
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1 3 .2 .2  Effect of Gallic Acid on Cell Cycle
Gallic acid induced a significant accumulation of cells in S phase corresponding with a 
significant decrease in Go/Gi phase in CCRF-CEM and MOLT-3 and M phase in HL-60 
cells at concentrations of 25, 50, 100 pM following 24 h treatment (P < 0.05) (Figure 
7.14). Gallic acid treatment to THP-1 cells resulted in a significant accumulation of cells 
in S phase, but only at 50 and 100 pM corresponding with decrease in Go/Gi phase 
following 24 h incubation (P< 0.05) (Figure 7.14).
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7.3.3 Quercetin
7.3.3.1 Effect of Quercetin on Induction of Apoptosis
7.3.3.1.1 Annexin V-FITC/PI based on flow cytometry
Quercetin showed a significant increase in the number of apoptotic and dead cells and 
a decrease in the number of live cells follow ing 24 h treatm ent in all four leukaem ia 
cell lines (CCRF-CEM, MOLT-3, HL-60, and THP-1) (P < 0.05) (Figure 7.15). Quercetin 
illustrated potent induction of apoptosis compared to EGCGC, gallic acid, and 
punicalagin in THP-1 cells.
Quercetin
ItfOuM ■  lO uM  ».< 25uM M 50uM  w 7 5 u M  WlOOuM
CCRF-CEM MOLT-3 HL-60
Figure 7.15: Annexin V-FITC/ PI based on flow cytometry following treatment with quercetin 
(0, 10, 25, 50, 75, and 100 pM) for 24 h on CCRF-CEM and MOLT-3. Mean ± SEM. * indicates 
significant difference (P < 0.05) vs. untreated control. n= 3.
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7.3.3.1.2 Caspase-3 Activity
Quercetin significantly increased caspase-3 activity in all four leukaemia cell lines 
(CCRF-CEM, MOLT-3, HL-60 and THP-1) with different sensitivity following 24 h 
treatment with CCRF-CEM being the least sensitive cells. Notably, quercetin illustrated 
potent increase in caspase-3 activity compared to EGCG, gallic acid, and punicalagin in 
THP-1 cells (Figure 7.16).
Quercetin
■ OuM ■ lOuM M 25liM w50uM u75uM  u  lOOuM
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CCRF-CEM MOLT-3 HL-60 THP-1
Figure 7.16: Effect of punicalagin on caspase-3 activation in four leukaemia cell lines (CCRF- 
CEM, MOLT-3, HL-60, and THP-1). Cells treated for 24at concentrations 10, 25, 50, 75 and 100 
pM. Caspase-3 activation was determined by NucView™ 488 Caspase-3 substrate based on 
flow cytometry analysis. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated 
control. n= 3.
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7.3.3.1.3 DAPI for Morphological Assessment
Quercetin-treated cells showed a significant increase in the number of apoptotic cells 
displaying condensed and fragmented nuclear structure and a decrease in cell size 
which are markers of apoptosis in CCRF-CEM, MOLT-3, HL-60 and THP-1 cells at all 
concentrations: 25; 50; 100 pM following 24 h treatment (P < 0.05) (7.17-7.20). 
However, quercetin illustrated potent increase in the number of apoptotic cells 
compared to EGCGC, gallic acid, and punicalagin in THP-1 cells as was observed with 
annexin V-FITC/PI and caspase-3 activity assessments (7.15 and 7.16).
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Figure 7.17: (1) Morphological staining analysis of CCRF-CEM with DAPI treated with quercetin 
at concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, 
and apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells 
determined from DAPI morphological assessment following treatment with delphinidin at 25, 
50, and 100 pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. 
untreated control. Scale bar= 12.5 pm. n= 3.
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Figure 7.18: (1) Morphological staining analysis of MOLT-3 with DAPI treated with quercetin at 
concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and 
apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells determined 
from DAPI morphological assessment following treatment with delphinidin at 25, 50, and 100 
pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. 
Scale bar= 12.5 pm. n= 3.
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Figure 7.19: (1) Morphological staining analysis of HL-60 with DAPI treated with quercetin at 
concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and 
apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells determined 
from DAPI morphological assessment following treatment with delphinidin at 25, 50, and 100 
pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. 
Scale bar= 12.5 pm. n= 3.
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Figure 7.20: (1) Morphological staining analysis of THP-1 with DAPI treated with quercetin at 
concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and 
apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells determined 
from DAPI morphological assessment following treatment with delphinidin at 25, 50, and 100 
pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. 
Scale bar= 12.5 pm. n= 3.
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7.3 .3 .2  Effect o f Quercetin on Cell Cycle
Quercetin treatment of CCRF-CEM, MOLT-3, HL-60, and THP-1 cells resulted in a 
significant accumulation of cells in S phase in all four leukaemia cell lines 
corresponding with a significant decrease in Go/Giand M phase at concentrations: 25; 
50 and 100 pM following 24 h treatment {P< 0.05) (Figure 7.21).
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7.3.4 Punicalagin
7.3.4.1 Effect of Punicalagin on Induction of Apoptosis
7.3.4.1.1 Annexin V-FITC/PI Based on Flow Cytometry
Punicalagin significantly increased the number of apoptotic and dead cells and 
decreased the number of live cells following 24 h treatment in all four leukaemia cell 
lines (CCRF-CEM, MOLT-3, HL-60, and THP-1) at concentrations of 10, 25, 50, 75, and 
100 pM (P < 0.05) (Figure 7.55). THP-1 was the least sensitive among the cell lines 
investigated, which illustrated small, but significant decrease in the number of live cell 
and an increase in the number of apoptotic and dead cells at all concentrations (Figure 
7.22).
Punicalagin
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Figure 7.22: Annexin V-FITC/ PI based on flow cytometry following treatment with punicalagin 
(0, 10, 25, 50, 75, and 100 pM) for 24 h on CCRF-CEM and MOLT-3. Mean ± SEM. * indicates 
significant difference (P < 0.05) vs. untreated control. n= 3.
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7.3.4.1.2 Caspase-3 Activity
Punicalagin significantly increased caspase-3 activity in all four leukaemia cell lines 
(CCRF-CEM, MOLT-3, HL-60 and THP-1) with different sensitivity following 24 h 
treatment (P < 0.05) (Figure 7.23). Punicalagin was considerably less effective 
towardsTHP-1 cells with only 19% of cells positive for casapse-3 activity at 100 pM 
following 24 h incubation compared to 10% in control cells (Figure 7.23).
Punicalagin
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Figure 7.23: Effect of punicalagin on caspase-3 activation in four leukaemia cell lines (CCRF- 
CEM, MOLT-3, HL-60, and THP-1). Cells treated for 24at concentrations of 10, 25, 50, 75 and 
100 pM. Caspase-3 activation was determined by NucView™ 488 Caspase-3 substrate based on 
flow cytometry analysis. Means ± standard error of the mean. *Significant difference (P < 0.05). 
n= 3.
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7.3.4.1.3 DAPI for Morphological Assessment
Punicalagin showed a significant increase in the number of apoptotic cells in all four 
leukaemia cell lines tested (CCRF-CEM, MOLT-3, HL-60 and THP-1) at all 
concentrations following 24 h treatment (P < 0.05) (Figure 7.24-7.27).
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Figure 7.24: (1) Morphological staining analysis of CCRF-CEM with DAPI treated with 
punicalagin at concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green 
arrows, and apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells 
determined from DAPI morphological assessment following treatment with delphinidin at 25, 
50, and 100 pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. 
untreated control. Scale bar= 12.5 pm. n= 3.
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Figure 7.25: (1) Morphological staining analysis of MOLT-3 with DAPI treated with punicalagin 
at concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, 
and apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells 
determined from DAPI morphological assessment following treatment with delphinidin at 25, 
50, and 100 pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. 
untreated control. Scale bar= 12.5 pm. n= 3.
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Figure 7.26: (1) Morphological staining analysis of HL-60 with DAPI treated with punicalagin at 
concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and 
apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells determined 
from DAPI morphological assessment following treatment with delphinidin at 25, 50, and 100 
pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. 
Scale bar= 12.5 pm. n= 3.
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Figure 7.27: (1) Morphological staining analysis of THP-1 with DAPI treated with punicalagin at 
concentrations 25, 50, and 100 pM for 24 h. Live cells are indicated by the green arrows, and 
apoptotic cells are indicated by the red arrows. (2) Percentage of apoptotic cells determined 
from DAPI morphological assessment following treatment with delphinidin at 25, 50, and 100 
pM for 24 h. Mean ± SEM. * indicates significant difference (P < 0.05) vs. untreated control. 
Scale bar= 12.5 pm. n= 3.
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7.3.4.2 Effect of Punicalagin on Cell Cycle
Punicalagin showed a significant accumulation of cells in S phase corresponding with a 
significant decrease in G0/G i phase in CCRF-CEM, MOLT-3 and HL-60 cells at all 
concentrations following 24 h treatment (P < 0.05) (Figure 7.28). Punicalagin treatment 
of THP-1 cells resulted in a significant accumulation of cells in S phase only following 
100 pM stimulation corresponding with decrease in G0/G i phase following 24 h 
incubation (P< 0.05 (Figure 7.28).
314
mo o o o o o o o oc o N t o m ^ m N H
uoj)etndod||3D% uo!iB|ndod||3D%
*  "S
8  «'  n  i
"OQJroX !
<u
~ o  c
C  3  ro too' >
* srsi O  
CO Cl
c
QJOcou
■Mnjc'cuO_TOTOy
‘c
Q.
QJuc
QJL_
QJi t
T3
4->
croy
' cop
‘to
$ -5=
I  ^£ UJ t  t o
TO I I <ut  c^  0300 QJ
E  ^  
$  ^  
=  rH  
£
QJk -CD 
$  it  ocn
0 _
1  ==
.9  cn
Q -
X
I -
Q
Z<
o't o
QD -Jc  O
cT ^4—' LU
QJ O£  i i  O QC
u '-J
LDrHro
uojjeindod |po % uoj)e|ndod ||93 %
£OJro
3
£  9
<-> i_  3
QJ £
u  c00 °  fM C
*  sflj fOI I  JD 
3  3op u
iZ  .£  ro
7 .4  Discussion
EGCG, gallic acid, quercetin, and punicalagin significantly induced apoptosis determined 
by AV/PI, caspase-3 activity and DAPI morphology in all leukaemia cell lines. Moreover, S 
phas arrest was observed following treatment with gallic acid, quercetin, and punicalagin, 
and in G0/G i following treatment with EGCG for 24 h.
7.4.1 EGCG
A number of laboratory studies in vivo and in vitro have demonstrated the inhibitory
action of green tea rich in EGCG as having anti-carcinogenic activities. Previously (Chapter
5), EGCG induced a potent decrease in ATP level. Here, its effect on induction of apoptosis
and cell cycle regulation showed promising results in all four leukaemia cell lines tested.
Using annexin V/PI-FITC based on flow cytometry and DAPI morphological assessment a
significant induction of apoptosis in leukaemia cell lines was observed. In addition,
caspase-3 which plays an important role in apoptosis increased in most cell lines. This is
consistent with Nakazato et ai. (2007) who showed that EGCG induced apoptosis in four
human leukaemia cell lines HL-60, U937, KG-la, and K562 following 24 h treatment. In
addition many studies have verified this observation in several cell types (Khan (3) et al,
2006). In breast cancer EGCG induced apoptosis in several cell lines including MCF-7 and
MDA-MB-231 by regulating pro- and anti-apoptotic proteins including Bcl-2, Bcl-XL, and
Bax (Thangapazham et al, 2007; Tang et al, 2007). In prostate cancer, induction of
apoptosis was identified in different cell lines (LNCap, PC-3 and DU145) (Paschtka et al,
1998; Hastak et al, 2005) in response to treatment with EGCG, which was also shown to be
mediated via altered expression of the Bcl-2 family, which triggered the activation of
initiator caspase-8 and -9 followed by activation of effector caspapse-3 (Hastak et al,
2005). Qanungo et al. (2005) observed that the anti-proliferative action of EGCG on
pancreatic cancer cells was mediated through induction of apoptosis as evident from
nuclear condensation, caspapse-3 activation and PARP cleavage. In addition he reported
that induction of apoptosis in pancreatic cells following treatment with EGCG was
accompanied by cell cycle arrest at Go/Gi. Here G0/G i arrest was also observed in all four
leukaemia cell lines tested following treatment with EGCG. Similarly, Nakazato et al (2005)
investigated the effect of EGCG in four human myeloid leukaemia cell lines (K562, U937,
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HL-60, and KU812) at a concentration of 100 pM for 24 h. Following treatment with EGCG 
increased the population of Go/Gi phase with a reduction of cells in S phase. This 
observation may indicate that EGCG is not one of major compounds present in PJ, as the 
current study has shown that PJ (Chapter 3) and acetonitrile fraction (Chapter 4) induce S 
phase arrest. However, G0/G i arrest following ECGC was also identified in many cancer cell 
lines including prostate (DU145 and LNCap) (Gupta et al, 2000), cervical (CaSKi) (Ahn et al, 
2003), breast (MDA-MB-231 and MCF-10A), human epidermal carcinoma (A431) (Ahmad 
et al, 2000). Other studies reported M Phase arrest following treatment with 50 and 100 
pM EGCG cancer cells such as lung cells (PC-9) (Okabe et al, 1997) and colon cells (Caco2) 
(Salucci et al, 2002) indicating that effect of EGCG on cell cycle may depend on cell type 
and tumour origin.
7.4.2 Gallic Acid
Gallic acid is well known to possess anti-oxidant and pro-oxidant properties in a 
concentration dependent manner which varies according to the presence of metal ions 
(Locatelli et al, 2012). This pro-oxidant property of gallic acid has been suggested as the 
trigger for apoptosis in cancer cell lines, however, it has also been shown to regulate 
Fas/FasL, p53, and Bcl-2 family leading to activation of the caspase cascade (Veluri et al, 
2006; Ji et al, 2009; Verma et al, 2013). Gallic acid has been shown to induce apoptosis in 
several cancer cell lines including: stomach (KATO III) (Yoshioka et al, 2000); colon (COLO 
205 and HT-29) (Yoshioka et al, 2000; Bernhaus et al, 2009); prostate (DU145 and 22Rvl) 
(Veluri et al, 2006; Kaur et al, 2009); lung (Calu-6, A459, and NCI-H460) (Ji et al, 2009; You 
and Park, 2010) and cervical cancer cell lines (Hela) (You et al, 2010). Here gallic acid 
significantly induced apoptosis and increased caspase-3 activity in CCRF-CEM, MOLT-3, 
and HL-60 cells, while had no effect on THP-1 cells.
In terms of cell cycle, gallic acid has been to shown to inhibit proliferation of cancer cells 
by inhibiting cell cycle progression at different stages of the cell cycle. Here, gallic acid 
treatment resulted in an increase in the number of cells in S phase. This arrest was also 
detected in prostate cancer cells (DU145) (Agarwal (1) et al, 2006). In contrast, Hsu et al. 
(2001) found that gallic acid induced significant M phase arrest in breast cancer cells
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(MCF-7). Ou et al. (2010) also reported that exposure of human bladder carcinoma cell 
lines (TSGH-8301) to gallic acid resulted in significant increase M phase cells, which was 
accompanied by a decrease in Go/Gi phase cells.
7.4.3 Quercetin
Here, quercetin significantly induced apoptosis and increased caspase-3 activity in all four 
leukaemia cell lines following 24 h treatment. Interestingly quercetin showed a potent 
effect in THP-1 cells comparing to other agents tested (EGCG, gallic acid, punicalagin). This 
confirms the effect of quercetin on ATP seen previously (Chapter 5). However these 
responses are inconsistent with the sensitivity of cell lines following treatment with PJ and 
acetonitrile fraction (Chapter 3 and 4) (Dahlawi et al, 2011; Dahlawi et al, 2013) indicating 
that quercetin is less likely to be one of the major bioactive compounds from PJ. However 
as quercetin is found in greater abundance in the peel from the pomegranate rather than 
the arils (Poyrazoglu et al, 2002), it is possible that limited quantities of querctin were 
seen in the PJ used in this study, which were isolated from the edible part of the 
pomegranate, the arils. This is further supported by the lack of quercetin identified during 
LC/MS analysis of whole PJ and the acetonitrile fractions in Chapter 4. A number of 
studies have shown that quercetin can induce cell death by an apoptotic mechanism in 
cancer cell lines including breast (MCF-7) (Chou et al, 2010) and (MDA-MB-231) (Chien et 
al, 2009), lung (A549) (Nguyen et al, 2004), colon (HT29 and SW480) (Kim et al, 2005), and 
prostate (DU-145) (Kim et al, 2008; Jung et al, 2010) (PC-3) (Vijayababu etal, 2005; Kim et 
al, 2008; Jung et al, 2010; Senthilkumar et al, 2010;) (LNCaP) (Lee et al, 2008; Jung et al, 
2010) and more recently in leukaemia cell lines (Mahbub et al., 2013). Some evidence has 
also been reported which indicates quercetin can modulate a number of key elements 
linked to the apoptosis including: activation of caspase-3, -8, and -9, release cytochrome c 
and cleavage PARP in cervical cells (Hela) (Bishayee et al, 2013) breast (MDA-MB-231) 
(Chien et al, 2009), prostate (DU-145) (Kim et al, 2008) and regulation of Bcl-2 family 
proteins (Vijayababu et al, 2005; Kim et al, 2005; Kim et al, 2008; Jung et al, 2010).
In addition to the effects on apoptosis it was also found that quercetin induced 
accumulation in S phase in all four leukaemia cell lines tested. This S arrest was also seen
in human leukaemia cells (MOLT-4) treated with quercetin (Mertens et al, 2004) and colon 
cancer cell lines (SW480 and T84) (Richter et al, 1999). In contrast, quercetin has also been 
shown to induce M phase arrest in human leukaemia cells (U937)( Lee et al., (2006); 
oesophageal squamous cell carcinoma (KYSE-510) (Zhang et al, 2009); lung (NCI-H209); 
and prostate cancer cells (PC-3 and DU-145) (Nair et al, 2004; Vijayababu et al, 2005; 
Senthilkumar et al, 2010). Conversley G0/Gi arrest has also been shown in breast (SKBr3, 
MDA-MB-435 and MDA-MB-231) (Jeong et al, 2009); liver (HepG2) (Mu et al, 2007) and 
liposacroma cell line (SW827)(Robaszkiewicz et al, 2007) cell lines. Suggesting that 
depending on cell type and tumour origin quercetin was found to arrest cell cycle at Go/Gi, 
S, or M phase.
7.4.4 Punicalagin
Punicalagin significantly induced apoptosis with an increase in caspase-3 activity in all four 
leukaemia ceil lines following 24 h treatment, however there is limited work on the effect 
of punicalagin on cancer cell lines, with the majority of studies focusing on colon cancers. 
Seeram et al. (2005) reported that punicalagin exhibited apoptotic activity in HT-29 and 
HCT116 colon cells. In another study, Caco-2 underwent apoptosis upon treatment with 
punicalagin after 24 h through Bcl-xl down-regulation with mitochondrial release of 
cytochrome c into the cytosol, and activation of initiator caspase-9 and effector caspase-3 
(Larrosa et al, 2005). In addition, the same study found that punicalagin treatment 
resulted in S phase arrest following 100 pM treatment, which is consistent with our results 
where S phase arrest was also seen. However, punicalagin is unique to pomegranate and 
was one of agents detected in the acetonitrile fraction (Chapter 4) which induced 
apoptosis and S phase arrest.
7.5  Conclusion
All selected compounds (EGCG, gallic acid, quercetin, and punicalagin which showed 50%
reduction in ATP levels (Chapter 5) induced apoptosis and resulted in cell cycle arrest in
the majority of the leukaemia cell lines. EGCG induced apoptosis in leukaemia cell lines
with sensitivity matching of PJ. However EGCG was found to induce G0/G i cell arrest in
contrast to the S phase arrest seen following PJ and ACN fraction of PJ. Suggesting EGCG
was not the main bioactive component in PJ. Gallic acid induced apoptosis in CCRF-CEM,
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MOLT-3, and HL-60 cells only and caused S phase arrest with sensitivity levels matching 
those seen following PJ and ACN fraction treatment. Suggesting gallic acid may be one of 
the bioactive compounds found in PJ, although MS analysis of his study failed to identify 
this as one of the key peaks. Quercetin induced apoptosis and S phase arrest in leukaemia 
cell lines. Although the order of sensitivity did not match that of PJ and ACN fraction as 
THP-1 cells displayed greatest sensitivity to quercetin compared to being the least 
sensitive following PJ whilst CCRF-CEM cells were the least sensitive to quercetin but most 
sensitive to PJ. Suggesting quercetin is not the main bioactive agent in the PJ studied here. 
Punicalagin induced apoptosis and S phase arrest with sensitivity levels matching those 
seen following PJ and acetonitrile fraction treatments. Suggests punicalagin may be one of 
the bioactive compounds found in PJ. Importantly MS analysis of the PJ used in this study 
identified punicalagin as one of the major components of the acetonitrile fraction of PJ. 
Interestingly to date punicalagin has only been associated from pomegranate.
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8.1  Key Findings
This study demonstrated for the first time that PJ displayed potential anti-cancer effects 
through induction of apoptosis, inhibition of cellular proliferation and arrest of cell cycle in 
four myeloid and four lymphoid human leukaemia cell lines. In addition, induction of 
apoptosis and inhibition of cellular proliferation was dose and time dependant. 
Interestingly, different degrees of cytotoxicity between leukaemia cell lines were 
identified, where most of the lymphoid leukaemia cells were more sensitive than the 
myeloid cell lines. In addition PJ treatments induced cell cycle arrest in different phases 
which was dependant on the type of cells investigated (myeloid/lymphoid), dose and 
incubation times. These differential sensitivity patterns seen within myeloid and lymphoid 
cell lines could be due to different cellular origin, genetic abnormalities and or expression 
of differential proteins by different types of cells. Importantly, PJ showed a lower level of 
cytotoxicity against normal HSCs than the effects seen in the majority of leukaemia cells.
Further SPE of PJ demonstrated bioactive compounds were found in the acetonitrile 
fraction which showed highest phenolic content suggesting polyphenols were the active 
component. Further analysis of the bioactive acetonitrile fraction using mass spectrometry 
identified a number of compounds including: the anthocyanins: cyanidin-3-gluocside; 
cyanidin 3,5-O-diglucosides; delphinidin-3-glucoside; delphinidin-3,5-0 diglucosides; 
pelargonidin-3-gluocside and pelargonidin-3,5-0-diglucosides; ellagitannins including 
punicalagin and phenolic acids including ellagic acid.
Comparison of IC5o (determined as 50% decrease in ATP levels) was used to determine the 
most effective compounds from PJ. Seven key polyphenols were identified as potent 
compounds including: delphinidin; pelargonidin; cyanidin; quercetin; EGCG; gallic acid and 
punicalagin.
Interestingly of the anthrocyanins investigated, delphinidin was more potent than cyanidn 
and pelargonidin suggesting the activity of the anthocyanins was related to the number of 
hydroxyl groups. In addition anthocyanidins which lacked sugar molecules displayed 
greater toxicity toward leukaemia cells than their glycosylated forms.
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The mechanisms of apoptosis for delphinidin were determined demonstrating delphinidin 
induced both caspase-8 and -9 in leukaemia cell lines, suggesting delphinidin activated 
both intrinsic and extrinsic pathways. Delphinidin also modulated expression of Bcl-2 
family proteins resulting in decreased expression of anti-apoptotic proteins: Bcl-2 and Bcl- 
xl, and increased pro-apoptotic proteins: Bax and Bad. In addition treatment of leukaemia 
cells with delphinidin resulted in increased expression of cytochrome C and Smac/Diablo
Quercetin induced apoptosis and S phase arrest in leukaemia cell lines. Although the order 
of sensitivity did not match that of PJ and ACN fraction as THP-1 cells displayed greatest 
sensitivity to quercetin compared to being the least sensitive following PJ whilst CCRF- 
CEM was the least sensitive to quercetin but most sensitive to PJ. Suggesting quercetin 
was not the main bioactive agent found in PJ. EGCG also induced apoptosis in leukaemia 
cell lines with sensitivity which matched that seen following PJ treatments. However EGCG 
was found to induce Go/Gi cell arrest in contrast to the S phase arrest seen following PJ 
and ACN fraction of PJ. Suggesting EGCG was not the main bioactive component in PJ.
Gallic acid induced apoptosis and S phase arrest with sensitivity levels matching those 
seen following PJ and ACN fraction treatment. Suggesting gallic acid may be one of the 
bioactive compounds found in PJ, although MS analysis of the PJ used in this study failed 
to identify gallic acid as a major component.
Punicalagin induced apoptosis and S phase arrest with sensitivity levels matching those 
seen following PJ and acetonitrile fraction treatments. Suggesting punicalagin may be one 
of the bioactive compounds found in PJ. Importantly MS analysis of the PJ used in this 
study identified punicalagin as one of the major components of the acetonitrile fraction of 
PJ. Interestingly to date punicalagin has only been associated from pomegranate, 
suggesting this could be a novel bioactive agent only sourced from pomegranates.
8.2  Fu ture D irections
In order to test the efficiency and safety of PJ and its bioactive compounds on human 
health, further studies are required including in vitro and in vivo studies. These phases are
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essential to approve the clinical use of these agents in general population prior to being 
used as a novel treatment for leukaemia
8.2.1 In vitro Studies
8.2.1.1 Investigation into the Mechanisms of Induction of Apoptosis
Experimental data obtained from this study has indicated that delphinidin, punicalagin, 
gallic acid, EGCG, and quercetin can induce apoptosis in leukaemia cell lines. Considering 
their beneficial effects in induction of apoptosis in prevention of leukaemia or as novel 
potential therapeutic agents more research is required to determine their mechanism of 
action in induction of apoptosis in leukaemia cell lines. Thus it is important to investigate 
their mechanistic effects on a number of pro- and anti-apoptotic proteins, caspase 
activation and other apoptotic proteins (Table 1.2 and 1.3). Mechanistic study by Larrosa 
et al. (2006) found that both punicalagin and ellagic acid induce apoptosis in human colon 
cancer cell line (Caco-2) as evidenced by an increase in cytochrome c release, decrease 
Bcl-xl, and increased caspase-3 and -9 expression. As such further investigations within 
leukaemia cell lines will aid in the identification of new therapeutic agents for the 
treatment of leukaemia.
8.2.1.2 Investigation into Cell Cycle Regulatory Proteins
This study showed that PJ and its bioactive compounds induce cell cycle arrest in different 
phases in leukaemia cell lines investigated, with the majority of agents inducing S phase 
arrest. Understanding the effects on progression of cell cycle is essential for the rational 
design of novel drugs to prevent abnormal cellular proliferation seen during cancer. The 
progression of cell cycle is regulated by the actions of protein kinase complexes composed 
of cyclin and cyclin-dependent kinases (CDK) (Table 1.1) in addition to other key 
regulators including CDK inhibitors and retinoblastoma (Section 1.1.1.2.3 and 1.1.1.2.4). 
Thus it is important to investigate the effect of PJ and its bioactive compounds on the 
activities of protein kinases and cell cycle regulators. Vicinanza et al. (2013) found that 
ellagic acid induced S phase which was associated with a decrease in cyclin B1 and cyclin
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D1 in prostate cancer cell lines (DU-145 and PC-3). Whilst quercetin has been shown to 
down-regulate cyclin B1 and CK1 and increase the levels of CDK inhibitors, including: p53; 
p21cipi/wafi. ancj p2 7 k,P1 jn human breast cancer cell lines (SK-Br3, MDA-MB-453, and MDA- 
MB-231 (Jeong et al, 2009; Jae-Hoon et al, 2009; Chou et al, 2010; Choi et al,)
8.2.1.3 Using Pomegranate Compounds in Combination
Although natural compounds naturally occur in combinations as seen within the PJ used 
within the current study, little information is available regarding possible additive or 
synergistic interactions between compounds naturally occurring. Synergism is important 
as it allows lower and potentially safer doses of each compound to generate the desired 
effect. Thus the identification of potential interactions between natural compounds may 
give information regarding the efficiency of compounds contained in foods in cancer 
prevention. Mertens-Talcott et al. (2006) reported that ellagic acid and quercetin interact 
synergistically with resveratol in the induction of apoptosis and cause transient cell cycle 
arrest in human leukaemia cells (MOLT-4). In addition the effects of quercetin, kaempferol, 
and catechin in combination in breast cancer cell line (MDA-MB-231) synergistically 
inhibited cell proliferation and induce apoptosis (Schlachterman etal, 2008)
8.2.1.4 Investigating the Effect of Pomegranate Compounds in Combination w ith 
Chemotherapy
Despite recent advances in cancer treatment, most of the current chemotherapy agents 
cause severe side effects in addition to high failure rates resulting in patient relapse 
following single agent therapies. Thus searching for safer and better drugs to eliminate 
side effects and prevent relapse are important. Punicalagin, delphinidin, gallic acid, 
quercetin, and EGCG are polyphenols which induce apoptosis and cell cycle arrest in 
leukaemia cell lines. However, using combinations of these compounds with 
chemotherapy drugs may open new avenues for the discovery of ideal drug combinations 
for leukaemia therapy. A number of studies in vitro have used polyphenols in combination 
with chemotherapy agents, demonstrating promising results in cancer treatment. Kubato 
et al., (2003) showed that combined effects in lung cancer cell lines of resveratrol and 
paclitaxel (an essential chemotherapeutic agent against lung cancer) significantly 
enhanced the effect of paclitaxel. Lev-Ari et al. (2009) reported that combined celecoxim
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(chemotherapy agent that used for colon cancer) and curcumin (a natural compound) 
showed synergistic inhibition of growth of colon cancer cell lines: HT-29 and SW480 cells. 
In prostate cancer, lycopene (natural compound) synergistically enhanced the anti­
proliferative effect of docetaxel (chemotherapeutic drug that clinically used to treat 
patients with advanced prostate cancer) (Tang et al, 2011).
8.2.1.5 Measuring Reactive Oxygen Species (ROS)
ROS are considered to be an important preventive biomarker and may be a crucial target 
for anti-cancer therapies by ameliorating oxidative stress and thus DNA damage (Valko et 
al, 2007; Lambert et al, 2010). Therefore it is important to measure ROS level in leukaemia 
cell lines following treatment with PJ and it bioactive compounds. Two studies have shown 
that treatment of cancer cells with extracted and purified anthocyanins resulted in an 
accumulation of ROS and subsequent induction of apoptosis (Feng et al, 2007; Hou et al, 
2005). EGCG has also been shown to induce ROS generation in a number of cancer cell 
lines including leukaemia (Jurkat) (Nakagawa, 2004), colon (HT-29) (Nie et al, 2002), and 
lung (H1299) (Li et al, 2010) cancer.
8.2.2 In vivo Studies
Most of the medicines that are used to treat animals are the same as those developed to 
treat human patients (Wienkers and Heath, 2005; Steele and Lubet, 2010). Although 
pomegranate products have shown promising anti-tumour activities in various organs of 
animals including: skin (CD1 mice) (Afaq et al, 2005), prostate (Athymic nude mice) (Malik 
et al, 2005), lung (Athymic nude mice) (Khan (2) et al, 2006), and colon (F344 rats) 
(Seeram et al, 2005), the chemo preventive potential of pomegranate has not been 
investigated against the pre-clinical model of leukaemia. Thus, in order to justify the non­
toxicity of the PJ and its effective compounds on human health and for predicting 
therapeutic responses in leukaemic patients, the effects of these agents in treatment of 
animal models to determine the effective doses and administration schedules of these 
compounds would need to be performed prior to clinical trials to investigate their use as 
potential chemo preventive and anti-leukaemic agents.
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8.2.3 Clinical Trials
Following investigation of the effect of PJ and its bioactive compounds in vitro and in vivo, 
the next step would be to examine the efficacy and safety in humans. Human clinical trials 
to date have involved consumption of a normal amount of PJ or a concentrated liquid or 
powder that is equivalent in polyphenolic content to an 8 oz serving of pomegranate juice 
(Johanningsmeier and Harris, 2011). In these studies no side effects were indicated and it 
is generally considered safe to consume the fresh fruit and juice of pomegranate, and 
indeed is a natural component of many normal diets.
PJ has been taken forward to phase II clinical trials, particularly in prostate cancers 
(Pantuck et al, 2006). In a phase II clinical trial, 46 men with rising prostate-specific 
antigen (PSA) levels following treatment for prostate cancer, were given 8 ounces of PJ 
daily during disease progression, PJ consumption significantly delayed the rise in PSA, 
increased the PSA doubling time from 15 months to 54 months based on baseline versus 
post-treatment measurements (Pantuck et al, 2006). In addition, analysis of plasma levels 
before and after treatment with PJ exhibited the treated subject plasma to have higher 
antioxidant and anti-proliferative activities (Pantuck et al, 2006). Thus the expansion to 
clinical trials in patients with leukaemia would be an essential step towards developing the 
use of pomegranate extracts in the treatment of leukaemia.
8 .3  Final Conclusions
Together this study has shown that PJ is a rich source of bioactive compounds which could 
hold promise for treatment of leukaemia. The most promising compounds found with PJ 
were delphinidin, gallic acid, and punicalagin. Further investigation into these agents in 
the treatment and prevention of leukaemia are essential to develop these potential 
agents as future treatments.
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